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(i) ABSTRACT 
Inflammation is the body's innate immune response to the damage caused to its cells 
and vascularised tissue, either by injury or microbial pathogens. Although these 
processes cause pain, swelling, redness and an increase in body temperature, 
inflammation is generally a beneficial salutary response. Since the 1940's 
glucocorticoids have been widely prescribed in treating inflammatory diseases, e. g. for 
inflammatory bowel disease and anaphylactic shock hydrocortisone is prescribed, 
whereas for asthma and rheumatic disease, betametasone and prednisolone are the drugs 
of choice. During the late 1970's and early 1980's a novel glucocorticoid regulated 
protein, termed annexin Al, was identified. This protein mediates and shares many of 
the anti-inflammatory and prostaglandin suppressive properties with glucocorticoids. 
More recently annexin Al has been shown to be an endogenous ligand for the fMLP 
receptor, termed the FPR. This thesis questions the fundamental basis of annexin Al 
leukocyte biology by examining the behaviour of neutrophils and macrophages 
collected from mice lacking either the protein or its receptor. 
The major finding in this thesis can be divided into two sections, focusing on the 
neutrophil activation or the macrophage phagocytosis. 
Neutrophils from FPR deficient mice could be activated at high concentrations with 
fMLP, and pre-incubating cells with either the annexin Al mimetic or the FPR 
antagonist Boc 2 abrogates these effects. Blood neutrophils purified from annexin Al 
null mice were more susceptible to inflammatory stimuli, causing an excessive increase 
in cell adhesion molecule expression, chemotaxis and ROS production, compared to 
littermate (wild type) controls. In contrast neutrophils over expressing this protein 
exhibited an attenuated degree of activation. 
Annexin Al null peritoneal macrophages exhibited defects in phagocytosis in a 
stimulus-specific manner. Annexin Al null macrophages incubated with non-opsonised 
zymosan, Neisseria or opsonised sheep red blood cells exhibited a grossly impaired 
uptake of particles. This was further confirmed by electron and confocal microscopy 
analysis. Furthermore, specific alterations in annexin Al null macrophage plasma 
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membrane CD1lb and F4/80 expression was observed in macrophages lacking this 
protein. Upon activation these macrophages synthesised an augmented concentration of 
proinflammatory cytokines. Annexin Al null macrophages were resistant to 
glucocorticoid inhibition during phagocytosis. These results suggest that the 
participation of endogenous annexin Al during phagocytosis is critical. 
In summary, this thesis has investigated for the first time in genetically modified mice 
the potential effects that the lack of annexin Al may have on specific cellular functions 
with a major impact on the inflammatory response, finding that indeed this protein 
exerts a tonic inhibitory action, in a stimulus- and cell-specific fashion, on leukocyte 
biology. 
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CHAPTER 1 
INTRODUCTION 
Chanter 1 Introduction 
1.1 The history of inflammation 
Inflammation: (in"Flah-ma'shun) [Latin. Inflammatio; Inflammare; to set on fire]. A localised 
protective response elicited by injury or destruction of tissues, which serves to destroy, dilute, or 
sequester both the injurious agent and the injured tissue. It is characterised in the acute form by the 
classical sings of pain, heat redness, swelling and loss of function. Histologically, it involves a complex 
series of events, including dilation of arterioles, capillaries and venules, with increased permeability and 
blood flow, exudation of fluids, including plasma proteins, and leukocyte migration into the inflammatory 
focus. (Dorland's illustrated Medical Dictionary 1998) 
1.1.1 Inflammation in the ancient world 
Inflammation is normally a localised protective response to trauma or microbial 
invasion that destroys, dilutes or wards off the injurious agent and infection. This 
process has had a long exciting history, closely linked to the history of wounds, war and 
infection. Inflammation was recognised by physicians prior to the Greek and Roman 
empires. The ancient Egyptians had records of pus formations in the "Ebers Papyrus" 
around 1550 BCE, which mentions inflammatory manifestations such as dysentery, 
abscesses and joint disease; they described pus, "as the demon of disease". The ancient 
Egyptians had numerous terms referring to inflammatory conditions derived from the 
hieroglyphic for fire (Majno., 1977). In his informative book; General Pathology, H. W. 
Florey describes that the Babylonian code of Hammurabi in 2000 BCE gave 
instructions how to deal with abscesses of the eye. Inflammation appears in the 
Babylonian Talmud (Shabbat 108b, 134a and Avodah Zarah 28b) as well as in other 
early writings, such as those of the Assyrians, the Indians and the Chinese (Florey, 
1970). It was the Greeks who most profoundly influenced western medicine. 
Hippocratic writings used the word "phlegmone", meaning fiery heat, to describe a 
variety of conditions thought to be due to an influx of blood into perivascular spaces. 
However, the Greek studies were weak as they did not conduct systematic observations 
of the body after death (cited by (Silva, 1979). Aulus Cornelius Celsus, a Roman 
encyclopaedist of the first century CE (30 BCE to 38 CE), presented the first coherent 
description of inflammation. 
"Notae vero Inflammationes sunt quattuor: rubor et tumor cum calore et dolore " was 
described in De Medicina, liber 3. "The characteristics of inflammation are four: 
redness (rubor), swelling (tumor) with heat (calor) and pain (dolor)". Only 120 years 
ago, Rudolph Virchow added a fifth cardinal symptom of the inflammatory response 
funtio laesa (loss of function) and not Galen as once thought (Majno., 1977). 
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Figure 1.1 Cartoon illustrating the cardinal inflammatory response with five 
Greeks depicting a different sign. This figure was commissioned by Prof. D 
Willoughby and Prof. W Spector, drawn by P. Cull at the Medical illustration 
Department at St Bartholomew's Medical College. 
1.1.2 Inflammation in the modern world 
The father of modern anatomy, pathology and inflammation for a Glaswegian studying 
at St Bartholomew's hospital has to be John Hunter (1728-1793), who contributed 
greatly to all three disciplines. Hunter highlighted the reactive nature of inflammation 
in his classical book "A treatise on blood, inflammation and Gun-Shot wounds" and 
placed great importance to the study of inflammation: "..... inflammation is itself not to 
be considered as a disease, but as a salutary operation consequent either to some 
violence or some disease ... ... ... and requires our greatest attention 
for it is the most 
common and one of the most intensive in its effects of any in the animal body" John 
Hunter 1794. 
Although microscopial observations had been made on tissues since the fifteenth 
century onwards, it wasn't until Virchow (1821-1905), who with the aid of a 
microscope conceived the idea that fundamental changes in disease can be traced to 
alterations in cells of the organism. The quest for a primary origin of the inflammatory 
response was being sought during nineteenth century. This caused great debate 
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between Cohnheim (1843-1884), Virchow (his supervisor), and Metchnikoff (1845- 
1916) a Russian zoologist (Karnovsky, 1981). 
Julius Cohnheim had deep respect for his supervisor (Virchow), nevertheless his 
conclusions differed from his mentor. Virchow's theory of inflammation was based 
upon the assumption of the non-migration of blood cells to the inflammatory site and 
considered leukocytes in situ to have stemmed from adjacent tissue. Cohnheim's 
studies on frog's tongues and mesenteries painted with various irritants and spread 
under a microscope, provided a detailed account of the early vascular events in 
inflammation. Cohnheim concluded, with the aid of the frog, that the essential feature 
of inflammation involves the migration of leukocytes through the capillary walls by 
their attraction to the site of injury and wrote, " there is no inflammation without 
participation of blood vessels" (Taibott, 1968). Cohnheim's conclusions could explain 
the four cardinal signs of inflammation, the vasodilatation accounts for the rubor; the 
increased blood flow for the calor; the exudation of the fluid for the tumor and although 
the frog could not speak the dolor may be assumed. Thus, Cohnheim described the 
emigration of leukocytes, though he did not know why these cells emigrated, it was Ilya 
Metchnikoff who delineated the function of the migrated leukocyte. 
In 1892 Ilya Metchnikoff was the first to observe and study phagocytosis, over a wide 
range of species, evolving from a mode of feeding in unicellular organisms to defence 
activity of specialised cells in multicellular organisms. In this work Metchnikoff 
challenged Cohnheim's views on leukocyte migration, for Metchnikoff the 
inflammatory process centred on phagocytosis, associated cellular motility and 
secretory activities of resident cells and stressed that the connective tissue cells play 
only a minor role in inflammation. Thus, Metchnikoff believed phagocytic cells had to 
recognise the object being engulfed, ingested and finally digested. Until Metchnikoff 
postulated his theory, phagocytes (white blood cells) were seen not as a defence against 
infection, rather a safe house for microorganisms to be carried to different parts of the 
body (Karnovsky, 1981). Looking back from the twenty-first century it's hard to 
understand why these outstanding scientists pursued the idea of a single mechanism of 
inflammation and could not conceive a symbiotic mechanism encompassing both their 
hypotheses. 
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1.1.3 The birth of immuno-pharmacology 
During the early part of the twentieth century, Sir Henry Dale (1875-1968) discovered 
that inflammation is dependent upon the formation, synthesis and release of endogenous 
active substances, which mediate the patho-physiological inflammatory response. At the 
time Dale postulated the auto-pharmacology theory, being: "The physiological 
occurrence of synaptic transmission, as well as many pathological events, for instance 
anaphylaxis, allergy and other inflammatory reactions, mediated by the release of 
choline esters, histamine and so on" (Dale., 1933). 
The concept of chemical mediation has been ascribed to Sir Thomas Lewis (1881- 
1945), due to his ingenious yet simple experiments on the "triple response", elicited in 
the skin of the forearm, by firm stroking (Lewis, 1927). From these experiments he 
proposed that the release of some histamine like substances by injured tissues is the 
cause of the dull red line, which he ascribed to vasodilatation, while Lewis attributed 
the wheal to increased vascular permeability resulting from leakage of fluid from post- 
capillary venules made more permeable by histamine. At the time scientists aimed 
towards identifying mediators responsible for the local inflammatory response. 
However, the only quantitative technique was the estimation of extravascular leakage 
by i. v. injected dye such as Evans Blue, in response to intradermal injections of noxious 
substances. 
Six years later in 1931, two American gynaecologists, Kurzrok and Leib, observed that 
strips of human uterus relax or contract when exposed to human semen. In 1933, 
Goldblatt, in England, and Von Euler in Sweden (1934), independently reported smooth 
muscle contraction and vasopressor activity present in the seminal fluid and accessory 
reproductive glands. Von Euler identified this substance as a lipid soluble acid, which 
he named prostaglandin (Reviewed by (Moore, 1985). Twenty years after the initial 
discovery of these prostanoids they were given the status of a distinct family of 
compounds with inflammatory diversity. 
In Asia and China, the beneficial effects of plants containing salicylic acid (myrtle and 
willow trees) had been known from early times, its anti-inflammatory properties are 
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mentioned in the Babylonian Talmud (Gitten 63a). However, during the middle ages 
pain relieving uses of the willow were forgotten, and only rediscovered by the Rev. 
Edward Stone in 1793 (cited by (Langenfeld, 1997). Finally, in 1897 Felix Hoffman 
successfully synthesised the salicylic acid derivatives. As early as 1972 Sir John Vane 
and Roderick Flower reported different prostaglandin's biosynthesis exists in particular 
parts of the body, thus possessing diverse sensitivities to aspirin and similar drugs 
(Flower & Vane, 1972). To date three isoforms of the prostaglandin synthesising 
enzyme, COX, have been identified each possessing similar activities, yet differing in 
tissue expression characteristics. Thus, explaining why the Ancient civilisations used 
willow and myrtle leaves (a rich source of salicylic acid) to alleviate joint pain. 
It was Atherton and Born in 1972, who refined Cohnheim's method for observing 
inflamed capillaries under the microscope, making it possible not only to observe but 
also quantify changes in granulocyte adhesiveness in living animals. This method 
allowed quantification of several parameters including rolling and migrating cells at a 
given visual position, plus determining the velocity of the rolling cells (Atherton & 
Born, 1972). This is just one example of the technological advances being made in 
experimental research during the 1970's and onwards resulting in an exponential 
explosion of information assembled relating to the inflammatory response. Today the 
inflammatory response is recognised as an integrated discipline in its own right. If 
Aulus Cornelius Celsus were capable of obtaining access to "pubmed " in 2004, he 
would comprehend that his observations some 2000 years ago could be explained by a 
plethora of inflammatory mediators at the site of injury. The redness is due to local 
vasodilatation and it may be mediated by agents such as the prostaglandins or 
histamine. The swelling, oedema formation, is due to increased vascular permeability 
with leakage of plasma proteins from the microcirculation into the extracellular space 
mediated by histamine or leukotrienes in a neutrophil dependent manner. All these 
microvascular changes eventually lead to pain, caused by the stimulation of sensory 
afferent nerves by inflammatory mediators and during chronic inflammation loss of 
function (Bayliss., 1901). Aulus Cornelius Celsus possibly would ask contemporary 
scientists an abundance of unanswered questions, allowing scientists today to appreciate 
we also have a place within the history of science, neither at start nor end point of this 
noble quest, rather as a vital link in a great chain. 
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Sign of inflammation Mediator 
Rubor & Tumor Histamine, bradykinin substance P. CGRP. 
PAF, NO, PGE2, LTC4, L'I'D4, PGI,, IL-8 
and other chemokines, MNILP 
Calor IL-1(3, TNFa, PGE,, IL-6 
Dolor PGE,, bradykinin, Substance P. capsaicin 
Funtio laesa 
(granuloma formation) 
INFy, TN Fa, II .-l (3 
Table 1.1 Some of the mediators responsible for Cornelius Celsus' observations 
2000 years ago. The inflammatory process described in the succeeding pages is by no 
means comprehensive rather it embraces the fundamental principles of inflammation 
alluding to the most significant processes concerning this thesis. 
28 
Chanter l 
1.2 The inflammatory response 
1.2.1 Cells associated with the inflammatory response 
Introduction 
Blood is a tissue consisting of a variety of cells suspended in the fluid medium plasma. 
Blood possesses diverse functions ranging from the transport of gases, nutrients and 
hormones to regulating and organising clotting and the immune response. In 
evolutionary terms, phagocytosis of invading pathogens is probably the most ancient 
inflammatory function of leukocytes; both neutrophils and mononuclear cells share this 
common burden, as a first line of defence. 
Figure 1.2 Circulating leukocytes of the immune system LM (light micrograph) 
EM (electron micrograph) (pictures taken from (Young el al., 2000)). 
1.2.1.1 Macrophages 
The macrophage plays a significant role during both the acute and chronic inflammatory 
response. The mononuclear phagocyte family may be found throughout development, 
and is located in every organ, where cells of this linage comprise 10-15% of the total 
cell mass. The term macrophage was coined by Ilya Metchnikoff over 100 years ago to 
describe a large irregularly shaped mononuclear cell observed in tissue (Peracchia et al., 
2001) (literally meaning: big eater: macrophage). Metchnikoff identified macrophages 
as possessing pluripotent functions enabling them to engulf and digest other cells, 
particulate nutrients and travel at will throughout the organism (Tauber, 2003). 
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The mononuclear phagocyte system is a specialised organ in its own right (Wiktor- 
Jedrzejczak & Gordon, 1996), distributed throughout the body and composed of diverse 
differentiated cell types. Nevertheless, all macrophages are derived from a series of 
haematopoietic progenitor cells, ultimately originating from the haematopoietic stem 
cells in the bone marrow. In mammals the bone marrow consists of resident 
macrophages as well as their precursors; monoblasts, promonocytes and monocytes, see 
Figure 2.7. A newly formed monocyte remains in the bone marrow for around 24 h 
prior to entering the peripheral blood as a non-dividing cell. Circulating monocytes 
contain cytoplasmic granules, express receptors for IgG and complement and possess 
migratory, chemotactic, pinocytic and phagocytic abilities (Auger & Ross, 1992). Half 
of the circulating monocytes leave the bloodstream each day and constitute a 
considerable systemic pool of myeloid precursors. Monocytes are thus recruited via 
either constitutive or inflammatory mechanisms to virtually all tissues in the body 
where they terminally differentiate into the various cell types including microglia in the 
brain, Langerhan cells in the skin and tissue resident macrophages such as the peritoneal 
macrophage. Resident macrophages are generally detectable with specific monoclonal 
antibodies such as F4/80 in the mouse. So, why do half the monocytes remain in the 
circulation each day and not migrate? Recently Geissmann et al., described the 
expression of the chemokine fractalkine receptor (CX3CR1) in long-lived tissue 
macrophages, for instance; Kupffer cells, Microglia and Alveolar macrophages express 
elevated levels of this receptor. In contrast inflammatory macrophage precursors such 
as elicited and antigen-presenting macrophages; monocyte precursor express low levels 
of CX3CR1 (Geissmann et al., 2003). Therefore, it is not only macrophages that form 
a heterogeneous population but monocytes too, appear to be pre-programmed. 
Macrophages are involved in all stages of the inflammatory response. For instance, one 
of the earliest leukocytes a pathogen encounters is the resident macrophage with the 
capacity to generate large amounts of inflammatory mediators. During the resolution of 
inflammation, macrophages act in a non-phlogistic manner as a housecleaner, where an 
earlier inflammatory insult took place, clearing up the debris (Fadok et al., 1998; Savill 
et al., 2002). The process of phagocytosis per se shall be discussed in greater depth in 
the succeeding pages. 
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1.2.1.2 Neutrophils 
Neutrophils also play a predominant role during the inflammatory response. The 
neutrophil is the major leukocyte constituent in human peripheral blood, accounting for 
around 60-70 % of the total white cell count under normal conditions (Kuijpers & Roos, 
2001). It was Paul Ehrlich (1854-1915) who discovered polymorphnuclear leukocytes, 
when he fixed and stained blood cells he observed cells with the same characteristics a 
lobulated nucleus and granules. Neutrophils are members of the polymorphonuclear 
superfamily of leukocytes covering also eosinophils and basophils. 
Similar to the mononuclear cells, neutrophils originate from haematopoietic progenitor 
cells, in the bone marrow but take two weeks to mature. Initially, these cells are 
relatively undifferentiated termed myeloblasts with a large nucleus and few or no 
granules, which evolve to become mature neutrophils containing many neutrophilic 
granules over this two-week period. During neutrophil development two types of 
granule are formed. Azurophil granules are the first to be formed followed by the 
specific granules. These two types of granules play functionally diverse roles, specific 
granules are secretors in nature and involved in initiating the inflammatory response 
while the azurophil granules are viewed as lysosomes rich in digestive enzymes, utilised 
to digest phagocytosed material (Borregaard & Cowland, 1997). 
During the initial stages of the inflammatory response, proinflammatory cytokines are 
produced and released from resident tissue macrophages, as discussed earlier. 
Neutrophils are able to recognise concentration differences in chemotaxins secreted by 
specific membrane receptors and direct their movement towards this chemical source, 
via the processes of chemotaxis and leukocyte migration, discussed in greater depth in 
the following pages. Once the neutrophil reaches the site of injury, it has a plethora of 
mechanisms to fight any invading organism for instance, phagocytosis of immune 
complexes, and opsonised particles and the release of ROS and proteolytic enzymes to 
eliminate pathogens (Kuijpers & Roos, 2001). Recently, Brinkman et al, have 
illustrated that upon activation by endotoxin or cytokines, neutrophils generate NETS 
(neutrophil extracellular traps). These extracellular fibres degrade bacteria with the aid 
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of enzymes such as DNase, histones and granule proteins such as elastase (Brinkmann 
et al., 2004). 
In 1908 both Ilya Metchnikoff and Paul Ehrlich were awarded the Nobel Prize for their 
pioneering work on the macrophage and neutrophil, respectively. Thus, not only do 
these phagocytes complement each others function during the inflammatory response, 
they also share a place in history. 
ERYTHROCYTE LYMPHOCYTE NEUTROPHIL MONOCYTE PLATELETS 
CELL TYPE 
Size 6.7-7.5 pm 6-12 pm 10-18 pm 10-16 pm 1.5-3.5 pm 
Differential 
leukocyte - 20-50% 60-70 % 2-10% - 
count in 
human 
Differential 
Leukocyte - 66-70% 15-20% 0.3-3 % - 
count in 
mouse 
Duration of 5-7 days 1-2 days 6-9 days 2-3 days 4-5 days 
development 
Lifespan of 120 days ? 4 hours -a Months to 4-5 days 
mature cell few days years 
Table 1.2 The leukocyte Fact File (adapted from Histology (Young et a/., 
2000). 
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1.2.2 Inflammatory mediators 
There are a plethora of chemical mediators involved during the inflammatory response 
and the inventory continues to grow. The major mediator groups include cytokines 
(encompassing chemokines), eicosanoids and free radicals, all of which are beyond the 
scope of this thesis. Neutrophils alone have at least five different receptor types for 
chemotactic stimuli including those for chemokines, PAF, complement and fMLP. 
Chemoattractants for neutrophils alone are synthesised by a wide variety of cells, 
including endothelial cells, macrophages, lymphocytes, platelets, monocytes and 
neutrophils themselves. The following section shall touch upon particular inflammatory 
mediator groups relevant to this thesis. 
fMLP (N formyl-methionyl-leucyl phenylalanine). The discovery of formylated 
bacterial peptides occurred in the 1970's and has greatly advanced the study of 
chemoattractants for neutrophils, monocytes and eosinophils (For review see (Dalpiaz 
et al., 2002). The N-formylated peptide originates from bacterial proteins, starting with 
a N-formyl-methionnyl structure, which is required for peptide potency. Similar 
formylated peptides may be produced by mitochondria in mammalian cells. Several 
natural N-formyl peptide chemoattractants, including fMLP have since been purified 
from bacterial supernatants. The formyl peptide receptor was initially cloned in 1990 
(Boulay et al., 1990) and is a member of the seven transmembrane GPCR family. The 
fMLP receptor will be discussed in greater depth in the proceeding pages (see section 
1.3.3.1). Thus, fMLP exerts pluripotent effects, by activating the FPR on neutrophils 
and monocytes. fMLP causes patho-physiological changes on phagocytes. In the 
neutrophil and monocyte, fMLP potentially provokes actin polymerisation, adhesion 
and chemotaxis (Le et al., 2001). 
Platelet-activating factor (PAF) was identified to be a biologically active 
phospholipid, generated and released from most inflammatory cells when stimulated, 
PAF is not known to be stored in cellular vesicles. Synthesis of PAF is a tightly 
regulated pathway. Initially, a species of phosphatyl-choline is hydrolysed by PLA2 
resulting in the formation of the intermediate Lyso-PAF, which is subsequently 
acetylated generating PAF itself (Barnes et al., 1998). Endothelial cells, neutrophils 
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and macrophages are all known to generate PAF in response to an inflammatory insult 
eliciting the proinflammatory response. PAF at nanomolar concentrations is capable of 
producing a wide range of patho-physiological actions associated with the inflammatory 
response. The general pattern that has emerged from numerous studies (for review see 
(Zimmerman et al., 1992)), is that PAF induces an array of functional alterations on the 
cells of the immune and inflammatory system by acting on the PAF receptor (a GPCR). 
One of the most studied cells is the neutrophil, where PAF is a potent agonist eliciting 
actin polymerisation, adhesion and chemotaxis. 
INFLAMMATORY 
MEDIATOR 
NEUTROPHILS MONOCYTES 
IL 8 +++ + 
PAF +++ ++ 
LTB4 + + 
fM LP +++ ++ 
Table 1.3 Leukocyte mediators. Mediator potency on neutrophil and monocytes 
by selected inflammatory mediators. 
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1.2.3 Leukocyte migration 
In general, the acute inflammatory process is a tissue based alarm to trauma, that is 
dependent on the generation of vasoactive and chemotatic mediators which diffuse from 
the site of injury or infection to the circulation (Florey, 1970). Local dilation of blood 
vessels increases regional blood flow to the affected area and together with an increase 
in microvascular permeability results in loss of fluid and plasma proteins exudation into 
the tissue (Ley, 2001). 
Leukocytes, especially neutrophils, play a fundamental role in the acute immune 
response to infection. Leukocytes aggregate at the site of injury from the blood 
circulation, this process involves direct interaction between leukocytes and endothelial 
cells, allowing for the leukocyte migration process. Recruitment of blood borne 
leukocytes into tissue involves a three-step paradigm promoting the interaction between 
a circulating leukocyte and the endothelium: tethering, rolling and firm adhesion all 
resulting in transendothelial migration / diapedesis. These sequential molecular 
interactions ensure leukocyte emigration. Classes of cell adhesion molecules (CAMs) 
on leukocytes and endothelial cells are able to initiate and sustain this process. Specific 
CAMs are recruited at a particular time attributed to their functions in this phenomena, 
from leukocyte rolling to migration (Kubes & Kerfoot, 2001). Simultaneously 
leukocyte and endothelial CAMs participate in slowing leukocytes down allowing for 
the migration through the microcirculation and allowing the leukocyte to enter the 
postcapillary venule, which is a major site of leukocyte-endothelial cell adhesion. The 
release of inflammatory mediators such as PAF and histamine from mast cells by IgE, 
induces the expression of adhesion molecules, whilst chemokine and cytokine release 
also affect this process (for review see (Panes et al., 1999). During various pathologies, 
including chronic inflammatory conditions, leukocyte extravasation persists 
excessively: these migrated leukocytes are responsible for tissue damage and 
subsequent irreversible alteration of organ functionality. 
Thus, rolling leukocytes evolve into cells firmly adherent to the vascular bed. If a 
chemotactic mediator is present in the perivascular space, there is the potential for 
transendothelial leukocyte migration to occur. Due to neutrophils possessing a 
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lobulated nucleus, they are very flexible allowing them to pass through pores as small 
as I gm across, even though they can be 10-12 µm in diameter. For emigration to occur 
multiple CAMs, each with a distinct function, provide "traffic" signals for leukocytes. 
During the succession of this section, we will explore particular families of CAMs and 
their function during leukocyte migration (see Figure 1.3). 
Figure 1.3 The Leukocyte recruitment cascade. Rapid travelling leukocytes in the 
blood stream roll onto activated endothelium via selectins and their ligands. Pro- 
inflammatory mediators released within the tissue and presented on the endothelium to 
rolling leukocytes, ensuing integrin activation and firm adhesion. Thus, permitting 
leukocyte migration to inflamed tissue. 
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1.2.3.1 Tethering to Rolling 
It was during the late nineteenth century when Julius Cohnheim first observed the 
cellular inflammatory hallmark of the rolling leukocyte (Florey, 1970). It was initially 
thought, using intravital microscopy studies, that the majority of these rolling cells were 
granulocytes (Atherton & Born, 1972), nevertheless mononuclear cells have also been 
shown to roll along the endothelium (Ley et al., 1995). The selectin family of CAMs 
weakly bind leukocytes to endothelium causing leukocytes to roll along the 
endothelium, as they successively stick and release. Once a leukocyte begins rolling it 
does not commit the cell to emigrating it may detach and rejoin the bloodstream. 
However, this process is a prerequisite for firm adhesion (Arfors et al., 1987). 
Selectins have been designated as L-(CD62L), P-(CD62P) and E-(CD62E) and 
represent a family of receptors expressed on leukocytes (CD62L), platelets (CD62P) 
and endothelial cells (CD62P/E), (For review see (Carlos & Harlan, 1994; Springer, 
1994)). 
E-selectin expression is limited to endothelium, and is induced in response to 
inflammatory cytokines. In contrast, P-selectin is stored in the Weibel-Palade bodies of 
endothelial cells and granules of platelets, and can be expressed on the surface within 
minutes of activation by inflammatory mediators (Kansas, 1996). Both E and P- 
selectin binds sialyl-Lewis X molecule (SLe") on neutrophils and monocytes. 
L-selectin is constitutively and solely expressed on leukocytes, unlike E-and P-selectin. 
L-selectin was initially identified in the mouse with the use of the MoAb MEL-14 
(Gallatin et al., 1983). Interestingly, the L-selectin knock out mouse has a decreased 
leukocyte recruitment into the inflamed peritoneum (Steeber et al., 1999) demonstrating 
the critical involvement of this CAM in leukocyte trafficking in the microcirculation. 
Once a leukocyte has entered into the process of rolling, L-selectin binds with CD34 
(Tedder et al., 1995), prior to being cleaved by proteolytic activity resulting in rapid 
shedding from the cell surface. The process of L-selectin shedding has a large impact 
on the subsequent stages of leukocyte migration, by activating the leukocyte to promote 
their arrest especially if other co-stimulatory signals are present, for example the 
chemokines (Hafezi-Moghadam et al., 2001). 
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1.2.3.2 Firm adhesion to migration 
During rolling leukocytes are constantly interacting with the endothelium. Throughout 
this time they interact with the CAMs displayed on the endothelial cell surface. If 
appropriate chemokines, lipid mediators or other proinflammatory stimuli are presented 
on the surface of the endothelium, a second family of CAMs are introduced into play, 
the integrins, causing leukocytes to firmly adhere to the endothelium. Integrins form a 
large family of cell membrane heterodimeric glycoproteins consisting of a and ß 
subunits, which are involved in a diverse array of cellular processes from cell migration 
to growth (Miranti & Brugge, 2002). 
Stationary adhesion or sticking of leukocytes to endothelial cells involves the activation 
of the 02 integrin family, the CD 18/CD 11 complex. These integrins are expressed on 
leukocytes and their ligands such as intracellular-adhesion molecule 1 (ICAM-1); a 
protein belonging to the immunoglobulin superfamily, expressed on endothelial cells. 
The integrins are heterodimeric proteins consisting of a and ß subunits. The ß2 
integrin subfamily consists of a common ß unit (CD 18) linked to one of the four a- 
subunits; lymphocyte function antigen (LFA-1 or CD 11 a/CD 18), macrophage antigen 1 
(MAC-1 or CD 11 b/CD 18), CD 11 c/CD 18 and CD 11 d/CD 18 forming the CD 11 /CD 18 
glycoprotein complex, all of which are structurally related. P2 integrins are found on 
circulating leukocytes. The CD ll a/CD 18 and CD! l b/CD 18 are the dominant members 
of this family, required for cell adhesion (Ley, 1996). Consequently, CD 18 knock out 
mouse phenotype has a decreased leukocyte recruitment. LFA-1 is found on 
lymphocytes, granulocytes, monocytes and macrophages whereas Mac-1 is found on 
granulocytes, monocytes, macrophages and NK cells. When an inflammatory stimulus 
is applied to these cells, it causes cell activation and mediates leukocyte-endothelial cell 
adhesion. Blocking CD18 integrins with neutralising antibodies essentially blocks 
adhesion of rolling neutrophils (Arfors et al., 1987). Functional studies have shown that 
adhesion of activated neutrophils to endothelial cells is largely controlled by Mac-1, in 
contrast to adhesion of unstimulated neutrophils, which is generally LFA-1 dependent. 
LFA-1 is the predominant integrin involved in lymphocyte homing. However, LFA-1 is 
only expressed in modest amounts upon neutrophils and it is unaltered by inflammatory 
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mediators (Wagner & Roth, 2000). A functional role for Mac-1 was initially observed 
with the capability of a specific MoAb to inhibit monocyte and granulocyte binding of 
iC3b-coated erythrocytes, thus indicating the identity of Mac-1 as the complement 
receptor type 3 (this will be discussed later). Within the neutrophil Mac-1 is stored in 
three separate compartments: Secretory vesicles, gelatinase granules and specific 
granules (Borregaard & Cowland, 1997). Thus, upon cell activation by inflammatory 
stimuli such as fMLP, PAF or once E-selectin binds to neutrophils (Simon et al., 2000), 
Mac-1 is rapidly recruited to the cell surface, thus encouraging firm adhesion to occur. 
An important complementary ligand for Mac-1 is ICAM-1 (CD54), which is 
constitutively present in a low concentration upon endothelial cell membranes but 
following endothelial cell activation by inflammatory cytokines; its expression can be 
markedly induced. LFA-1 also binds to ICAM-1, though it has a higher affinity to 
ICAM-2. More recently it has been shown that the ß2 integrin MAC-1 plays an 
important role in the adaptation from leukocyte rolling to arrest, known as slow rolling. 
During this process of slow rolling ICAM-1 functions as a ligand for MAC-1, in 
leukocyte rolling and arrest of the inflamed endothelium and LFA-1 is not involved in 
this process (Dunne et al., 2003). 
The process of transendothelial migration has remained elusive relative to its preceding 
stages in this paradigm. Leukocytes migrate through endothelium at the intercellular 
clefts (Florey, 1970). The CAM Platelet-Endothelial Cell adhesion Molecule-1 
(PECAM-1 or CD3 1) another member of the IgG superfamily, expressed on a number 
of cells including neutrophils, monocytes and endothelial cells. PECAM-1 boasts 
homologous binding. It has been demonstrated that the MoAb for PECAM-1 inhibits 
both monocyte and neutrophil migration elicited by inflammatory mediators. Upon 
activation by inflammatory mediators PECAM-1 is redistributed to the junction 
connecting endothelial cells (Muller et al., 1993). 
Another novel CAM family are the Junctional Adhesion Molecules (JAM), JAM-A and 
C are expressed by endothelium and leukocytes and are capable of homophilic binding 
although their roles in leukocyte migration may require heretrophilic interactions. JAMs 
are exclusively expressed at junctional complexes between quiescent endothelial cells. 
Upon stimulation by inflammatory mediators JAM-A is relocated to the surface of 
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endothelial cells where it interacts with its ligand LFA-1 on leukocytes (Ostermann et 
al., 2002); this contact causes transmigration of the leukocytes. 
PECAM-1 and the JAMs are members of the Ig superfamily whereas other key players 
during transendothelial migration are the cadherins, including all VE-cadherin since 
these molecules are potentially capable of homophilic interactions as well as 
heterophilic interactions, this has favoured confusion into the specific role that each 
CAM plays in leukocyte endothelial cell interaction during this final step out of the 
circulation (Muller, 2003). To date it is not clear if transendothelial migration 
commences with PECAM-1-to-PECAM-1 or LFA-1 to JAM-A interactions or whether 
these mechanisms operate symbiotically (Aurrand-Lions et al., 2002; Ostermann et al., 
2002). Dangerfield et al., have shown that inhibiting the novel CAM a6 ßi with 
neutralising antibodies inhibits leukocyte trans endothelial migration. Interestingly, 
a6ß, expression is up-regulated by PECAM-1 interaction (Dangerfield et al., 2002). 
Evolution generally dictates that one mechanism alone rarely exists for such pivotal 
physiological processes thus, several CAMs may play central roles in this process, and 
the future shall enlighten our understanding of new molecules and novel CAM 
interactions. 
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1.2.4 Phagocytosis 
It was in 1882 when Ilya Metchnikoff initially described the role of phagocytosis as a 
significant contributor of the inflammatory response (Florey, 1970; Taibott, 1968). 
Evolution has awarded both the unicellular organisms and higher eukaryotic cells the 
ability of internalising particles and fluids, by different mechanisms including 
pinocytosis, receptor-mediated endocytosis and phagocytosis. Pinocytosis refers to the 
uptake of fluid and is intimately linked to receptor-mediated endocytosis: both of these 
processes share a clathrin-based mechanism occurring in the absence of actin 
polymerisation (Alberts et al., 1995). By contrast, phagocytosis is the uptake of 
particles larger than 0.5 . tm into cells, dependent upon actin and independent of 
clathrin. Lower organisms exploit phagocytosis primarily for eating (the so called Pac- 
Man response), while higher organisms have specialised or professional phagocyte cells 
such as macrophages and neutrophils. Other cells have some phagocytic capacity, for 
instance epithelial cells are known to phagocytose erythrocytes. 
Phagocytosis plays a key role in host defence, this response requires phagocytes to 
recognise, engulf, ingest and finally destroy invading pathogens (for review see 
(Aderem & Underhill, 1999). In addition this process may also remove apoptotic 
neutrophils in a non-phlogistic manner (Fadok et al., 1998; Savill et al., 2002). The 
latter cellular procedure involves different phagocytic mechanisms but it has a number 
of shared characteristics with classical phagocytosis. Particle internalisation is initiated 
by the interaction and recognition by receptors on the surface of the phagocyte. In 
either case the process leads to the polymerisation of actin at the site of engulfment with 
the formation of pseudopods facilitating the internalisation of the particle via an actin- 
based process. After internalisation, actin is shed from the phagosome and the 
phagosome matures culminating in the formation of a mature phagolysosome. In this 
manner the lysosome (rich in hydrolytic enzymes) fuses with the phagosome resulting 
in the digestion and destruction of the particle / pathogen. 
Functional surface receptors found on macrophages and other phagocytes determine 
many activities of the cell, including growth, differentiation, activation and recognition 
of foreign particles to name a few. Phagocytes are able to internalise particles by virtue 
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of the different families of receptors found on their cell surface. Several ligands have 
been documented in the literature to binding the surface of macrophage receptors, 
mediating the process of phagocytosis. 
Figure 1.4 The phagocytosis process: Once foreign particles have been recognised 
(1) by a macrophage via membrane bound receptors they attach the particle (2), the 
macrophages membrane now becomes activated by the foreign particle which is taken 
into a phagosome by pseudopodia extending around it (3). Once inside (4), lysosomes 
fuse with the phagosome to form a phagolysosome and the particle will be destroyed 
(taken from (Underhill et al., 1999). 
Two distinct categories of phagocytosis have evolved depending on the receptor type 
engaged; these are opsonic and non-opsonic receptors. During opsonic phagocytosis 
there are an additional two further subsets relative to the mechanism of phagocytosis: 
type I phagocytosis mediated by recognising FCyRs, binding IgG-coated particles, 
while type II phagocytosis is mediated by binding complement. The earliest 
macrophage family of receptors to be detected and best studied are the opsonic 
receptors the Fcy region of the IgG molecule, FcyR and the receptor for the third 
component of complement C3 receptor (Lay & Nussenzweig, 1968). FcyRs are 
triggered into phagocytosis by binding to the Fc portions of Ig molecules to a given 
particle FcyRs. Within the Fc receptor superfamily there are those for IgG: FcyRI 
(CD64), which has a high affinity towards monomeric IgG; FcyRII and FcyRIII (CD32 
and CD16, respectively) which have low affinity for the monomeric IgG but can bind 
immune complexes by multiple receptor ligand interactions (Unkeless et al., 1988). 
Complement receptors found on the macrophage are involved in binding and, in the 
case of type II phagocytosis, ingestion of opsonised particles. CR1 (CD35) recognises 
and binds C3b and Cb4 (Brown, 1991). CR3 is a (32 integrin made up of aM (32 
heterodimers (as discussed in section 1.2.3.2 referred to as Mac-i), which specifically 
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binds C3bi, fixed on foreign particle surfaces such as bacteria. While type I mediated 
phagocytosis obeys classical membrane ruffling and pseudopodia extension associated 
with phagocytosis, type II phagocytosis appears to be a passive process where the 
particle sinks into the cell, generating little or no membrane protrusions (Allen & 
Aderem, 1996). Importantly, CR3 mediated phagocytosis does not elicit the release of 
inflammatory mediators (Wright & Silverstein, 1983). 
In addition to opsonic phagocytosis, microorganisms can be phagocytosed independent 
of opsonins on the particle surface. A plethora of macrophage receptors are involved in 
the phagocytosis of diverse group microbes, such as scavenger, Toll-like, CD 14 and 
3 glucan receptors (Brown et al., 2002; Peiser et al., 2002). To complicate matters 
somewhat, CR3 in its own right serves as a non-opsonic recognition receptor for 
particles by interacting directly with their cell surface; this form of phagocytosis has not 
been fully defined. Non-opsonic zymosan is phagocytosed through a different CR3 
mechanism (Le Cabec et al., 2000) and is similar to type I phagocytosis, involving 
pseudopodial extensions; in contrast phagocytosis of opsonised zymosan is more similar 
to type II phagocytosis characterised by the particle sinking into the cell (Le Cabec et 
al., 2002). Thus, CD 11 b appears to be an elaborate receptor able to activate different 
signalling pathways resulting in different forms of phagocytosis depending on the 
ligand attached. 
Once bacteria/particles have been recognised and internalised into a phagocyte the 
engulfed material enjoys a short rest-bite in a phagosome. Phagosomes undergo 
extensive and rapid remodelling through fission and fusion events with a plethora of 
intercellular vesicles, culminating in the formation of the vacuole fused with acidic 
lysosomes rich in hydrolytic enzymes leading to digestion of the unwelcome bacteria. 
Phagosome-lysosome fusion is enhanced in activated macrophages and occurs in the 
presence of cytochalasins, indicating this event to be independent of actin (Kielian & 
Cohn, 1981). This process of fusion remains quite unclear relative to the earlier stages 
involved. ROS such as the superoxide and hydrogen peroxide are produced as an active 
mechanism to kill pathogens. In addition, certain bacteria are capable of surviving in 
the phagolysosomal system. 
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1.3 Annexin 
1.3.1 The annexin superfamily 
The annexin family of proteins are members of a super family of calcium and 
phospholipid binding proteins. This intricate family has recently been split into five 
major categories: (A). the vertebrate annexins (annexin Al- A13) that are unlikely to be 
widely found in invertebrate species. (B) The animal annexins lacking human 
orthologs, (C) the annexins of fungi and moulds, (D) the plant annexins and, finally, (E) 
the protists annexins. Thus, annexins are distributed throughout both the plant and 
animal kingdom implying that they serve fundamental cellular and physiological 
functions. 
The name annexin is derived from the Greek annex "to bring/hold together" and has 
been selected to describe a principal property of all or nearly all annexins e. g. the 
binding to and possibly holding together of biological structures. All annexins fulfil 
two fundamental criteria: firstly they must be able to bind negatively charged 
phospholipids in a calcium dependent manner; secondly, they all contain a conserved 
structural repeat (the annexin repeat). Thus, all annexins are structurally related with 
two principal domains, the divergent NH2-terminal and the conserved COOH-terminal 
protein core. This annexin core domain comprises four (or in the case of annexin A6 
eight) homologous helical regions consisting of 70 amino acids each (see figure 1.5A). 
The repeat region is arranged into a slightly curved disc with the calcium binding sites 
on the convex side, nevertheless, the NH2 terminal of each member is unique to each 
annexin in terms of size and amino acid composition thus granting biological and 
functional idiosyncrasies to individual members of the family. 
A precise physiological function for the annexin family as a whole has remained elusive 
for many years. However, annexins have been implicated in a number of physiological, 
pharmacological and pathological processes, including modulation of blood 
coagulation, regulation of membrane trafficking, inhibition of PLA2 activity, 
modulation of cell signalling (cited by (Gerke & Moss, 2002), anti-inflammatory and 
neuroendocrine actions by glucocorticoids (Buckingham & Flower, 1997). 
Dysregulation of annexins has been associated with human tumour cells (Garcia 
Pedrero et al., 2004; Xin et al., 2003) and expression of annexin is found in multiple 
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sclerosis plaques (Probst-Cousin et al., 2002). Annexin Al expression is also 
associated with drug resistance in tumour cells (Wang et al., 2004) (Table 1.5). 
1.3.2 Annexin A1 
Annexin Al is a 37-kDa protein (consisting of 346 amino acids) whose structure can be 
seen in Figure 1.5. The X-ray crystal structure of annexin Al has recently been 
determined, with the classical conserved four repeat annexin COOH core and the unique 
NH2 terminus (Rosengarth & Luecke, 2003) consisting of 41 residues, known to be 
anti-inflammatory (Flower & Rothwell, 1994). The first 26 amino acids of the NH2- 
terminal domain is recognised to be the active constituent of annexin Al (Perretti & 
Flower, 1993), which forms two a-helices. 
Annexin Al, was one of the first annexins to be discovered, also the first to be cloned 
hence the name annexin Al; this discovery occurred simultaneously in three different 
laboratories. Each group demonstrated with different in vitro models, showing that the 
anti-inflammatory actions displayed by glucocorticoids was due to inhibition PLA2 
activity, thus inhibiting eicosanoid production. The factor was subsequently 
characterised and termed macrocortin, lipomodulin and renocortin by each group 
(Flower & Blackwell, 1979) an adjective of its discovery, e. g. macrocortin 
"glucocorticoid inducible from macrophage protein". A comparison of the protein 
isolated lead to the term lipocortin "steroid inducible phospholipase inhibitors" for the 
protein, as it is regulated by glucocorticoids (Di Rosa et al., 1984). Further purification 
led to the isolation of lipocortin (Cloix et al., 1983), which was sequenced and cloned 
by Wallner et al., (in 1986) when lipocortin became known as lipocortin 1. 
Following further analysis it was realised that lipocortin 1 was a member of a family of 
proteins' that bind calcium and phospholipids (Pepinsky et al., 1988). This family was 
subsequently termed "the annexins" leading to the current nomenclature annexin Al 
briefly illustrated above. 
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The biology of annexin is beyond the scope of this thesis and the following pages will 
focus instead upon a few important areas. These include the effects of annexin Al 
during the inflammatory response as well as the elusive annexin Al "receptor". 
1.3.2.1 Annexin A1's distribution 
Annexin Al is widely distributed throughout the immune system, and is particularly 
abundant in murine neutrophils, with lowest expression in lymphocytes, and an 
intermediate level of expression in monocytes (Perretti & Flower, 1996). More recently 
annexin Al has been localised in the cytosol in eosinophils (Oliani et al., 2002). An 
analogous picture is apparent in human leukocytes with monocytes and neutrophils 
strongly annexin Al positive (Morand et al., 1995). Annexin Al has been localised in 
the human neutrophil through confocal and electron microscopy studies. The gelatinase 
granule of the neutrophil contains approximately 60-70% of the protein (Perretti et al., 
2000) and in this cell type it can represent up to 4% of cytosolic proteins. Annexin Al 
has also been detected in many tissues including the lung, intestine, seminal fluid and 
bone marrow in some cases at concentration greater than 50 ng/ml, while it appears 
undetectable in plasma (Christmas et al., 1991). 
1.3.2.2 Annexin Al pharmacology during the inflammatory response 
It was in 1949 that Philip Hench discovered the anti-inflammatory properties of 
Cortisone and ACTH. When these hormones were administered to patients suffering 
from rheumatoid arthritis their condition was remarkably improved. Instantly 
glucocorticoids became miracle drugs. Endogenous glucocorticoids, e. g. cortisol and 
hydrocortisone, synthesised in the adrenal cortex have potent anti-inflammatory activity 
and are released under conditions of stress, a consequence of the activation of the HPA 
axis (CRF=> ACTH= cortisol synthesis). Anti-inflammatory steroids are comparable 
to the endogenous steroid hydrocortisone. Annexin Al has been shown to mediate 
many glucocorticoids induced anti-inflammatory effects (Goulding & Guyre, 1993a). A 
large amount of physiological and pharmacological research over the past 25 years in a 
wide range of animal models using recombinant annexin Al and its derived mimetics 
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indicate annexin Al regulates the inflammatory response. Originally the anti- 
inflammatory activity of annexin Al was attributed solely to its ability to inhibit PLA2 
(Blackwell et al., 1980), and thus the production of eicosanoids. More recently it has 
become clear that this is a non-specific activity, as nearly all annexins display similar 
effects on PLA2 (Raynal & Pollard, 1994), although annexin Al is the only member of 
the annexin family regulated by glucocorticoids known to date. Annexin Al's anti- 
inflammatory activity is almost certainly pleiotropic yet specific as it interferes in 
several features of the inflammatory response including neutrophil and monocyte 
activation and migration (Flower, 1988; Getting et al., 1997; Lim et al., 1998). The 
extracellular actions of annexin Al on cells during the inflammatory response are 
significant and parallel many of the effects of glucocorticoids. 
It was Becker et al., in 1988, who demonstrated that dexamethasone inhibition of 
macrophage phagocytosis was mediated by a glucocorticoid induced protein termed PIP 
(Phagocytosis Inhibitory Protein) (Becker et al., 1988). PIP suppresses phagocytosis of 
murine peritoneal macrophages. However, the annexin Al neutralising antibody 
abolished this antiphagocytic activity, suggesting that PIP and annexin Al were most 
probably synonymous (Becker & Grasso, 1988). The immunoneutralisation strategy 
has been used in other studies to confirm many of the anti-inflammatory activities 
produced by glucocorticoids were reliant upon annexin Al. Passive immunisation of 
mice with annexin Al neutralisation serum abolishes the inhibitory effects of 
dexamethasone on neutrophil migration in the murine air pouch (Perretti & Flower, 
1993) and hamster check pouch (Mancuso et al., 1995). In both these assays, the 
annexin Al mimetic Ac2-26 mimics the effect of glucocorticoids reducing neutrophil 
migration. Also passive immunisation to annexin Al increased cytokine production and 
neutrophil migration (Perretti, 1998). Furthermore, the inhibitory effects of 
dexamethasone are impeded, as both neutrophil and monocyte recruitment is reduced 
during zymosan peritonitis (Getting et al., 1997). 
Intravital microscopy studies have revealed an inhibitory role for annexin Al during 
leukocyte trafficking. Both recombinant annexin Al and the peptide Ac2-26 cause 
detachment of adhering leukocytes to the endothelial wall of capillaries (Lim et al., 
1998). This phenomenon of "annexin Al induced detachment" correlates with the 
ability, annexin Al and its mimetics have on systemic neutrophilia (Harris et al., 1995). 
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The peptide Ac2-26 causes a concentration dependent inhibition of peritoneal 
macrophage phagocytosis (Getting et al., 1997) and suppresses the respiratory burst 
(Euzger et al., 1999) when incubated in vitro with human blood monocytes. 
During the development of the phagosome during phagocytosis members of the annexin 
family have been implicated. As an example, during neutrophil phagocytosis of 
opsonised yeast annexin AIII translocates from the cytoplasm to the phagosome (Ernst, 
1991). Focusing on endogenous annexin Al in the macrophage: annexin Al is the main 
component of the annexin family involved in this process and has been shown to 
translocate from the cytoplasm to the phagosome rapidly (Harricane et al., 1996). 
Annexin Al may also be involved in endosome-phagosome interactions culminating in 
phagosome maturation in the macrophage. 
Deletion of the N-terminal domain of annexin Al alters its cellular distribution during 
phagocytosis indicating a regulatory role for the N-terminal domain in this process 
(Seemann et al., 1996). When Ser-27 is phosphorylated, the ability of annexin Al to 
aggregate liposomes is abolished (Porte et al., 1996) and is no longer associated amid 
the phagosomal protein complex (Harricane et al., 1996). 
Thus, there is a wealth of experimental evidence supporting the importance of annexin 
Al as an anti-inflammatory protein and its involvement during the innate inflammatory 
response, in particular neutrophil activation and macrophage phagocytosis. 
Characterisation of the potential changes in the latter two phenomena due to the absence 
of endogenous annexin Al will be a major aim of this thesis. 
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MODEL OF OUTCOME REFERENCE 
INFLAMMATION 
Carrageenin arthritis Ac2-26 reduced severity of (Yang el at, 1997) 
(rat) arthritis 
Carrageenin paw oedema Annexin Al reduces fluid (Cirino cal al., 1993) 
(rat) accumulation 
Carrageenin paw oedema Annexin Al null mice produce a (Roviezzo el a!., 
(mouse) more pronounced inflammation 2002) 
Cheek pouch inflammation Ac2-26 delays leukocyte (Mancuso el al., 
(hamster) migration 1995) 
IL -1 (3 peritonitis Ac2-26 induces detachment of (Lim el a!., 1998) 
(mouse) rolling leukocytes 
IL-I (3 air pouch Ac2-26 reduces neutrophil (Perretti & Flower, 
(mouse) migration 1993) 
Ischaemia reperfusion Annexin Al reduces infarct size (D'Amico el al., 
(rat) 2000) 
Macrophage activation Annexin Al reduces superoxide (Maridonneau-Parini 
(human) generation el al., 1989) 
Monocyte activation Ac2-26 reduces PMA induced (Fuzger el at. 1999) 
(human) ROS production 
Monocyte activation Act-188 inhibits TNF and PGF2 (Sudlow ef a!., 
(human) synthesis 1996) 
Neutrophil recruitment Annexin Al induces L-sclectin (Strausbaugh & 
(human) shedding Rosen, 2001) 
Zymosan peritonitis Ac2-26 inhibits neutrophil & (Getting el al., 
(mouse) monocyte recruitment 1997) 
Table 1.4 The anti-inflammatory properties of recombinant annexin Al and 
its mimetics, have shown to posses in many in vivo and in vitro models. 
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DISEASE ANNEXIN Al 
... 
REFERENCE 
CNS pathology During alzheimer's disease, staining is ([herhard et 
(hippocampus) reduced in tangles and degenerating neurones al., 1994) 
Crohn's disease IgM auto-antibodies to annexin Al is (Stevens et al., 
(serum) elevated 1993) 
Cystic fibrosis Is metabolised abnormally to a 33 kDa (Tsao et al., 
(BAL fluid) protein 1998) 
Fragile X syndrome Is metabolised abnormally (Sun et al., 
(lymphocyte) 2001) 
Hairy cell leukaemia Is highly expressed on cell membrane (Falini et al., 
(B-cell) 2004) 
Lung cancer Is highly expressed in adenocarcinomas, with (Brichory ei 
(tumour and serum) the synthesis in auto-antibodies al., 2001) 
Multiple sclerosis Is highly expressed at lesion edges, in plaque (Probst-Cousin 
(plaques) on macrophages and astrocytes et al., 2002) 
Perennial rhinitis Is highly expressed on ciliated cells in the (Rodrigo et 
(turbinates) epithelium & migrated neutrophils al., 2004) 
Prostate cancer mRNA is decreased in hormone refractory (Xin et cal., 
(tumour) Pca compared to hormone sensitive cells 2003) 
Psoriasis Is highly expressed on keratinocytes (Kitajima ei 
(lesion) al., 1991) 
Rheumatoid arthritis Auto-antibodies, may play a pathological (Podgorski et 
(blood) role by dampening annexin Al's effects al., 1992) 
Table 1.5 Malfunction of endogenous annexin Al, associated with the 
involvement in human disease. 
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Three-dimensional structures of 
A) annexin I comprising protein core B) annexin I lacking the first 32 amino 
and N-terminal domain acids 
repeat IVn (A repeat II ..,.. ý.,. ,,, fvNvat III 
°I 
HZN COOH 
Anti-Flammin 2 
CH -CO AMVSEFLKOAWFIENEEOEYVOTV 
Peptide Ac2-26 
Figure 1.5 Annexin Al structure. (A) Ribbon diagram of (a) protein core 
domain and the N-terminal domain (b) human annexin Al lacking the first 32 amino 
acids (Rosengarth et al., 2001). (B) A cartoon illustration of annexin Al and its 
mimetic (peptide Ac2-26 and AF 2) derived from it. 
O Ca++ 
/ANX-A1 (1-188) 
Iý, 
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1.3.3 The annexin Al binding site 
Annexin Al's anti-inflammatory properties have been established over the past quarter 
of a century, yet its mechanism of action is still incompletely elucidated. Many have 
postulated a physiological anti-inflammatory mechanism of action for this protein as 
discussed on the preceding pages. The extracellular binding of annexin Al and Ac2-26 
on monocytes and neutrophils has been shown to mimic many of the effects seen with 
corticosteroid suppression during the inflammatory response, for instance inhibiting 
superoxide generation in monocytes (Euzger et at, 1999). When monocytes and 
neutrophils are pre-treated with annexin Al they demonstrate inhibition of Fcy receptor 
binding, which directly relates to the extent of annexin Al binding site expression on 
the cell surface (Goulding & Guyre, 1993a). This may account for the impaired 
phagocytosis and subsequent ROS generation described previously. Annexin Al's 
number of receptors for binding to neutrophils during murine peritonitis and rheumatoid 
arthritis on synovial cells appears to be reduced relative to naive cells (Goulding & 
Guyre, 1993b; Perretti & Flower, 1993). Thus, during the inflammatory process 
impaired annexin Al binding to primed cells may contribute to the ongoing 
inflammatory response. Specific protease-sensitive binding sites for annexin Al have 
been detected on the extracellular membrane of neutrophils and monocytes (Euzger et 
al., 1999). This binding site appears to be modulated by different mechanisms 
depending on the leukocyte population; the neutrophil binding affinity for annexin Al 
increases following adhesion to endothelial cells, thus perhaps increasing the chances of 
detachment; while annexin Al binding to the plasma membrane on monocytes is 
instrumental in its inhibitory properties. Further characterisation of the annexin Al 
binding site may explain the need for the protein to translocate to the plasma membrane 
to implement its anti-inflammatory activity. 
1.3.3.1 The FPR(s) and annexin Al 
It was Walther et al., (2000) who published the first convincing evidence of the 
existence of a functional interaction between the annexin Al mimetic Ac2-26 and the 
receptor for fMLP (FPR) on the surface of human monocytes and neutrophils. This 
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study used calcium flux and L-selectin shedding assays illustrating that annexin Al N- 
terminus interacts with the FPR on neutrophils, eliciting receptor-mediated cellular 
responses leading to the inhibition of neutrophil migration (Walther et al., 2000). 
Furthermore, they showed that relatively low peptide concentrations, which possibly 
occur during the inflammatory response, cause calcium transients without activating cell 
transduction pathways. Furthermore, the FPR antagonists Boc 1 and Boc 2 exert a 
potent antagonism on the anti-migratory action associated with the annexin Al mimetic 
Ac2-26 during murine peritonitis; Ac2-26 nearly lost all its anti-migratory effects in 
FPR KO mice (Perretti et al., 2001). Nevertheless, full length Annexin Al protein 
retained a good degree of efficacy in both Boc-treated and FPR KO mice signifying the 
existence of an additional receptor(s) or mechanism of action for annexin Al (Perretti et 
al., 2001). The annexin Al mimetic Ac2-26 has also been shown to protect against 
myocardial ischaemia reperfusion in the rat heart and these protective properties are 
abrogated in the presence of the FPR antagonist Boc 2 (La et al., 2001). This suggests 
that annexin Al must interact with the FPR to a certain degree, protecting 
cardiomyocytes during ischemia reperfusion. Recently, Perretti et al., (2002) have 
correlated the actions of non-steroidal anti-inflammatories with glucocorticoids at the 
molecular level; both aspirin and dexamethasone share the ability of inhibiting 
leukocyte migration, initially thought to work through diverse mechanisms. However 
this study, using in vivo air pouch and in vitro ligand binding and chemotaxis assays, 
suggested that both annexin Al and lipoxin directly interact with human ALXR/FPRL1. 
Thus, steroidal and NSAID's functional pharmacology might overlap by converging 
onto at least one identical anti-inflammatory receptor (Perretti et al., 2002). 
1.3.3.2 The FPR s) nomenclature and function 
The FPR family of receptors have an interesting story yet perplexing nomenclature. 
The human FPR was initially cloned in 1990 (Boulay et al., 1990) and belongs to the 
seven transmembrane GPCR family. It is expressed in high levels in neutrophils and 
monocytes and its actions are pertussis toxin sensitive. The FPR is one of the best 
studied chemoattractant receptors, in line with other chemoattractant receptors it 
produces a range of responses upon cell activation including stimulating F-actin 
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formation, endocytosis, changes in CAM and promotion of leukocyte migration; at 
higher doses of ligand the opening of calcium channels occurs, correlating with the 
induction of exocytosis and respiratory burst (Ali et al., 1999). The FPR is a well 
characterised receptor, yet the endogenous ligand is obviously not fMLP, Table 1.6 
illustrates this receptor to be promiscuous for a plethora of biologically diverse ligands. 
In humans two additional genes encode FPR subtypes, designated FPRL 1 (FPR like 1) 
and FPRL2 (FPR like 2), both are present on neutrophils and monocytes. All three 
genes are clustered on chromosome 19 and the pattern of expression of these genes can 
be seen in Table 1.6. The FPR binds fMLP with approximately 1000-fold higher 
affinity than the FPRL 1, resulting in calcium mobilisation. FPRL 1 is also known as 
ALXR and is highly expressed on murine neutrophils (Takano et al., 1997). Lipoxin A4 
and annexin Al are the endogenous ligands for this receptor. When LXA4 and aspirin 
triggered lipoxin acts on ALXR they inhibit neutrophil migration in vivo (Takano et al., 
1997) and neutrophil transmigration in vitro, whereas it seems that synthetic ALXR 
ligands such as MMK-1 stimulate chemotaxis and other pro-inflammatory signals 
(Chiang et al., 2000). 
In rodents evolution of the FPR family is more complicated. This is reflected in the 
current nomenclature of the murine FPR gene family (Wang & Ye, 2002), which has at 
least eight members compared with the human family see Table 1.6. However, only 
three of these eight members appear to be functional. mFPR (murine FPRI) is 
considered the murine orthologue of human FPR, whereas Fpr-rsl and Fpr-rs2 encode 
receptors that are structurally and functionally similar to FPRL1 (Takano et al., 1997) 
as can be seen from Table 1.6. 
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RECEPTOR AGONISTS EXPRESSION 
HUMAN 
FPR fMLP, HIV envelope Neutrophils, 
peptides, Monocytes, 
WKYMVm peptide Dendritic cells 
Annexin peptidesAc 1 -26 Endothelial cells 
A9-25 Hepatocytes 
Astrocytes 
Nervous system 
FPRL1 Lipoxin A4, SAA, HI', Neutrophils, 
ALXR fMLP, WKYMVm peptide, Monocytes, 
HIV envelope peptides, Epithelial cells, B 
gp4I derived peptides Lymphocytes 
MMK-1 , PrP' 
6 126 Spleen, Lung, Testis 
annexin Al, Ac2-26, Ac2- 
12 
FPRL2 FMLP, annexin Al, Ac2- Macrophages, Dendritic 
26, Ac2-12 cells 
MOUSE 
mFPRI fMLP, HIV envelope Neutrophils, 
peptides, Ac2-26 Spleen, Lung, 
Liver, Mononuclear cells 
Fpr-rsl LXA4, Ac2-26 Neutrophil, Spleen, Lung, 
iLXAR Heart, Liver 
Fpr-rs2 FMLP, HIV envelope Neutrophil, Microglia, 
peptides, SAA Spleen, Lung 
Table 1.6 FPR agonists and expression in human and mouse This table is an 
amalgamation of data reviewed (Le et al., 2002). 
55 
Chanter 1 Introduction 
1.4 Knock out mice 
Millions of mice are bred each year and utilised in science to mimic human diseases, 
screen pharmacological and physiological effects of drugs and toxins. Ninety percent 
of mammals used in research are mice. The mouse genome has been sequenced and 
99% of it has direct counterparts within the human genome (Gunter., 2002). The 
history of the genetic lab mouse started in 1909 with the dilute brown non-agouti, a 
recessive mouse bred at Harvard Medical School. However, it wasn't until the late 
1970's and early 1980's that saw the advances in molecular biology and recombinant 
DNA technologies being applied to the mouse (Maher, 2002). The emergence of 
knockout mice allowing scientists to silence certain genes by deleting critical exons, as 
well as the over expressing transgenic mice, has had an impact on pharmacological and 
physiological research. With the emergence of more novel genetic manipulation, for 
instance over expressing mice and RNA interference technology, genetically modified 
mice shall not only be an ends to a means, however, it shall be the experiment itself. 
Gao et al developed a FPR KO mouse reporting that these mice have no obvious 
developmental defects. However, we have found them very slow to breed and whilst it 
did not develop spontaneous infection in pathogen-free conditions, it appeared to be 
more susceptible to bacterial infections (Gao et al., 1999). 
During the course of this PhD. our department at the William Harvey Research Institute 
have developed the only annexin Al-null mouse (Hannon et al., 2003). These mice 
appear to be more vulnerable to inflammatory stimuli for instance, in the mouse paw 
carrageenin-induced oedema, annexin Al null mice displayed increased sensitivity to 
this inflammatory stimulus. For specific phases of the inflammatory response these 
mice appear to be resistant to glucocorticoids relative to their wild type littermates. 
These two groups of genetically modified mice play a pivotal role throughout this 
thesis. 
More recently Dr N Wells (Imperial College London) has developed and provided our 
department with an annexin Al over expressing mouse. This strain express enhanced 
levels of the annexin Al protein. 
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4 to 4AW 
Annexin Al null Wild Type 
Figure 1.6 Lac z staining of annexin Al null and WT ear clips confirming 
genotype. Ear clips of in bred mice bred from either genotype were taken at random, to 
confirm our breeding programme is proceeding in the approved manner by blue Lac z. 
staining (Hannon etal., 2003). 
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Aim of this thesis 
The aim of this thesis is to assess the patho-physiological biology, of the endogenous 
anti-inflammatory mediator annexin Al, using for the first time a combined 
pharmacological and genetic approach. 
Goals of this thesis 
In particular, I have taken advantage of this integrated approach to analyse, on one 
hand, the functional role of endogenous annexin Al, and on the other hand the 
receptor(s) potentially involved in annexin Al behaviour on the complex process of cell 
activation. Thereby, I have focused on a series of in vitro assays to study two leukocyte 
populations central to host innate inflammation, the resident macrophage and the 
circulating neutrophil. 
Key questions addressed 
To what extent do neutrophils lacking the FPR respond to inflammatory 
mediators, in particular fMLP? 
Does annexin Al operate solely through the FPR1 in the murine neutrophil? 
Do neutrophils lacking annexin Al respond to inflammatory mediators in an 
analogous fashion, compared to wild type cells? 
Is phagocytosis affected between littermate (wild type) and annexin Al null 
macrophages? 
Does annexin Al play a role during macrophage phagocytosis? 
_% 
Are annexin Al macrophages still sensitive to glucocorticoids? 
58 
CHAPTER 2 
Methods and Materials 
Chapter 2 Methods & Materials 
2.1 Animals 
Genetically modified mice: FPR KO mice, back-crossed for six generations with 
C57BL/6 mice, were generated at the National Institute for Health, Maryland, USA (a 
generous gift from Gao (Gao et al., 1999). This colony was re-established at the 
William Harvey Research Institute, BSU. C57BL/6 mice (purchased from Banton and 
Kingsman, Hull, UK) body weight 20-22 g were used as wild type control animals. 
Using conventional gene targeting technology our department has constructed the only 
annexin Al null mouse colony (Hannon et al., 2003). Annexin Al null mice were bred 
alongside their littermate control wild type mice in the William Harvey Research 
Institute, BSU clean unit. The annexin Al null mice were generated with conventional 
techniques and dual purpose targeting (i) to inactivate the gene (ii) to report on gene 
activity through the annexin Al promoter. Gene activity could be measured by Lac z 
staining, and was carried out at regular intervals to confirm mice genotype, see Figure 
1.6 and 2.1. All animals were maintained on a standard chow pellet diet with tap water 
ad libitium and a 12 h light / dark cycle. Animals were housed for l week prior to 
experimentation allowing body weight to reach 25-30 g. All experiments were carried 
out in accordance with the UK Animals (Scientific Procedures) Act 1986. 
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Figure 2.1 Structure of the annexin Al gene (A) Structure of murine annexin Al 
gene (the horizontal line). Unfilled boxes are untranslated exons; filled boxes are 
translated exons. (B) Structure of the targeting construct. Lac z and Neo sequences are 
shown boxed; note the absence of exons 3 and 4. (C) Structure of the correctly targeted 
allele. Adapted from (Hannon et al., 2003). 
60 
Chapter 2 Methods & Materials 
2.2 Flow Cytometry 
Flow cytometry is a rapid method used for the quantitative analysis of cell protein 
expression, regulation, function and kinetics by determining light scatter and the 
fluorescent properties of leukocyte populations, depending on an optical-to-electronic 
coupling system. This technique enables cells to be distinguished according to their 
unique size, granularity and fluorescence properties. As cells enter the flow cytometer, 
they are accelerated past a beam of light, one at a time this light is scattered in many 
directions. These resulting signals may be measured, by the means of separate light 
detectors making rapid measurements on cells as they flow in this fluid stream one by 
one through a sensing point. Forward Scatter relates to cell size whilst Side Scatter 
determines the granularity of the cell. The FACScan or FACScalibur (Becton 
Dickinson, Cowley, UK) are capable of measuring three different spectral regions of 
fluorescence intensity. An air-cooled 100 mW argon ion laser emits a blue light beam 
at 488 nm, measurements are made on a cell by cell basis, at a rate of 100-4000 cells per 
second. Any fluorochrome molecules attached to the cell absorb energy from the argon 
laser, become excited and emit photons at a higher wavelength (fluorescence): FL-1 
(yellow/green) FL-2 (red/orange) and FL-3 (red). Thus, distinct cell population's 
fluorescence may be studied simultaneously. 
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Figure 2.2 A typical flow chamber. Cells are passed through the chamber as single 
cells. The beam of the laser light excites the cells and each cell scatters some of light as 
well as emitting fluorescent light following excitation by the laser. Data may then be 
analysed by light scatter and fluorescence by specific detectors. 
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2.3 Neutrophil assays 
2.3.1 CAM measurements on the neutrophil and monocyte 
Cell surface adhesion molecule expression on leukocytes was assessed using 
fluorescence flow cytometry. This technique allows alterations in murine leukocyte 
adhesion molecule expression, induced by incubation of varying concentrations of 
inflammatory mediators, to be measured in vitro. 
Mice were bled by cardiac puncture under halothane (3%) anaesthesia, using 
heparinised syringes (10 pl of 2000 U/ml). Blood was pooled in 15 ml tubes, 
siliconised the previous day with SigmacoteTM to prevent adherence of leukocytes and 
clotting. Aliquots of blood (950 µl) were then incubated with 50 µl of agonist either 
PBS (vehicle), fMLP (1-30 µM), PAF (0.3-3 µM) or PMA (1-10 µM) for 10-15 min at 
37'C in a slow moving water bath 60 cycles/min. In certain experiments blood was 
preincubated with antagonists PBS (vehicle), Ac2-26 (200 pg/ml) or Boc 2 (1 x10-4 M) 
for 10 min, prior to the addition of agonist. Cells were then washed with 5 ml of PBS 
supplemented with 3% sodium azide (400 x g, 5 min, 4°C). Aliquots (200 µl) of blood 
were labelled with either 50 pl of rat anti-mouse CDI lb (5 pg/ml; clone 5C6; Celltech, 
UK) or rat anti-mouse CD62L (5 µg/ml; clone MEL14; A gift from P Hellewell, 
University of Sheffield, UK) for 60 min at 4°C; the concentration of antibody chosen 
following antibody titration see Figure 2.3b. After two washes with PBS, cells were 
stained with 50 µl (1: 80 dilution of stock) of fluorescein isothiocyanante (FITC)- 
conjugated rabbit anti-rat IgG antibody (Serotec, UK), and samples were incubated for 
5 min at room temperature. Following two washes in PBS, erythrocyte lysis was 
performed with Immuno-Lyse'" (Coulter, UK): 1 min incubation with the lysis solution 
(1 ml of 1: 25 dilution of the stock solution) followed by the addition of 250 pl fixative. 
After two washes in PBS flow cytometry was performed using a FACScan (Becton 
Dickinson, Cowley, UK) with an air-cooled 100 mW argon ion laser tuned to 488 nm 
connected to a Apple Mac G3 computer running Cell Quest II software. Forward 
(relating to cell size) and side (determining granularity) scatter characteristics were used 
to distinguish between the three distinct cell populations (lymphocytes, monocytes and 
PMN), see Figure 2.3A. The rat anti-mouse CD1lb antibody recognised the 
CD 11 b/CD 18 antigen on neutrophils and monocytes as these leukocytes are known to 
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express this adhesion molecule on their cell surface, whereas lymphocytes as expected 
did not express the antigen. The number of molecules of endogenous CD I lb/CD 18 per 
sample was quantified in median fluorescence intensity (MFI) units in the FL-I channel 
(wavelength of 548 nm). 
ö 
-ý ý -ý 
A 
200 400 600 800 
SSC-H 
B 
O 
100 , o` 
FL1 H 
Figure 2.3 Flow cytomete plots (A) A typical dot plot of FSC versus the SSC in a 
mixed population of murine leukocytes. The distinct cell populations could be identified 
on the basis of their different scatter characteristics as indicated above. RI (Green) with 
a relatively large SSC is the PMN population. R2 (purple) with the relatively high FSC 
is the monocytic population. R3 (brown) with the Low FSC and SSC is the lymphocyte 
population. (B) Rat anti-mouse CD 1lb antibody (clone 5C6) was incubated at different 
concentrations (Black 0 g/ml, Orange 0.1 µg/ml, Green I µg/ml blue 5 . tg/ml grey 10 
µg/ml and pink 15 µg/ml) for 1h at 4 °C, samples were stained with FITC anti rat IgG 
and prepared for flow cytometry analysis. 
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2.3.2 Cytoskeletal alterations during n eutrophil activation 
F-actin polymerisation during neutrophil activation was measured by a single step 
technique using N-(7-nitrobenz-2-oxa-1,3-diazole-4y1) (NBD)-phallacidin. Phallotoxins 
are isolated from the deadly Amanita phalloides mushroom and bind F-actin. 
Polymerisation of actin subunits to filamentous actin occurs rapidly during neutrophil 
activation, prior to these filaments dissociating back to their actin subunits. (NBD)- 
phallacidin, allowed for the visualisation of cytoskeletal reorganisation during this 
process. 
Mice were bled by cardiac puncture under halothane (3%) anaesthesia, using 
heparinised syringes (10 gl of 2000 U/ml). Blood was transferred into 3 ml Dextran 
T500 solution (1.25% in saline). Tubes were filled up to a total of 10 ml with the 
Dextran solution and inverted once. Erythrocytes were allowed to sediment for 30 min 
at room temperature. The leukocyte-rich supernatant was collected and the sedimented 
erythrocyte population discarded. Following two washes with PBS supplemented with 
0.5 % BSA (400 x g, 5 min, 4°C), erythrocytes were removed by hypotonic lysis. 7.5 ml 
of distilled ice cold water was added then gently inverting the tube ten times, followed 
by hypertonic rescue of leukocytes with 2.5 ml of 3.6 % sodium chloride solution 
supplemented with 0.1% glucose and inverted once again. Following another two 
washes with PBS supplemented with 0.5 % BSA (400 x g, 5 min, 4°C), aliquots (1 ml) 
of leukocytes were resuspended in RMPI 1640 supplemented with 2% FCS before 
being incubated with 10 µl of agonist, either PBS (vehicle), fMLP (1 µM) or PAF (1 
µM), at 37°C in a slow moving water bath 50 cycles/min. At particular time points 0- 
45 - 180 - 300 and 600 seconds, 100 µl of cells were placed into an eppendorf 
containing 100 µl of PBS supplemented with 8% paraformalhyde (pH 7.4), 0.2 mg/ml 
lysophosphatidylcholine and 0.3 mM NBD-phallacidin (Molecular Probes, USA), and 
incubated in the dark for 30 min at room temperature. The cells were then washed with 
PBS in a micro centrifuge (1500 rpm, 5 min), prior to being resuspended in 200 .d 
PBS. 
Flow cytometry was performed using a FACScalibur (Becton Dickinson, Cowley, UK) 
with an air-cooled 100 mW argon ion laser tuned to 488 nm connected to a Apple Mac 
G3 computer running Cell Quest II software. Forward (relating to cell size) and side 
(determining granularity) scatter characteristics were used to distinguish between the 
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three distinct cell populations (lymphocytes, monocytes and PMN). An increase in 
florescence inferred actin monomer polymerisation to F actin. 
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Figure 2.4 F actin polymerisation, in activated neutrophils. Preliminary data 
collected from isolated human neutrophils, treated with 1 µM fMLP. Neutrophils 
become highly activated, as assayed by the transient polymerisation of actin. 
2.3.3 ROS production in activated neutrophils 
The neutrophil ROS burst is associated with the neutrophil during cellular activation 
and phagocytosis. Dihydrorhodamine 123 (DHR 123) (Molecular Probes, USA) 
allows for the quantification of reactive oxygen intermediates produced by murine 
phagocytes. DHR 123 is the uncharged and non-fluorescent reduction product of the 
mitochondrion-selective dye rhodamine 123, which passively diffuses across leukocyte 
cell membranes where it is oxidised to cationic rhodamine 123. DHR 123 does not 
directly detect superoxide, but rather reacts with hydrogen peroxide in the presence of 
peroxidase, cytochrome C, peroxynitrate or Fee+. DHR 123 reacts with the fluorescent 
form that can be detected in the FL-i channel of the flow cytometer. 
Mice were bled by cardiac puncture under halothane (3%) anaesthesia, using 
heparinised syringes (10 µl of 2000 U/ml). Blood was transferred into 3 ml Dextran 
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T500 solution (1.25% in saline). Tubes were filled up to a total of 10 ml with the 
Dextran buffer and inverted twice. Erythrocytes were allowed to sediment for 30 min at 
room temperature and the leukocyte-rich supernatant was collected and washed (400 x 
g, 5 min, 4°C). Erythrocytes were removed as described in section 2.3.2 prior to two 
subsequent washes with PBS supplemented with 0.2 % BSA (400 x g, 5 min, 4°C), 
aliquots from 3 mice were pooled together and resuspended to 1.5 ml of leukocytes in 
PBS supplemented with 0.2 % BSA. 50 gl of cell suspension was added to 200 µl 
saline supplemented with 5 mM HEPES pH 7.4. Cells were allowed to equilibrate to 
their new environment for at least 30 min in a water bath at 37°C. Cells were then 
loaded with 2 mM (stock) DHR 123 (1 . 
d) for 10 min, allowing the DHR 123 to diffuse 
across the cell membrane and enter the mitochondria, prior to stimulation with the 
agonist saline (vehicle) or PMA (0.1 µM). The reaction was halted at particular time 
points: 0-1-5- 15 and 20 min with ice cold PBS supplemented with 4% 
paraformaldehyde. Samples were placed in an ice bath and analysed immediately by 
flow cytometry. Flow cytometry was performed using a FACScan (Becton Dickinson, 
Cowley, UK) with air-cooled 100 mW argon ion laser tuned to 488 nm connected to a 
Apple Mac G3 computer running Cell Quest II software, in the FL-1 channel 
(wavelength of 548 nm). An increase in fluorescence inferred greater production in 
ROS intermediates. 
2.3.4 Neutrophil isolation 
Magnetic bead technology allows for efficient enrichment or depletion of specific 
mixed cell populations. A novel technique allowing for pure neutrophil fractions to be 
isolated from whole blood, by negative magnetic cell sorting has recently been 
developed. This technique involves labelling unwanted cells and eliminating them from 
whole blood, by MicroBead staining then passing the cells through a separation column 
in a strong magnetic field (Cotter et al., 2001). The magnetically labelled cells are 
retained in the column, whilst unlabeled neutrophils pass through allowing for the 
collection and utilisation of isolated circulating murine neutrophils. 
Mice were bled by cardiac puncture under halothane (3%) anaesthesia, using 
heparinised syringes (10 gl of 2000 U/ml). Blood was transferred into 3 ml Dextran 
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T500 solution (1.25% in saline). Tubes were filled up to a total of 10 ml with the 
Dextran solution and inverted. Erythrocytes were allowed to sediment for 30 min at 
room temperature and the leukocyte-rich supernatant was collected. After two washes 
with PBS supplemented with 0.5 % BSA (300 x g, 6 min, 4°C), the leukocyte 
population was resuspended to 200 µl in PBS and a total leukocyte count was 
performed. 10 pl of cells was diluted in 90 µl Turk's solution, the samples were then 
vortexed, and 10 gl of the stained cell solution was placed in a Neubauer 
haematocymometer for quantification. Only the cells in the middle 20 squares of the 
chamber were counted. Identification of the different leukocyte cell types was 
performed using the following criteria as a standard: neutrophils and eosinophils were 
easily identifiable by their multilobular nuclei, the presence of a cytoplasm and a strong 
uptake of stain; monocytes and macrophages had a single kidney shaped nucleus and a 
much larger cytoplasm, which stained pale blue; lymphocytes had a large round dark 
staining nucleus, which formed the majority of the cell and a small cytoplasm illustrated 
in Figure 1.2. Following counting in the Neubauer haematocytometer, the total number 
of cells was calculated according to the following formula: 
Number of cells counted in the grid x 10 (dilution factor) x 104 (factor of 
chamber) = Number of cells per ml of fluid 
Number of cells per ml of fluid x2 ml (volume of leukocyte suspension) _ 
Number of cells in leukocyte suspension. 
Differential leukocyte cell counts for the strain of mouse used were also performed. 
Lymphocytes constitute 70% of mouse leukocyte population in all strains assessed 
however, the monocyte population differs in the: Balb C 4% - C57BL/6 11% - Annexin 
Al null mice 8% FPR KO 7%. An antibody cocktail targeting lymphocytes and 
monocytes (non-neutrophil) murine peripheral leukocytes was selected (Cotter et al., 
2001). Anti-CD2 (1.5 µg/106 lymphocytes), anti-CD5 (2 µg/106 lymphocytes); and anti- 
CD45R (10 µg/106 lymphocytes) were chosen to specifically label lymphocytes, anti- 
F4/80 antigen (2 µg/106 monocytes) to specifically label monocytes; and anti-ICAM-1 
(0.6 µg/106 leukocytes) as a pan-lymphocyte / monocyte antibody. Flow cytometry was 
used to determine that the antibodies specifically bound non-neutrophil cell types as 
described in section 2.3.1. The antibody cocktail was incubated for 30 min at 4°C. 
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After 2 washes with PBS, cells were resuspended in 80 µl PBS and incubated with goat 
anti-rat IgG MicroBeads (20 µl/10' cells) at 4°C for 15 min. A chilled BS separation 
column connected to a VarioMACS'" magnet (Miltenyi Biotec, Bisley, UK) was 
prepared with cold sterile water and buffer according to manufactures instructions. The 
leukocyte MicroBead mixture was added to the column and the neutrophil rich effluent 
collected. Unwanted cells, labelled with the magnetic beads were retained within the 
metallic matrix of the column; the procedure was performed at 4°C. To conceptualise 
the procedure see Figure 2.5. 
Magnetic labeling " 
with MACS MicroBeads I 
Positive selection " 
using a MACS Column ý 
P,. 
H 
Non-magnetic 
Elution of positively " fraction 
selected cells 
Figure 2.5 Separation of peripheral murine neutrophils using MACS 
technology. The diagram illustrates negative selection strategy, antibody targeting non- 
neutrophil cells allowing a highly pure neutrophil fraction to elute the column (taken 
from www. miltenyibiotec. com). 
The neutrophil rich effluent was washed twice. Erythrocytes were removed with 
hypotonic lysis that is by adding 7 ml of 0.2% sodium chloride solution then gently 
inverting the tube ten times, followed by hypertonic rescue of neutrophils with 7 ml of 
1.6% sodium chloride solution supplemented with 0.1% glucose and inverted once. 
Neutrophils were washed and resuspended in I ml of PBS. Total cell counts were 
performed using a Neubauer hemocytometer. Differential cell counts were performed 
using cytospins. Cytospins were prepared by loading 100 ml of the neutrophil 
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suspension (lx 106 cells/ml) into a Shandon cuvette and centrifuged onto the slide (500 
rpm, for 5 min), slides were left to air dry prior to staining with Diff-Quick rapid 
staining set consisting of 1. Methanol 2. Eosin 3. Methylene blue. Neutrophils were 
identified by their multilobular nuclei, from this data the purity and yield of neutrophils 
was established see Figure 2.6. Typically, the purity of the eluted cells was -97% 
neutrophils with a return of -0.6 x 106 neutrophils/mouse. Neutrophil purity was also 
established by flow cytometry, whole blood leukocytes were identified on a dot plot by 
forward and side scatter characteristics as described in section 2.3.1. The neutrophil 
population was separated using the granulocyte-specific antibody GR-1 following the 
same protocol as described in section 2.3.1. Gating this population revealed the number 
of neutrophils as a percentage of the acquired leukocyte events. Viability of isolated 
neutrophils was initially determined by flow cytometric analysis of the cell surface 
marker CD11b at basal 63±6 and following activation with fMLP 102±7 CDI lb 
expression on neutrophils as described in section 2.2.1. Thus, the results of these 
functional assays proved positive. 
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Figure 2.6 Neutrophil Purity of cells recovered after negative selection using 
MACS technology (A) Cytospin of eluted fraction illustrating the high yield of 
purified neutrophils. (B) Flow cytometric analysis of eluted leukocytes for the murine 
neutrophil marker GR-1 (purple) isotype control (green). 
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2.3.5 Chemotaxis assay 
Chemotaxis enables phagocytes to migrate from the circulation and accumulate at sites 
of inflammation and injury in response to proinflammatory chemical mediators 
(chemoattractants). This assay monitors in vitro neutrophil migration, from the upper 
chamber of a chemotatic plate through a semi-permeable membrane (with 3 µm pores) 
to the basement chamber beneath, containing a high concentration of chemoattractant. 
Mouse circulating neutrophils were isolated as described in the previous section 2.3.4 
and resuspended to a concentration of 4x 106 cells/ml in RPMI 1640 supplemented 
with 0.1% BSA. Neuro Probe ChemoTx-101-3T" (Gaithersburg, Maryland, USA) 96 
well disposal chemotaxis plates (3 µm pore size) were used. 27 µl of Chemoattractant: 
fMLP (10-1 nM), PAF (10-0.1 nM), Ac2-26 (30-10 µg/ml) or RPMI 1640 
supplemented with 0.1% BSA (vehicle) was negatively pipeted in duplicate into the 
basement wells, the polycarbonate filter was placed on top of chemoattractant, and 25 
µl (containing approximately 1 x105 cells) of the neutrophil cell suspension was placed 
on top of the filter. After a2h incubation at 37°C in a 5% CO2 / 95% 02 atmosphere, 
the remaining cells on top of the filter were aspirated with a cotton swab, the filter was 
washed three times with 25 pl (BSA free) RPMI 1640 medium to ensure removal of any 
non-migrated cells. The ChemoTx-3 ' plate was then centrifuged (312 x g, 5 min) to 
pellet the migrated cells from the undersides of the filter. The filter was removed and 
discarded; neutrophils that had migrated through the pores to the basement chamber 
were retrieved and resuspended by repeated pipetting. A total cell count was 
performed, 20 µl of cells was diluted in 20 pl Turk's solution, samples were then 
vortexed, 10 pl of the stained cell solution was placed in a Neubauer 
haematocymometer for quantification as described in previously in section 2.3.4, to 
ascertain the extent of neutrophil migration. A chemotaxis index was calculated by 
dividing the number of neutrophils migrated towards chemoattractant by control 
migration. In certain experiments chemoattractants were incubated along with the cells, 
in a checkerboard style fashion, to assess if the mediator itself was chemokinetic or a 
chemoattractant. 
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2.4 Macrophage assays 
Experiments concerning the characterisation of annexin Al null macrophages utilised 
two macrophage subsets. (1) The resident peritoneal macrophages and (2) bone marrow 
derived macrophages. 
2.4.1 Bone marrow derived macrophage differentiation 
Mice 4-6 weeks old were killed by exposure to CO2. The skin of the abdomen and hind 
legs were sterilised with 70 % ethanol spray. To expose the hind limbs, the skin was 
dissected away from the abdomen and hind legs following a transverse cut through the 
skin of the abdomen. The muscles attaching the hind limb to the pelvis and those 
attaching the femur to the tibia were dissected away exposing the bones. Only once the 
femur was well exposed the tibia was cut straight through beneath the knee joint, and 
the femur freed from the mouse by cutting through the pelvis close to the hip joint, the 
femur was stored in RMPI 1640 supplemented with 10 % FCS on ice for no more than 
5h at 4 T. Bones were then transferred onto a Petri dish containing 70 % ethanol 
solution for 1 min to maintain sterility, prior to washing the bones in tissue culture 
grade PBS. Each femur was then held firmly with forceps and in a single motion the 
epiphyses (expanded ends) were removed. A 10 ml syringe connected to a 25-gauge 
needle was placed into the bone shaft and PBS solution forced down the shaft flushing 
out the bone marrow. The bone became white when all the marrow was expelled. The 
marrow plugs were mechanically disrupted by puncture with a 19G needle twice prior 
to washing (1000 x g, 5 min, 4 °C). Cells were then resuspended in RPMI 1640 
supplemented with 25 mM HEPES pH 7.4,10 % FCS and 20 % LCM, 25 ml of cell 
suspension was plated onto 15 cm bacteriological plastic Petri dishes (1 dish per 
animal) and incubated at 37 °C in a 5% CO2 and 95% 02 atmosphere. Fresh RPMI 
1640 culture medium supplemented with 10 % FCS, 25 mM HEPES pH 7.4 and 15 % 
LCM was added on day 3 and at day 6. Cultures were confluent by day 7, incubating 
cultures with PBS supplement with 10 mM EDTA and 4 mg/ml liodocaine-HC1 for 10 
min prior to removal, loosened cells by pipetting allowing them to be harvested. 
Typically, the bone marrow from two femurs of one mouse gave 7-10 x106 
macrophages following 7 days in culture. 
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L929 supernatant: Frozen L929 fibroblasts, stored in liquid nitrogen (-196 °C), were 
thawed quickly in a 37°C water bath. RPMI 1640 supplemented with 10 % FCS was 
added so that the cells could adapt to the new osmolarity. Following two washes (500 
x g, 10 min), L929 fibroblasts were plated in T175 cm2 flasks with 40 ml RPMI 1640 
supplemented with 10 % FCS and incubated at 37 °C in a 5% CO2 and 95% 02 
atmosphere. Once the cells became confluent the medium was removed and washed 
twice with 100 ml PBS. Following the addition of 100 ml RPMI 1640 supplemented 
with 10% FCS, the cells were incubated for a further at 37 °C in a 5% CO2 and 95% 02 
atmosphere. On day 2 the supernatant medium was collected, washed (1000 x g, 5 
min) and filtered through a 0.22 . im filter. Aliquots of L929 cells in 10% DMSO and 
conditioned medium were then stored at -80 °C ready for use as and when required. 
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Figure 2.7 Stages of macrophage development in the bone marrow. 
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2.4.2 Harvesting peritoneal macrophages 
The peritoneal cavity was used for the collection of resident macrophages by lavage. 
Mice were killed by exposure to CO2. To expose the peritoneal cavity a small incision 
at the level of the abdominal midline was made and skin reflected back on both sides. 
The exposed cavity was injected with 3 ml of sterile PBS supplemented with 3 mM 
EDTA and 25 U/ml heparin. After gentle massage (-20 seconds) the cavity was opened 
by abdominal incision and lavage fluid collected with a sterile I ml plastic Pasteur 
pipette. Samples containing blood were deemed to be contaminated, and were 
discarded. The average recovery was 1.8-2.2 ml from the 3 ml injected. Samples were 
pooled in 15 ml polypropylene tubes and kept on ice until required. 
2.4.3 CAM expression on macrophages 
Cell surface adhesion molecule expression on macrophages was assessed using 
fluorescence flow cytometry. Saponin permeablisation of cells allowed quantification 
of total protein being quantified. 
Murine peritoneal macrophages collected or differentiated BMDMo were prepared as 
described in sections 2.4.1 and 2.4.2 above and placed on ice. An aliquot (100 µl) was 
taken and stained with 900 gI of Turk's solution to identify the different leukocytes 
present in the lavage fluid. The sample was then centrifuged at 400 xg for 10 min and 
the supernatant discarded. The pellet was then resuspended to a concentration of 1 x106 
cells/ml in PBC. 250 µl of cells were plated into 96 well plate (containing 
approximately 2.5 x105 cell/well) together with 20 µl blocking human IgG (y-gobilins, 
16 mg/ml) and 20 µl of rat anti-mouse CD 11 b (0.8 µg/ml; clone 5C6; Celltech, UK), rat 
anti-mouse F4/80 (5 gg/ml Clone CI: A31; Serotec, Oxford, UK), rat anti-mouse 
FcyRIII/II (5 µg/ml Clone 2.4G2 BD PharMingen) and rat anti-mouse dectin 1 (10 
µg/ml Clone 2A11, (a generous gift from Dr G Brown, Sir William Dunn School of 
Pathology, University of Oxford, UK) for 45 min at 4°C, the concentration of antibody 
was chosen. Following preliminary titration experiments. After three washes in PBC 
(2000 x rpm, 10 seconds), cells were stained with 40 µI (1: 80 dilution of stock) of 
FITC-conjugated rabbit anti-rat IgG antibody; samples were then incubated for 30 min 
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at 4°C. Following three washes in PBC, samples were resuspended in 200 µ1 PBC and 
flow cytometry was performed. 
For quantification of total cell CD11b expression, macrophages were initially fixed in 
2% paraformaldehyde at 4 °C for 30 min, prior to immunostaining. During the 
remainder of the staining process, a saponin (0.02%) was added to permeablise the cells 
throughout the experiment. In all cases, flow cytometry was performed using a 
FACScan (Becton Dickinson, Cowley, UK) with an air-cooled 100 mW argon ion laser 
tuned to 488 nm connected to a Apple Mac G3 computer running Cell Quest 11 
software. The rat anti-mouse antibody recognised the specific antigen on macrophages 
and the number of molecules of endogenous antigen per sample was quantified in 
median fluorescence intensity (MFI) units in the FL-1 channel (wavelength of 548 nm). 
Cells were also visualised by confocal microscopy. Cytospins of FITC labelled cells 
were prepared as described in section 2.3.4 and left overnight to air dry. The nuclear 
stain PI (15 µl) and SlowfadeTM (15 µl) were administered to the slide prior to mounting 
the cover slip. The cells were viewed on a Zeiss LSM 510 confocal microscope 
connected to a PC running LSM 510 software. 
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Figure 2.8 Representative flow cytometry analysis of antibodies. (A) CDI lb 
(clone 5C6) and (B) FcRyII/III (clone 24G2). Isotype control in grey and specific 
antibody binding to naive BMDMo is shown in black. 
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2.4.4 FcOxyburstTM kinetic assay 
Phagocytic uptake of antigen-antibody complexes by macrophages was monitored by a 
real-time flow cytometric assay (Getting et al., 1997). This assay relies upon the 
intracellular oxidation of an X-rhodamine derivative of dihydrodichlorofluorescein 
(XR-DHDCF: Molecular probes, USA), upon excitation at 488 nm it emits light at 670 
run, which is detectable in the FL-3 channel of the flow cytometer. The FcOxyburstTM 
RED reagent consists of XR-DHDCF conjugated to bovine serum albumin, which are 
subsequently reacted with rabbit polyclonal anti-BSA antibodies to form insoluble 
complexes in antibody excess. FcOxyburstTM complexes free in suspension, or bound to 
Fc receptors on the external face of the plasma membrane, are not susceptible to 
oxidation, thus the probe remains colourless. However, upon uptake into phagosomes 
and activation of NADPH oxidase, the FcOxyburstTM reagent is oxidised to the 
fluorescent form, which can be detected in FL-3 channel on the flow cytometer. 
Murine peritoneal macrophages were lavaged from the peritoneal cavity as described 
above, and placed on ice. An aliquot (100 µl) of the lavage fluid was then stained with 
900 µl of Turk's solution, described in section 2.4.2. Samples were then resuspended to 
a concentration of 5 x106 cells/ml in RPMI 1640 medium supplemented with 2% FCS. 
Macrophages (900 µl) were then treated with either PBS (vehicle) or 10 µM 
hydrocortisone in a 50 µl volume and incubated at 37 °C for 60 min in a slow moving 
water bath. The cell suspension was then diluted in Krebs' solution to a concentration 
of 1x 106 cells/ml. An aliquot of the cell suspension (250 µl) was removed and 10 µ1 
of FcOxyburstTM RED was added to 115 µl of Krebs' solution, both samples were then 
placed in a water bath at 37°C for 5 min allowing them to reach 37 °C. At time 0 the 
two samples were combined and uptake of these complexes by the peritoneal 
macrophages was monitored in real time by flow cytometry as described in section 
2.3.1. Quantification of the fluorescence was acquired in the FL-3 channel (670nm) 
during 204 seconds of reaction. Cumulative changes of fluorescence at constant time 
intervals were then constructed and the rate and maximum fluorescence measured 
(Figure 2.9B). 
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Figure 2.9 (A) A Cartoon illustrating phagocytic uptake of labelled antigen- 
antibody complexes followed by intracellular oxidation of a rhodamine derivative, 
which upon excitation at 488 nm emits light at 670 nm (FL-3 channel) detected by flow 
cytometer (Haugland., 2002) (B) Representative graph illustrating the phagocytosis 
profile of murine macrophages in the presence FcOxyburst' RED reagent 
containing XR-DHDCF. Fluorescence measured in the FL-3 channel by flow 
cytometry, over a 204 second time course. 
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Figure 2.10 Analysis of FcOxyburst'". Illustrates the formulas used during the 
analysis of the raw phagocytic profile data obtaibned from the flow cytometer. To 
obtain the rate: % Rate of inhibition = 100- ((y2/x) / (yi/x)) and the maximum 
%maximum height = 100- (h2/h1). 
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2.4.5 Zymosan preparation 
Zymosan was prepared by boiling and subsequent washing prior to opsonisation. 500 
mg of zymosan A was placed in a 500 ml conical flask and covered with 200 ml of 
PBS. The mixture was continuously stirred and boiled for 30 min. The suspension was 
then placed on ice and washed 3 times with ice cold PBS (400 x g, 15 min at 4°C), 
resuspended in 50 ml of PBS and aliquoted (10 mg in 1 ml) into eppendorf tubes. After 
further pelleting in a mini-centrifuge, any excess supernatant was removed and the 
zymosan pellets were stored at -20°C until the day of use. On the day of the 
experiment, zymosan was slowly thawed for 30 min and opsonised by incubating 10 mg 
of boiled zymosan with 1 ml of serum (prepared from same genotype mouse blood) for 
30 min in a moving water bath at 37°C. The zymosan was then washed twice in PBS 
containing 0.9% glucose and 1 mM calcium chloride (15,000 x rpm, 3 min) and 
resuspended to 10 mg/ml in PBS supplemented with 0.1% BSA homologous 
suspension. 
2.4.6 Oxidative burst assay 
The oxidative burst induced during phagocytosis of opsonised zymosan by phagocytes 
was monitored by flow cytometry. Dihydrorhodamine 123 (DHR 123) (molecular 
Probes, USA), allows for the quantification of reactive oxygen intermediates produced 
by murine phagocytes as described previously in section 2.3.3. 
Murine peritoneal macrophages were lavaged from the peritoneal cavity, as described in 
section 2.4.2 and placed on ice. An aliquot (100 µl) was taken and added to 900 µl of 
Turk's solution to identify and quantify the different leukocytes present in the lavage 
fluid. The cell suspension was then washed (400 x g, 10 min) and the supernatant 
discarded, the pellet was then resuspended to a concentration of 2.5 x106 cells/ml in 
PBS supplemented with 0.1% BSA. 50 µl (containing approximately 1.25 x105 cells) 
was added to 200 . tl saline supplemented with 5 mM HEPES pH 7.4, cells were 
incubated with either PBS (vehicle), hydrocortisone (10 µM) or Ac2-26 (100 µg/ml) for 
70 and 30 min respectively in a slow moving water bath 60 cycle/min, at 37°C. DHR 
77 
Chanter 2 Methods & Materials 
123 (1 µl, 2mM stock solution) was added for 5 min prior to stimulation with saline 
(vehicle) or opsonised zymosan (500 gg/ml) prepared as described in section 2.4.5. The 
reaction was halted at particular time points: 0-2-5- 15 - 30 - 45 and 60 min with 
ice cold PBS supplemented with 0.02% sodium azide. Samples were placed in an ice 
bath and analysed immediately by flow cytometry. Flow cytometry was performed as 
described in section 2.3.1. 
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Figure 2.11 Time course of ROS production by murine macrophages. During the 
incubation of zymosan particles with macrophages, a steady increase of MFI over time 
signifies ROS production during phagocytosis. 
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2.4.7 Macrophage uptake of fluorescent particles 
The uptake of fluorescent particles can be used to quantify phagocytosis by measuring 
cellular fluorescence. Yet its drawbacks are its inability to distinguish between binding 
and ingestion, which will collectively be referred to as uptake. Attempts to modify the 
flow cytometric assay in order to measure ingestion alone by trypan blue and ethidium 
bromide quenching (Drevets & Campbell, 1991; Giaimis et al., 1994) of extracellular 
fluorescence proved to be unsuccessful in my hands. Extensive washing of the cells 
proved the best method to remove the majority of unbound FITC labelled particles. 
Peritoneal macrophages were lavaged from the mouse cavity as previously described in 
section 2.4.2 and were placed on ice, alternatively differentiated BMDMe prepared as 
described previously in section 2.4.1 were used. The samples were centrifuged at 400 x 
g for 10 min. An aliquot (100 µl) was taken and stained with 900 µl of Turk's solution 
to identify and quantify the different leukocytes present in the lavage fluid. The cells 
were then centrifuged (400 x g, 10 min, 4°C) and the supernatant discarded, the pellet 
was then resuspended to 1x 106 cells/ml in RPMI 1640 supplemented with 10% FCS 
and 25 mM HEPES buffer. 
Cells of either type were resuspended to a concentration of Ix 106 cells/ml in RPMI 
1640 supplemented with 10% FCS and 25mM HEPES pH 7.4 and 3 ml of the cell 
suspension (containing approximately 3x 106 cells) was placed in each well of a6 well 
plate, and were allowed to adhere for 2h (peritoneal) and 24 h (BMDMe) at 37°C, in a 
5% CO2 and 95% 02 atmosphere. (After cells had adhered they were preincubated at 
4°C for 30 min) A subset of control cells were incubated with 2µM cytochalasin D and 
was retained throughout the assay allowing for the observation of actin independent 
events. Following two washes with 1.5 ml PBS at 4°C, adherent macrophages were 
incubated with FITC-labelled particles at a MOI of ranging from 1: 5 to 1: 20 for 1 h, this 
allows particles to adhere to cells but not for cells to phagocytose particles. Cells were 
then washed three times with 3 ml of warm RPMI 1640 supplemented with 10 % FCS 
and 25 mM HEPES pH 7.4, prior to being incubated at 37 °C in a 5% CO2 and 95% 02 
atmosphere allowing for phagocytosis of particles. Cells were harvested from the 
culture dishes at particular time points chosen from preliminary data 0-5 -15 - 30 -45 
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- 60 mins, with PBS supplemented with 10 mM EDTA and 4 mg of Lidocaine-HC1 per 
ml and fixed with PBS supplemented with 4% paraformaldehyde. Flow cytometry was 
performed using a FACScan (Becton Dickinson, Cowley, UK) as described in section 
3.2.1. The mean fluorescence of unloaded control cells was subtracted from the mean 
fluorescence of each assay condition, and the average was determined. 
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Figure 2.12 Flow cytometry analysis characteristics, SSC (granularity) against 
FL-1 (green fluorescence). (A) Depicts quiescent macrophages. Here the cell 
population is found in negative quadrant for fluorescence, whereas, (B) exhibits cells in 
the presence of fluorescent particle. A split population of macrophages may be 
observed, where the rightwards shift of a cloud of cells, indicates the uptake of 
fluorescent particles. 
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2.4.8 Zymosan peritonitis 
The peritoneal cavity was used for administering zymosan and the subsequent 
collection of leukocytes in the lavage fluids at particular time points. In certain 
experiments this model was used to assay phagocytic events in vivo. Peritonitis was 
induced using 1 mg zymosan (in 0.5 ml of saline) injected locally into the peritoneal 
cavity i. p. (Perretti et al., 1992). Animals were then killed at particular time points 4- 
12 - 24 - 48 and 96 h, by exposure to CO2. The peritoneal cavity was exposed and 
sterile PBS supplemented with 3 mM EDTA and 25 U/ml heparin. The lavage fluid 
collected with a sterile I ml plastic Pasteur pipette described in section 2.4.2. 
Differential cell counts were performed as described in section 2.3.4. 
FITC-labelled zymosan (2.3 x 107 /particles per mouse) was injected i. p. and the 
uptake over time was measured by cellular fluorescence, as in section 2.4.7. The 
animals were then killed at different time-points, chosen from preliminary data 0-2 
-10 - 20 and 30 min. Samples were fixed with 4% paraformaldehyde and kept on ice. 
Flow cytometry was performed using a FACScan (Becton Dickinson, Cowley, UK) as 
described in section 2.3.1. The mean fluorescence of unloaded control cells was 
subtracted from the mean fluorescence of each assay condition, and the average was 
determined. 
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Figure 2.13 Leukocyte inflammatory profile over time during peritonitis (images 
taken from(Young ei al., 2000). 
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2.4.9 Primary culture of murine macrophages 
Murine peritoneal macrophages were lavaged from the cavity as described in section 
2.4.2 and placed on ice. An aliquot (100 µl) was taken and added to 900 µl of Turk's 
solution to identify the different leukocytes present in the lavage fluid. The cell 
suspension was then centrifuged at 400 xg for 10 min and the supernatant discarded, 
the pellet was then resuspended to 2x 106 cells/ml in RPMI 1640 supplemented with 
10% FCS and 1% Penicillin-streptomycin. Or differentiated BMDMe prepared as 
described previously in section 2.4.1 were harvested, culture plates were incubated with 
25 ml PBS supplement with 10 mM EDTA and 4 mg/ml Lidocaine-HC1 for 10 min at 
room temperature prior to removal (this loosens cells in conjunction with pipetting). 
500 µl of cell suspension (containing approximately 1 x106 cells) was placed in 24 or 6 
well cell culture plate for 2h at 37'C in a 5% CO2 and 95% 02 atmosphere, to ensure 
adherence of the macrophage population to the culture plate. After the adherence 
period, the medium was aspirated and the plates washed three times with RPMI 1640 
medium, to remove non-adherent cells. FCS-free medium was replaced and drugs added 
to the medium for a 60 min incubation period. 
Cells were then stimulated with either of boiled zymosan, heat aggregated IgG, LPS or 
Neisseria. Heat aggregate's were prepared by heating a solution of human Cohn 
fraction II and III (20 mg/ml in PBS) to 63 °C for 30 min (Jones et al., 1982). The cell 
free supernatants were collected 2-4 -6 - 18 6- 24 h later. These samples were then 
frozen at -80°C prior to detection of the release of IL-1ß, IL-6, TNF-a and PGE2 using 
commercially available EIA (see below). 
2.4.10 Bradford Protein Assay & sample preparation 
Cell pellets from primary culture experiments were stored at -80°C; samples were 
defrosted at 4°C, and resuspended in 100 µl/ 5x106 cells in protease inhibitory buffer 
(Complete Mini EDTA-free Protease Inhibitory Cocktail), to prevent protein 
degradation during cell lysis. Samples were then sonicated for 10 s at 20 kHz. A 
protein standard curve ranging from 0-0.5 mg/ml of BSA in PBS was prepared, 10 gl of 
standard or unknown was added to the plate in duplicate followed by the addition of 
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200 µl of the Bradford Reagent (1: 5 of commercial stock solution in d-water). The 
absorbance of each sample was then read at 560 nm in a microplate reader (GENios, 
Tecan UK Ltd, Reading, UK), absorbance units were converted to protein 
concentration, calculated from the standard curve. 
Once the protein concentration was determined, the samples were adjusted to 
2 mg/ml concentration. A 1: 1 dilution in Laemmli gel loading buffer (sodium dodecyl 
sulphate, Glycerol, 2-mercaptoethanol, EDTA, Coomassie brilliant blue in HC1), 
samples were then boiled for 5 min. The combination of Laemmli buffer and the 
denaturing of the samples, linearise and equilibrating the charge density on the proteins 
in the samples. The preparations were now equilibrated to a final concentration of 1 
mg/ml total protein. 
2.4.11 Western blotting 
Western blotting analysis allows the resolution and detection of proteins of interest. It 
involves firstly electrophoresis on a resolving gel, and subsequently the transfer of 
separated proteins onto a nitrocellulose membrane. Incubation of the membrane with 
specific antibodies identifies the proteins of interest and bound antibodies may be 
detected using the ECLTM system. 
The SDS-page gel is in essence split into 2 segments: the stacking gel and the resolving 
gel. The stacking gel consists of d-water supplemented with Tris HCl pH 6.8, Proto Gel 
Acrylamide, Ammonium Persulphate and TEMED, and provides the lanes for each 
individual sample. The ingredients of the resolving gel were d-water, Tris HCl pH 8.8, 
Proto Gel polyacrylamide, Ammonium Persulphate and TEMED. Using the BioRad 
Mini-PROTEAN® III Electrophoresis System in running buffer d-water supplemented 
with Trizma Tris Base, glycine and SDS. Then the gel was loaded with a rainbow 
recombinant protein molecular weight marker or unknown samples and stacked at 90 V 
for 10 min. The samples were then run on the resolving gel at 180 V in running buffer 
until the blue protein front reach the bottom of the gels. The separated proteins were 
then transferred onto the Immobilon '-P transfer membrane at 100 mA per blot using 
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the semi-wet transfer system in presence of transfer buffer d-water supplemented with 
Tris Base, glycine and methanol, for 1 h. 
Membranes were pre-blocked, by incubating them in 5% powdered milk and 0.1% BSA 
in PBS-T at 4°C for 18 h to coat the membrane for the blocking of non-specific binding. 
The membranes were washed three times in PBS-T for 30 min, followed by a1h 
incubation at room temperature with primary antibody (iNOS detection 1: 3000 Santa 
Cruz Rabbit anti-mouse iNOS antibody in blocking solution; COX-2 detection: 1: 1000 
Cayman rabbit anti-mouse COX-2 antibody in PBS-T containing 0.1% BSA (Gilroy et 
al., 1999). Membranes were washed three times for 45 min in PBS-T prior to incubation 
with 1: 2000 peroxidase-conjugated goat anti-rabbit IgG (Dako) at room temperature for 
1 h. Membranes were washed a further three times in PBS-T prior to being incubated 
with ECL" for 1 min, allowing the specific antibody binding to be detected through 
enhanced chemiluminescence. The exposed film was then developed in PolyconTM 
Technical Developer and stablised in Amfix® High Speed fixer before analysis. 
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2.4.12 PGE, 7 enzyme immunoassay 
The BIOTRAK prostaglandin E2 enzyme immunoassay system was purchased from 
Amersham Pharmacia Biotech. The methods were conducted according to the 
manufacturers instructions. A standard curve ranging from 2-320 pg/well was prepared 
using the reagents provided, 50 µd of standard was added to the plate in duplicate and 50 
µl of unknown from the primary culture experiment added to the appropriate wells. The 
assay is based on the competition between unlabelled PGE2 and a fixed quantity of 
peroxide-labelled PGE2, for a limited number of binding sites on a PGE2 specific 
antibody. With fixed amounts of antibody and peroxide-labelled PGE2, the amount of 
peroxidase-labelled ligand bound by the antibody will be inversely proportional to the 
concentration of the unlabelled ligand. The peroxidase ligand that is bound to the 
antibody is immobilised onto the microtitre plate precoated with the secondary 
antibody. Thus, any unbound ligand was removed by washing. The amount of 
peroxidase labelled PGE2 bound to the antibody is determined by addition of a 
tetramethybenzidine (TMB hydrogen peroxide). This was incubated for a further 30 
min on a shaking plate at room temperature; the reaction was stopped by the addition of 
100 µl of 1M sulphuric acid to each well. The absorbance of each sample was then 
read at 450 nm in a microplate reader (Anthos plate reader 2001, Salzburg, Austria), 
within 30 min and the concentration calculated from the standard curve (see Figure 
2.14) 
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Figure 2.14 Typical standard curve obtained for the PGE2 EIA system assay. 
Absorbance values were read at 450 nm and PGE2 concentration were determined from 
the standard curve-using Graph Pad Prism`" 
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2.4.13 Cytokine enzyme immunoassay 
The optEIA. Elisa kits for measuring cytokine production are commercially available 
from Pharmingen`M and were purchased to detect TNF-a, IL-I ß or IL-6. The methods 
were conducted following the manufacturers instructions. A standard curve ranging 
from 15.6-1000 pg/well was prepared using the reagents provided, 100 µl of standard 
was added to the plate in duplicate and 100 µl of unknown form the primary culture 
experiments to the appropriate wells, for a2h incubation. The microtitre plate had 
been precoated the previous day with the specific cytokine capture-antibody. This first 
incubation allowed the antigen present in the cell free supernatants to bind to the 
immobilised antibody already bound to the plate; any sample that was unbound was 
removed by extensive washing. The samples bound to the antibody were detected by 
the addition of 100 41 of a enzyme-linked polyclonal antibody specific for the desired 
cytokine (dection antibody and Advidin-HRP reagent). Unbound antibody-enzyme 
reagent was removed by washing, prior to the addition of 100 41 (tetramethybenzidine 
TMB and hydrogen peroxide) to produce the colour. This reaction was then terminated 
by the addition of 50 pi of 1M sulphuric acid turning the samples from blue to yellow. 
The absorbance of each sample was then read at 450 nm in a microplate reader (Anthos 
plate reader 2001, Salzburg, Austria), within 30 min and the concentration calculated 
from the standard curve (see Figure 2.15) 
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Figure 2.15 Typical standard curve obtained during a TNF-a ELISA assay. 
Absorbance values were read at 450 nm and TNF-a concentration were determined 
from the standard curve-using Graph Pad Prism". 
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2.4.14 Microscopy 
Three hundred and thirty nine years ago saw the seminal observation of the cell by 
Robert Hooke and this has clearly revolutionised our understanding of how cells live 
and die. In this part of experimental work the powerful technique of electron and 
confocal microscopy permits a greater understanding of annexin Als' localisation and 
function in the macrophage. 
2.4.15 Confocal microscopy 
Cells were grown on 13 mm diameter glass coverslips, which had been immersed in 
70% ethanol, heat dried and placed at the bottom of a 24 well tissue culture plate. 
Differentiated BMDMe were prepared as described previously in section 2.4.1. An 
aliquot (100 µl) of cells was taken and added to 900 gl of Turk's solution to identify and 
quantify the different leukocytes present in the lavage fluid. The cells were then 
centrifuged (400 x g, for 10 min, 4 °C) and the supernatant discarded. Cells were 
resuspended to a concentration of 2x 106 cells/ml in RPMI 1640 supplemented with 
10% FCS and 25mM HEPES, pH 7.4. Initially, 500 µl of cell suspension (containing 
approximately 1x 105 cells) were seeded onto the glass cover slips in the 24 well plates. 
Following a overnight incubation, at 37°C, in a 5% CO2 and 95% 02 atmosphere, to 
ensure adherence of macrophages onto glass cover slip, the plate was placed on ice and 
wells were washed three times with 1.5 ml of tissue culture grade PBS to ensure 
removal of any cell debris. 
FITC-conjugated zymosan particles were added to each well at a MOI of 1: 5 for 1h on 
ice, to allow for cell to particle adhesion but not phagocytosis. Following aIh 
incubation on ice wells were washed three times with ice-cold RPMI 1640 to remove 
non-adherent zymosan particles. Plates were then incubated at 37°C in a 5% CO2 and 
95% 02 atmosphere, for either 5 min to monitor phagocytic cup formation or Ih to 
observe engulfment over a prolonged period of time. At the appropriate time point the 
cover slips were washed twice with ice cold PBS, prior to the addition of ice cold PBS 
supplemented with 4% paraformaldehyde solution and 200 mM HEPES buffer to fix the 
cells for at least 15 min. Cells were then permeablised for 30 min at room temperature 
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using PBS supplemented with 0.25% saponin, 1% BSA and 1% goat serum. Using this 
buffer, cells were first washed with the staining solution prior to being incubated at 
room temperature with a rabbit anti-annexin Al antibody (1: 1000 dilution) for Ih 
(which recognises the full length annexin Al). Cells were then washed three times with 
the staining buffer before being incubated with TRITC phalloidin (1: 100 dilution of 
stock) and AlexaFluor 647 goat anti-rabbit IgG (1: 150 dilution) the secondary antibody 
for annexin Al for 1h at room temperature coverslips were washed four times prior to 
mounting them onto slides. Cover slips were removed from the wells and dried with 
tissue paper, two drops of fluorescent fixing mount was placed on the centre of each 
slide, the cover slip was placed over the fixing mount ensuring no air pockets were 
formed were and allowed to dry for 12 h at 4°C, where slides were stored until day of 
analysis. Analysis by confocal laser scanning microscopy was performed using 
LaserSharp software mounted on a 2000 MP BioRADTM microscope. Representative 
pictures of slides were collected and saved in a QuickTimeTM format, prior to being 
imported to Adobe PhotoshopTM version 7.0 software for single colour analysis. 
2.4.16 Real-Time confocal microscopy 
In order to gain a better understanding of the events taking place during phagocytosis 
we employed the technique of real time confocal microscopy. This is a powerful 
technique allowing the visualisation of kinetic events involved during phagocytosis. 
Differentiated BMDMe prepared as described previously in section 2.4.1 were 
harvested. An aliquot (100 µl) of BMDMo's was taken and added to 900 µl of Turk's 
solution to identify and quantify the macrophages present in the lavage fluid. The 
sample was then centrifuged (400 x g, 10 min, 4°C) and the supernatant discarded, the 
pellet was then resuspended to 0.2 x 106 cells/ml in Optimum supplemented with 10% 
FCS and 10 mM HEPES pH 7.4.500 µl of cell suspension (containing approximately 1 
x 105 cells) was added to each cover slip. 
Following an overnight incubation, at 37 °C, in a 5% CO2 and 95% 02 atmosphere, to 
permit adherence, the cover slips were washed three times with 1.5 ml of tissue culture 
grade PBS to ensure removal of any cell debris. Cells were then incubated again with 
Optimum supplemented with 10% FCS and 10 mM HEPES pH 7.4 at 37 °C, 5% CO2 
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and 95% 02 and placed on warmed and gas incubated stage to allow visualisation of 
cells via the confocal microscope. FITC-conjugated zymosan particles were added at a 
MOI of 1: 5, analysis by confocal laser scanning microscopy was performed using 
LaserSharp software, cells were mounted on a 2000 MP BioRADTM microscope and 
images captured over a1h period every 5 seconds. Movies were composed and saved 
as QuickTimeTM movie documents and played back to analysis. 
2.4.17 Electron microscopy 
Murine peritoneal macrophages were lavaged from the cavity and analysed as 
previously described in section 2.4.2 and placed on ice. 3 ml of cell suspension 
(containing approximately 3x 106 cells) was placed in a well of a six well cell culture 
plate with MelonexT" inserts, for 2h at 37 °C in a 5% CO2 and 95% 02 atmosphere, 
ensuring the adherence of the macrophage population to the MelonexTM inserts. 
Following the adherence period, the medium was aspirated and the plates washed three 
times with RPMI 1640 medium, to remove non-adherent cells. Cells were then 
stimulated RPMI 1640 supplemented with 10 % FCS and 200 µg/ml boiled zymosan. 
Phagocytosis was halted at particular time points 0- 45 - 120 - 180 min, by fixing the 
cells in 2.5 % gluaraldehyde for 20 min at room temperature, followed by two washes 
in 5 ml sodium cacodylate (0.1M). Macrophages were then incubated in fresh sodium 
cacodylate over night. 
Dr. Barbara Ward from the William Harvey Research Institute conducted the next 
section of this assay. Fixed cultures were washed twice with sodium cacodylate 
(0.2M) for 10 min. Cells were post-fixed together with sodium cacodylate (0.1M) 
supplemented with 1% osmium tetroxide and potassium ferrocyanide for 30 min. 
Followed by three washes in distilled water for 5 min, cultures were dehydrated through 
graded ethanol (50%, and 70% for 5 min each, 90% for 10 min, 2 changes of 100%, 15 
min at each concentration). The cells were then transferred into small aluminium dishes 
and further dehydrated with propylene oxide twice for 10 min. The propylene oxide was 
removed and immediately replaced with a freshly prepared Araldite mix containing 9.5g 
Araldite 10.5g DDSA (dodecenyl succinic anhydride, 0.6g BDMA 
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benzyldimethylamine). The dishes were left overnight at room temperature, prior to 
being placed in an oven at 60 °C for 2 days. After cooling, the cultures were removed 
from the aluminium dishes and the Melinex'M peeled away, leaving the cells embedded 
in the Araldite. This was then cut into 2mm blocks using a hacksaw and mounted on to 
stubs. Using a Reichert-Jung Ultracut E microtome the blocks were trimmed to size 
and 80 nm thick sections were cut on a diamond knife and collected on 300 mesh 
copper grids. The grids were stained with 2% aqueous uranyl acetate for 40 min and 
rinsed in 3 changes of distilled water, the first change being at 45 C. The sections were 
viewed and photographed on a JEM-1200 EX electron microscope at an accelerating 
voltage of 60 kV, prior to being imported to Adobe PhotoshopTM version 7.0 software 
for analysis. 
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2.5 Buffers and stains 
Turk's stain: 0.01% crystal violet in 3% acetic acid 97% distilled-water. 
Diff Quick: Reagent 1: Methanol Reagent 2: Eosin 
Reagent 3: Methylene blue 
PBS: Prepared as described by manufacturers (Sigma, UK). One tablet 
dissolved in 200 ml of distilled water: 0.01 M phosphate buffer, 
0.0027 M potassium chloride, 0.137 M sodium chloride and a 
pH7.4. 
PBS-T (wash buffer): PBS supplemented with 0.05% Tween-20 
PBS/EDTA: PBS supplemented with 3 mM EDTA 
PBC: PBS supplemented with 0.02% BSA and 1 mM CaC12 
Krebs': 0.044 g calcium chloride, 0.12 g magnesium chloride, 0.88 g 
glucose made up to 400 ml with PBS. 
Dextran T500: 1.25% Dextran T500 in 100 ml saline 
Tris buffer saline: 0.05M Tris buffer saline, 0.1% Triton X-100 
Confocal Buffer: PBS supplemented with 0.25% Saponin, 1% BSA and 1% goat 
serum 
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2.6 Materials 
The following chemicals were purchased from Sigma-Aldrich Chemical Company 
(Poole, Dorset, UK): ammonium persulphate, low endotoxin Bovine Serum Albumin, 
crystal violet, dimethyl sulfoxide, EDTA sodium salt, fMLP, gentamicin solution, 
gluaraldehyde, glycine, glycerol, D-glucose, goat serum, y-gobulins (Cohn fraction II 
III), HEPES buffer, hydrocortisone-21 hemisuccinate, 2-mercaptoethanol, magnesium 
chloride, liodocaine-hydrochloride, lysophosphatidylcholine, lipopolysaccharide 
(0111: B4), PAF (c16 form: C26H54NO7P), paraformaldehyde, 4a-phorbol-12- 
myristate- 13 -acetate, phosphate buffered saline tablets, saponin (saponaria species), 
sheep red blood cells (R3378), anti-sheep red blood cell stroma (S1389), Sigmacote', 
sodium cacodylate, sodium chloride, sodium dodecylsulphate (SDS), TEMED, TRITC 
phalloidin, Trizma Tris base, Tris hydrochloride, and zymosan A. 
The following antibodies were purchased from BD PharMingen, (A Becton and 
Dickinson Company, Cowley, Oxfordshire, UK): OptEIA" Elisa kits for TNFa or IL-6. 
Rat anti-murine CD2 (Clone RM2-5), Rat anti-murine CD5 (Clone 53.73), Rat anti- 
murine CD45R B220 (Clone RA3-6B2), FITC-anti-murine Ly6G (GR-1) (Clone RB6- 
8C5), Rat anti-murine FcRyRII/III (clone 24. G2). 
S1owFade ' AlexaFluor 647 goat anti-rabbit IgG (A21245), anti fade kit, 
Dihyrorhodamine 123, FcOxyburst RED and N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl), 
FITC zymosan (Z-2841), (NBD)-phallacidin (N-354/300U) were purchased from 
Molecular Probes (Distributed by Cambridge Bioscience, Cambridge, UK). 
The following chemicals were purchased from BDH (Lutterworth, UK): EDTA, eosin, 
acetic acid, calcium chloride, ethanol, formaldehyde, hydrochloric acid, methanol, 
methylene blue solution, saline, sodium azide and sulphuric acid. 
Rat anti-murine F4/80 (Clone C1: A31) and FITC-conjugated F(ab')2 rabbit anti-rat IgG 
were purchased from Serotec (Oxford, Oxfordshire, UK). 
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Rat anti-murine ICAM-1 (Clone YN 1.1) and Rat anti-murine CD I1 b (clone 5C6) was a 
gift from Mrs H Brand and Dr A Chapman at Celltech Bioscience LTD. (Slough, 
Berkshire, UK). 
ECL western blotting system, PGE2 enzyme immuno assay (EIA) system and Dextran 
T500 was purchased from Amersham Pharmacia Biotech (Amersham, 
Buckinghamshire, UK). 
N-[2-hydroxyethyl]piperazine-N'-( 2-ethane sulfonic acid) (HEPES), Phosphate 
Buffered Saline RPMI 1640 medium and Foetal Calf Serum were purchased from 
GIBCO BRL (Paisley, Scotland, UK). 
Rat anti-murine CD62L (clone MEL 14) was a gift from Professor P. G. Hellewell at the 
University of Sheffield (Sheffield, UK). 
Rat anti-murine Dectin 1 and heat killed Neisseria particles (clone 2A11) was a gift 
from Dr. G Brown at the Sir William Dunn School of Pathology, University of Oxford, 
(Oxford, UK). 
Rabbit anti-annexin-1 polyclonal antibody (71-3400) which recognises whole length 
annexin Al, was purchased from ZYMED Laboratories Inc. (Distributed by, Cambridge 
Bioscience, Cambridge, UK). 
Rabbit anti-mouse COX-2 Cayman (distributed by Alexis Cooperation Chemical 
Nottingham, UK). 
Rabbit anti-mouse iNOS Santa Cruz Biotechnology, Inc (distributed by Autogen 
Bioclear UK Ltd, (Wiltshire, UK). 
Whole Blood lysing kit Immuno-Lyse was from Coulter Electronics Ltd. (Cowley, 
Oxford, UK). 
CellFixT , 
FACSRinse and FACSF1ow were purchased from Becton and Dickinson 
(Cowley, Oxford, UK). 
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Goat anti-rat IgG MicroBeads was purchased from Mitenyi Biotec. MACS (Bisley, 
Surrey, UK). 
The murine fibroblast cell line L929 was purchased from the American Type Tissue 
Collection (VA, America). 
The LCl-derived peptide Ac2-26 (acetyl-AMVSEFLKQAWFIENEE QEYVVQTVK), 
was prepared by The Advance Biotechnology Centre (The Charing Cross and 
Westminster Medical School, London, UK) using solid phase step-wise synthesis. 
Purity was more than 90% as assessed by high-pressure liquid chromatography and 
capillary electrophoresis (data furnished by the manufacturer). 
Mini, EDTA-free Protease Inhibitor Cocktail Tablets purchased from Roche 
Diagnostics Ltd (West Sussex, UK). 
DAKO Fixing reagent and Peroxidase-conjugated goat anti-rabbit IgG were purchased 
from Dako Cytomation Ltd (Cambridgeshire, UK). 
Bradford reagent was purchased from Bio Rad laboratories LTD. (Hertfordshire, UK). 
ProtoGel (Acrylamide) was purchased from National Diagnostics (UK) Ltd, 
(Yorkshire, UK). 
Boc 2 (N-T Boc Phe-d-Leu-Phe-d-Leu-Phe) was purchased from ICN Pharmaceuticals 
Inc. (Basingstoke, Hampshire, UK). 
Heparin (sodium) was from Leo Laboratories (Risborough, Buckinghamshire, UK). 
All other chemicals were of analytical grade. 
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2.7 Data and Statistics 
Data is reported as mean ± standard error of the means (SEM) of n experiments 
performed in duplicate, triplicate or quadruplicate. Statistical differences were analysed 
by analysis of variance, using the software Graph Pad Prism' (version 3), if the pre-test 
was successful, the analysis was continued. 
Once the F value was found to be significant, post-analysis intergroup comparisons 
were made by the Bonferroni test. When only two groups were compared, statistical 
differences were evaluated using the two tail unpaired student's t-test. In all cases a 
threshold value of p<0.05 was sufficient to reject the null hypothesis, and differences 
between groups was considered significant. 
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Studies on neutrophil activation 
3.1 To what extent do neutrophils lacking the FPR respond to 
inflammatory mediators, in particular f 4LP? 
Prior to the start of this thesis, it was accepted from literature that the peptide Ac2-26, 
fMLP and Boc 2 all interacted at the same receptor in human neutrophils. One 
objective of this study was an investigation into the receptor responsible for annexin 
Al's action in the murine system. The whole blood technique was used to measure cell 
adhesion molecule expression on the plasma membrane following cellular activation. 
Circulating phagocytes express basal levels of the ß2 integrin CD11b (Figure 3.1); upon 
stimulation with inflammatory mediators CD I lb levels increase (Figure 3.2) and this 
up-regulation was used as a measure of cellular activation. Preliminary studies 
illustrated that neutrophils taken from either C57BL/6 or FPR KO mice displayed 
different basal expression of CD11b and was not modified by either peptide Ac2-26 
(200 µg/ml, equivalent to 66 µM) or Boc 2 (100 µM) alone (Figure 3.1). 
3.1.1 Markers of FPR-KO neutrophil activation 
Inflammation is characterised by the appearance of mediators such as fMLP and PAF 
and cellular activation may be mimicked in vitro by incubating aliquots of whole blood 
with these inflammatory compounds. Initially, it was observed that CD1 Ib expression 
on C57BL/6 neutrophils was significantly augmented by as little as 3 µM fMLP, and 
was increased further by 10 µM and 30 pM fMLP (Figure 3.2). In cells taken from FPR 
KO mice fMLP was only active at the maximum concentration tested, 30 µM (Figure 
3.2), and its efficacy was significantly attenuated compared to with the response 
observed in C57BL/6 neutrophils (Figure 3.2). In C57BL/6 cells, the peptide Ac2-26 
abrogated CD1lb up-regulation induced by fMLP alone at either low (3 µM) or high 
(30 µM) concentrations of fMLP (Figure 3.3A). Interestingly, this response was 
mimicked in cells taken from FPR KO mice stimulated with 30 pM fMLP where both 
the peptide Ac2-26 and the FPR antagonist Boc 2 (100 µM) significantly reduced 
neutrophil activation, as can be seen in Figure 3.3B. Whole blood incubation with the 
potent lipid mediator PAF (1 µM) induced a significant increase in CD 11 b expression 
in both C57BL/6 and FPR KO neutrophils from basal expression (127 t3 and 161 ± 
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13% respectively, Figure 3.4). When whole blood was pre-incubated with the peptide 
Ac2-26 prior to the addition of PAF (1 µM), this caused a modest yet significant 
inhibition CDl lb expression compared to PAF alone, in both genotypes analysed. 
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Figure 3.1 Basal CD11b expression. (A) Representative flow cytometry 
histogram, black isotype control, blue C57BL/6 and red FPR KO cells, data corresponds 
to in bars in B. (B) Peptide Ac2-26 and the FPR antagonist Boc 2 do not alter CD] lb 
basal expression in either FPR KO or C57BL/6 mouse neutrophils. Blood aliquots were 
incubated with CDllb antibody (clone: 5C6) and CDllb expression on the cell 
membrane was measured by flow cytometry. Basal CDl lb expression appears to be 
persistently reduced in FPR KO neutrophils compared with C57BL/6. The peptide 
Ac2-26 and the FPR antagonist Boc 2 incubation had no consequence on CDI lb cell 
membrane expression. Data are mean ± SEM of n= 6-8 experiments performed with 
n=4-5 mice each. 'P<0.05 compared with C57BL/6 CDI lb expression. 
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Figur 3. Concentration-response curves for fMLP in C57BL/6 and FPR KO 
mouse neutrophils. Blood aliquots were incubated with fMLP for 15 min. 
Subsequently CD 11 b (clone: 5C6) and FITC labelling was performed. CD! 1b 
expression on the cell surface was measured by flow cytometry. Data are mean ± SEM 
of n=6-8 experiments performed with n=3-4 mice each. *P<0.05 compared with un- 
stimulated cells (basal values were 86 ±9 and 54 ±3 units of fluorescence intensity for 
C57BL/6 and FPR KO cells, respectively). 
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Figure Peptide Ac2-26 and Boc 2 inhibit fMLP-induced CD11b up 
regulation on C57BL/6 and FPR KO mouse neutrophils. Blood aliquots were incubated 
with either peptide Ac2-26 (200 pg/ml or 66 µM) or Boc 2 (100 µM) for 10 min prior to 
addition of fMLP. Subsequently CDllb (clone: 5C6) and FITC labelling was 
performed. CDI lb expression on the cell surface was measured by flow cytometry. 
(A) The peptide blocks the fMLP induced CDI lb activation on WT neutrophils. (B) 
The inhibitory effects of peptide and Boc 2 were observed at 30 µM fMLP-induced 
CDI lb up-regulation in FPR KO neutrophils. Data are mean ± SEM of n=6-8 
experiments performed with n=3-4 mice each. *P<0.05 compared with un-stimulated 
cells (basal values were 86 ±9 and 54 ±3 units of fluorescence intensity for C57BL/6 
and FPR KO cells, respectively). 
100 
Chanter 3 Results 
C 175-ý 
0 
C57BU6 
FPR KO 
* 
Z 
O+ 
T 
oý vý ý 150-I 
CA r 
ýV 125 ý 
EL d 
ý 
?: 100ý F 
Wv 
n 
.a 16 754, T" 
ý '0 50ý I'" - 
+ + 
PAF (1 µM) 
Ac2-26 (200µg/ml) 
Figure 3.4 Peptide Ac2-26 causes a modest reduction in PAF-induced up- 
regulation of CD11b expression, uniformly on neutrophils prepared from either 
C57BL/6 or FPR KO mice. Blood aliquots incubated with peptide Ac2-26 (200 
pg/ml) for 10 min prior to addition of 1 mM PAF. CD 11 b expression on the cell surface 
was measured by flow cytometry. PAF induced CD11b up-regulation on both C57BL/6 
and FPR KO neutrophils. *P<0.05 compared to un-stimulated cells (basal values for 
FPR KO and C57BL/6 were 51±8 and 74±8 MFI respectively, while Ac2-26 reduced 
this up regulation modestly O P<0.05 compared to PAF stimulated cells (same 
genotype). All Data are mean ± SEM of n=4-5 experiments performed with n=3-5 mice 
each. 
3.1.2 Isolated FPR KO neutrophil chemotaxis 
To determine whether cell activation observed during CDllb activation effected 
neutrophil function, isolated FPR KO cells were tested for altered locomotor activity, 
using the NeuroProbeTM chemotaxis assay. 
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Exposure of isolated C57BL/6 neutrophils to as little as 100 pM of the chemoattractant 
PAF caused a characteristic migration response towards basement chamber 
(Figure3.5A). Chemotaxis was observed with 1 nM PAF in both C57BL/6 and FPR KO 
neutrophils (Figure 3.5A). Both the FPR KO and C57BL/6 mouse neutrophils migrate 
towards PAF to a similar degree (Figure 3.5A), supporting the previous data (Figure 
3.4). 
The involvement of the FPR receptor in the chemotactic response was investigated next. 
The peptide Ac2-26 previously has been shown to exhibit chemoattractant properties in 
human neutrophils (Walther et al., 2000). Initially, it was observed that the C57BL/6 
mouse neutrophils migrate towards peptide Ac2-26 at both 30 gg/ml and 10 gg/ml 
(Figure 3.5B). Interestingly, chemotaxis towards the annexin Al peptide Ac2-26 was 
significantly attenuated, at both 30 and 10 µg/ml in FPR KO neutrophils compared to 
C57BL/6 with a migratory index of 1.8 ± 0.1 compared with 3.3 ± 0.3 and 1.275 ± 0.02 
compared with 1.9 ± 0.07, respectively. This indicates that the annexin Al mimetic 
interacts with the mouse FPR (Figure 3.5B). 
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Figure 3.5 PAF-provoked neutrophil chemotaxis in C57BL/6 and FPR KO 
mouse neutrophils. Chemotaxis provoked by Ac2-26 is decreased in FPR KO 
neutrophils. Isolated neutrophils were placed on the upper chamber of a ChemoTxTM 
plate with chemoattractant located below the semi-permeable membrane and incubated 
for 2 h, prior to migration being assessed. Data expressed as Migration Index (No. of 
migrated cells / No. of migration to vehicle) mean ± SEM of n= 4-5 experiments 
performed with n= 3 mice each per experiment. *P<0.05 compared with C57BI. /6 
migration. 
* 
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3.2 Do annexin Al null neutrophils respond to inflammatory mediators 
differently from their wild type controls? 
The activation status of circulating annexin Al null neutrophils was initially 
investigated using whole blood flow cytometric analysis of the cell surface membrane 
marker CD 11 b expression. Circulating monocytes and neutrophils express basal levels 
of CDI lb and CD62L (Figure 3.6). Preliminary data revealed that WT neutrophils and 
monocytes CD1lb expression was elevated compared to annexin Al null cells (Figure 
3.6A). Interestingly, WT monocytes and neutrophils expressed less CD62L compared 
with annexin Al null mice (Figure 3.6B). Stimulation with pro-inflammatory mediators 
such as PAF, has previously been shown to induce leukocyte adhesion to post-capillary 
endothelium (Gaboury 1996). 
3.2.1 Markers for annexin A1 null neutrophil activation 
The anti-migratory / inflammatory actions of annexin Al and its N-terminal mimetic 
Ac2-26 have been established for over a decade (Perretti & Flower, 1993). Preliminary 
concentration-response curves to the chemotactic inflammatory mediators fMLP and 
PAF were constructed to assess the role of endogenous annexin Al in the context of 
neutrophil and monocyte activation, (Figures 3.7 and 3.8). In both WT and annexin Al 
null cells incubation with as little as 1 . tM fMLP caused a significant increase in CD I1b 
expression, this was further increased at 3 pM and 10 µM fMLP, (Figure 3.7). The 
activation profile of cells taken from annexin Al null mice were significantly 
augmented compared with WT cells at all concentrations of fMLP analysed (Figure 
3.7). 
When cells of either genotype were incubated with as little as 0.3 µM PAF this caused a 
significant increase in CD1lb expression, this increased in a concentration dependent 
manner at 1µM and 3 pM (Figure 3.8). Whole blood incubation with PAF from 
annexin Al null mice exhibited a significantly enhanced CD1lb expression compared 
to WT cells at all concentrations assayed (Figure 3.8). When PMA was incubated with 
whole blood aliquots, a significant increase in CD1lb expression was observed in WT 
and annexin Al null cells at 1 µM and this was further increased in a concentration 
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dependent manner at 3µM and 10 µM (Figure 3.9). CD 11 b expression in neutrophils 
analysed from the annexin Al null mouse was increased compared to WT cells; e. g. at 3 
µM, the MFI was 280 : 70 compared with 123 ± 2, respectively. Thus, compared to 
WT cells annexin Al null cells exhibit an enhanced response to all inflammatory 
stimuli examined. 
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Figure 3.6 Basal CD11b and CD62L expression on annexin Al null neutrophils 
and monocytes, differ from WT cells. Blood aliquots were incubated with CDI lb 
antibody (clone: 5C6) or CD62L (clone: MEL 14). And expression on the cell surface 
was measured by flow cytometry analysis. (A) Basal CDI 1b expression was reduced in 
both neutrophils and monocytes from the annexin Al null mouse compared with WT. 
(B) In contrast to the CD 11 b data, CD62L expression was elevated in annexin Al null 
neutrophils and monocytes compared with WT. Data are mean ± SEM of n= 5-7 
experiments performed with n= 3-5 mice each. *P<0.05 compared with WT. 
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Figure 3.7 Alteration in adhesion molecule expression by fMLP, during whole 
blood activation, in annexin Al null and WT leukocytes. Blood aliquots were 
incubated with varying concentrations of fMLP and CI) l1b expression on the cell 
surface was measured by flow cytometry analysis. (A) Expression of CDl lb, induced 
by fMLP on peripheral blood neutrophils. Basal CDI lb expression in W"I' and annexin 
Al null cells was 86 ± 11 and 54 ±7 respectively. (B) Basal CD I1b expression in WT 
and annexin Al null monocytes was 122 ±8 and 88 ±5 respectively. Data are mean ± 
SEM of n=4-6 experiments performed with n=4-5 mice each. *P<0.05 compared with 
WT CD I1b expression. 
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Figure 3.8 Alteration in adhesion molecule expression by PAF, during whole 
blood activation, in annexin Al null and WT leukocytes. CDI lb expression on the 
cell surface was measured by flow cytometry analysis. Expression of CDI Ib, induced 
by varying concentrations of PAF on peripheral blood (A) neutrophils; basal CDl lb 
expression in WT and annexin Al null was 94 ± 11 and 62 f8 respectively. (B) 
Monocytes; basal CD 1Ib expression in WT and annexin Al null was 123 ± 12 and 82 ± 
2 respectively. All Data are mean ± SEM of n=4-6 experiments performed with n=4- 
5 mice each. *P<0.05 compared with respective WT. 
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Fiore 3.9 Alteration in adhesion molecule expression by PMA, during whole 
blood activation, in annexin Al null and WT mouse neutrophils. Peripheral blood 
aliquots were incubated with PMA for 10 min. CD I lb expression induced by PMA on 
the cell surface was measured by flow cytometry analysis. Basal CDl lb expression on 
WT and annexin Al null cells were 95 ± 14 and 70 ±8 respectively. All Data are mean 
t SEM of n=4 experiments performed with n=4-5 mice each. *P<0.05 compared with 
WT CDl lb expression. 
3.2.2 Neutrouhil activation in the trans enic annexin Al over expresser g 
To conclude this section detailing leukocyte activation as determined by cell adhesion 
molecule regulation, the annexin Al transgenic over expressing mouse was utilised. 
Whole blood aliquots from either WT or annexin Al over expressing mice were 
incubated with increasing concentrations of PAF (see Figures 3.4 and 3.8). Incubation 
of whole blood from WT mice with as little as 0.3 µM PAF increased CDllb 
expression above basal (62 ±4 and 30 ±7 respectively), and this was further augmented 
in a concentration dependent manner at 3 µM and 10 µM, (Figure 3.10). In cells taken 
from annexin Al over expressing mice, CDIlb expression was markedly depressed 
compared to WT cells at all concentrations tested. It may be concluded that these mice 
appear to be less able to respond to this inflammatory mediator. 
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Figure 3.10 Alteration in adhesion molecule expression by PAF in neutrophils 
from transgenic annexin Al over expressing and WT mice. Blood aliquots were 
incubated with PAF and CDI lb expression on the cell surface was measured by flow 
cytometry analysis. (A) Expression of CD 11 b, induced by PAF on peripheral blood 
neutrophils of both genotypes. (B) Data as in panel A highlighting annexin Al over 
expresser, with increasing concentrations of PAF. Data are mean ± SEM of n=4 
experiments performed with n=3 mice each. *P<0.05 compared with WT CD I1b 
expression (basal values were 84 ±7 and 88 ±5 units of fluorescence intensity for WT 
and annexin Al over expresser cells, respectively). 
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3.2.3 Annexin Al null neutrophil chemotaxis 
To determine whether this over activation of cell adhesion molecule expression in 
response to fMLP, PAF and PMA affects neutrophil function, locomotor activity was 
studied in isolated annexin Al null neutrophils. The Neuro Probe'" chemotaxis assay 
monitors neutrophil migration in vitro. Exposure of WT isolated circulating neutrophils 
to the chemoatractant PAF caused a characteristic migration response towards the 
basement chamber with as little as 0.1 nM PAF (Figure 3.11B). Chemotaxis occurred 
at all concentrations analysed (0.1 nM to 10 nM). Interestingly, the annexin Al null 
neutrophil migration index was significantly augmented compared to that of WT cells 
e. g. with 1 nM PAF the index was 3.7 ± 0.2 compared with 2.3 ± 0.1 respectively, 
(Figure 3.11). WT isolated neutrophils migrated towards fMLP Figure (3.11A) with as 
little as at 100 pM. Both fMLP and PAF act in an analogous fashion; the migration 
index for annexin Al null cells was significantly increased compared with WT cells: for 
instance, with 1 nM PAF, the index was 3.6 ± 0.4 and 1.8 ± 0.3, respectively. 
As shown in Figure 3.5, the peptide Ac2-26 possessed chemoattractant properties. To 
study this in greater depth a checkerboard analysis was used to investigate 
chemokinetic, compared to chemoattractant, properties on murine neutrophils. Data in 
Figure 3.12 illustrate that both WT and annexin Al null neutrophils migrate towards 
peptide Ac2-26 to a similar degree, and that this occurred with a combination of 
checkerboard analysis. In spite of this, neutrophils did not migrate when the peptide 
was incubated with neutrophils alone (top chamber only). These data demonstrate that 
the peptide Ac2-26 behaves as a chemoattractant, to both genotypes, to an analogous 
degree. Thus, while the annexin Al protein is lacking in these mice the receptor(s) 
putatively involved for the effects of the peptide is present and functional. 
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Figure 3.11 Chemotaxis in neutrophils from WT and annexin Al null mice. 
Isolated neutrophils were placed on the upper chamber of aC hemoTx 1M plate with 
chemoattractant located below and incubated for 2 h, prior migration to being assessed. 
All data expressed as Migration Index (No. of migrated cells / No. of migration to 
vehicle) mean ± SEM of n= 4-5 experiments performed n= 2 mice per group. (A) fMLP 
(B) PAF. *P<0.05 compared with WT migration. In response to both PAF and tMLP (I 
nM). Annexin Al null neutrophils demonstrate enhanced chemotaxis compared with 
WT neutrophils. 
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Figure 3.12 Peptide Ac2-26 acts as a chemoattractant in murine neutrophils. 
Isolated neutrophils from either annexin Al null or WT mice were placed on the upper 
chamber of a ChemoTx TM plate with chemoattractant located below the semi-permeable 
membrane and incubated for 2 h, prior to migration being assessed with a phase contrast 
microscope. Data is expressed as Migration Index (No. of migrated cells / No. of 
migration to vehicle) mean ± SEM of n= 4 experiments performed with n= 2-3 mice in 
each group. 
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3.2.4 Annexin Al null neutrophil actin polymerisation 
One of the initial events that take place, during neutrophil activation is the 
polymerisation of intracellular actin, to form fibrous actin or F-actin. Using a specific 
fluorescent probe it is possible to detect the transient formation of F actin following the 
addition of the inflammatory mediators PAF or fMLP. Incubation of WT leukocytes 
with 1 µM PAF resulted in a transient polymerisation of cellular actin, thus increasing 
the amount of F-actin detected, with a peak at 30 sec (Figure 3.13A). This is consistent 
with annexin Al null cells, that produced similar results. WT cells incubated with 1 
µM fMLP showed a transient polymerisation of actin resulting in the formation of F- 
actin, with a peak at 30 seconds Curiously, annexin Al null cells incubated with fMLP 
produced a surprising effect, with a delayed (and long lasting) formation of F-actin 
(Figure 3.13B). 
3.2.5 Annexin Al null neutrophil ROS production 
Until now the events involved during neutrophil migration from the circulation to the 
perivascular space and site of inflammation have not been studied in detail in the 
annexin Al null mouse. Neutrophils are recruited to the site of infection to destroy and 
remove pathogens and damaged tissue cells. Biochemical reactions within the 
neutrophil produce a plethora of toxic mediators including the ROS (e. g. hydroxyl and 
oxygen radicals) that are critical in killing bacteria. To detect the generation of ROS 
production, cells were loaded with dihydrorhodamine 123, a non-fluorescent component 
that becomes the fluorescent rhodamine in the presence of ROS precursors. The 
addition of I µM PMA to WT cells induced a time dependent release of ROS over the 
20 min period examined (Figure 3.14). Cells lacking the annexin Al protein produced a 
significantly amplified quantity of ROS over the same time period, compared to 
littermate control cells (Figure 3.14). 
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Figure 3.13 Effects of fMLP and PAF on actin polymerisation in mouse 
neutrophils. Aliquots of whole blood from annexin Al null and WT were incubated in 
the presence of (A) 1 pM PAF or (B) I µM fMLP at 37°C. At the reported time the 
experiment was terminated. The cells were stained with 100 µl of NBD-phallacidin, a 
marker of F-actin, prior to being analysed by flow cytometry, an increase in 
fluorescence inferred actin polymerisation. Data are mean ± SEM of n=4 experiments 
performed with n=3 mice each. *P<0.05 compared with WT value. Data are mean t 
SEM of n=4 experiments performed with n=3 mice each. *P<0.05 compared with WT. 
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Figure 3_14. Alteration in ROS production induced by PMA; whole blood assay. 
Annexin Al null or WT neutrophils pre-loaded with di-hydrorodhamine 123. Cells 
were then incubated with PMA for 0-2-5-15-20 and 30 min. Flow cytometry analysis 
measured ROS generation at the particular time points. Annexin Al null cells exhibit an 
enhanced production of ROS compared to WT cells by 15 min. All data are mean ± 
SEM of n=4 experiments performed with cells from 4 mice each. *P<0.05 compared 
with WT. 
3.3 Leukocyte and c okine dynamics during murine zymosan peritonitis 
The aim of the final set of experiments with annexin Al null neutrophils was to 
examine whether the defect measured in selected in vitro assays could impact on 
cellular recruitment in vivo. Local administration of zymosan (1 mg in 0.5 ml saline) 
produced a time-dependent leukocyte accumulation into the peritoneal cavity, which 
followed a typical time dependent profile, associated with the acute inflammatory 
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response. Neutrophil influx into the cavity was initially observed during the first 4 h, 
although these levels declined to near basal values by 48 h (Figure 3.15). Following the 
initial influx of neutrophils came an influx of monocytes, which peaked at 24 h post- 
zymosan injection, and remained elevated. Very few resident lymphocytes could be 
counted in the lavage fluids, with no major fluctuations within the 96 h time-course 
(Figure 3.15A). A significant augmentation in neutrophil migration and macrophage 
efflux was observed in the annexin Al null mice at 4 h. In both genotypes, leukocyte 
profiles followed a uniform pattern in both genotypes in both a quantitative and 
qualitative manner, at all other times tested. 
Zymosan peritonitis also induced a time dependent endogenous release of the 
inflammatory cytokines IL-lß, IL-6 and KC into the cavity and was measured by 
standard ELISA practices. The cytokines KC and IL-6 peaked at 4h in WT mice, this 
response was hugely exacerbated in the annexin Al null mouse for instance IL-6 levels 
from WT were 854 ±9 compared to 1023 ± 46 in the annexin Al null mouse. By the 
24 h time point cytokine levels had declined considerably and returned to near basal 
levels by 48 h post zymosan injection (Figure 3.17). Interestingly, peritoneal cells also 
release IL-1 P. The concentration of these cytokines peaked at 4h in WT mice, and the 
annexin Al null mouse generated at least three times the amount of this cytokine. By 
the 48 h time point IL-1 ß levels had returned to basal, prior to a second wave of IL-1 
generation. 
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Figure 3.15 Time course of neutrophil infiltration into the murine peritoneal 
cavity, following a local injection of zymosan. Peritonitis induced using 1 mg 
zymosan (in 0.5 ml of saline). Neutrophil influx was significantly augmented in the 
annexin Al null cells at 4h post zymosan. All data are mean t SEM and are from two 
different experiments with 5 mice each. *P<0.05 compared with correspondent WT 
value. 
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Figure 3.16 Time course of monocyte access into the murine peritoneal cavity, 
after the local injection of zymosan. Peritonitis was induced using 1 mg zymosan (in 
0.5 ml of saline) injected locally into the peritoneal cavity. Differential cell counts of 
leukocyte accumulation into the cavity were quantified at the reported time-points. 
Monocyte/macrophage migration was reduced in annexin Al null cells at 4h and 48 h 
post zymosan. All data are mean ± SEM and are from two different experiments with 5 
mice each. *P<0.05 vs. correspondent WT value. 
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Figure 3.17 Time course of cytokine generation in the zymosan peritonitis model. 
ELISAs were performed to detect either: (A) KC (B) IL-6 and (C) IL-1(3. Annexin Al 
null mice exhibit an augmented cytokine production at the 4h time points. Values are 
mean ± SEM of n=5 mice per group. *P<0.05 compared with respective WT value. 
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3.4 Is phagocytosis affected between WT and annexin Al null 
macrophages. 
3.4.1 Ph gocytosis assays measuring ROS production 
In evolutionary terms, phagocytosis of invading pathogens is probably the most ancient 
inflammatory function of blood leukocytes. The phagocytic ability of naive peritoneal 
macrophages obtained from both WT or annexin Al null mice was compared using 
three distinct assays. Phagocytosis of IgG complexes was monitored using 
FcOxyburst" beads antigen-antibody complexes by real time flow cytometry. No 
differences were observed in rate or the maximal response of bead phagocytosis in WT 
cells compared to annexin Al null cells, assessed by the generation of ROS, when the 
IgG complexes were used as a stimulus (Figure 3.19A). Nevertheless, when measuring 
the generation of ROS during (non-opsonised) zymosan phagocytosis, with peritoneal 
macrophages loaded with dihydrorhodamine 123, annexin Al null mice exhibited a 
reduction in phagocytosis compared to WT cells (Figures 3.18A); MFI at 45 and 60 min 
were 78 ±2 compared to 102 ±3 and 85 ±4 compared with 106 ±6, respectively. 
However, during opsonised zymosan phagocytosis, any differences in ROS generation 
between WT and annexin Al null cells disappeared (Figure 3.18B). 
3.4.2 Uptake of zymosan fluorescent particles 
Uptake of zymosan fluorescent particles was quantified over time using (FITC)- 
zymosan particle phagocytosis, by measuring cellular fluorescence. Peritoneal 
macrophages were incubated with (FITC)-labelled zymosan with a MOI of 1: 10, and in 
the absence of annexin Al exhibited a lower degree of particle uptake compared to WT 
cells (Figure 3.19B). The difference was already significant by 30 min (15 ± 1.7 
compared to 23 ± 2.5) and marked at 45 and 60 min post-zymosan incubation. 
However, the latter experiment could not differentiate between cell attachment and 
actual ingestion of zymosan particles per se. 
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Figure 3.18 Annexin Al null macrophages display a stimulus-dependent defect 
in ROS production. Peritoneal macrophages from WT and annexin Al null mice were 
tested for their ability to phagocytose zymosan particles. Cells (1 . 25 x 10-' per sample) 
loaded with DHR123 and stimulated by addition of either (A) non-opsonised zymosan 
or (B) opsonised zymosan. The reaction was halted at particular time points, by the 
addition of ice cold PBS supplemented with 0.02% sodium azide and samples were 
analysed by flow cytometry. For both panels, data are mean ± SEM of n=4 experiments 
performed with n=3-4 mice each. *P<0.05 compared with respective WT value. 
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Figure 3.19 Annexin Al null macrophages display a stimulus-dependent defect 
in phagocytosis / adhesion. (A) Peritoneal macrophages from WT and annexin A] 
null mice were (2.5 x105 per sample) incubated with IgG complexes and monitored by 
real time flow cytometry for phagocytosis-related oxidation and associated fluorescence 
over a 204 sec time frame. (B) Analysis of non-opsonised FITC-zymosan association 
(MOI 1: 10), cytochalasin D control for WT and annexin A1 null macrophages. Samples 
were then analysed by flow cytometry. All data are mean ± SEM of n=4 experiments 
performed with n=3 mice each. *P<0.05 compared to respective WT value. 
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3.4.3 Electron microscopy analysis following zvmosan phagoc osis 
To determine how this phagocytic impairment was occurring, electron microscopy 
investigation was employed. Macrophages were incubated with 200 pg/ml of zymosan 
and fixed prior to analysis. Resting cells did not display any apparent morphological 
differences between the two-macrophage genotypes under resting conditions (Figure 
3.20 A and B). During phagocytosis WT cells ingested a large number of particles 
(Figure 3.20) and this was visibly attenuated in the annexin Al null macrophage (Figure 
3.20). Analysis of this process demonstrated that 3h was the optimum sampling point 
since a large majority (-85%) of zymosan particles were ingested in wild type cells, 
with few particles associated with the external macrophage plasma membrane (Figure 
3.21). Annexin Al null macrophages particles were not ingested but remained loosely 
attached to the cell membrane. Figure 3.20D inset shows an example of one annexin 
Al null macrophage surrounded by zymosan particles that it is apparently unable to 
ingest compared to WT cells. 
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Figure 3.20 Electron micrographs of peritoneal macrophages before and after 
non-opsonised zymosan incubation. Peritoneal macrophages from WT and annexin 
Al null mice were incubated with 200 gg/ml non-opsonised zymosan for 3 h, prior to 
fixation and processing. (A) Resting WT macrophages. (B) Resting annexin Al null 
macrophages. (C) WT macrophages engulfed with several zymosan particles (asterisks 
highlight some of these phagosomes). (D) Annexin Al null macrophages with fewer 
zymosan particles. Arrowheads indicate particles associated with the plasma membrane 
rather than fully internalized. Inset: lower magnification image showing an example of 
disturbed phagocytosis with several zymosan particles in close vicinity, but not 
internalized, of the cell. Images are representative of experiments from 14 distinct 
animals. Panel A-D, bar I µm, inset, bar 2 gm. 
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Figure 3.21 Quantification of zymosan particle association with WT and annexin 
Al null macrophages following a3h incubation. Analysis of fully internalized or 
loosely associated (clearly in contact with the plasma membrane) particles was blindly 
performed on 9 distinct electron micrographs prepared as in Figure 3.20. Data are mean 
f SEM of n=9 from 14 distinct animals a genotype. *P<0.05 compared with WT value. 
3.4.4 Analysis of macroyha 9 e plasma membrane markers 
Particle internalisation is initiated by the interaction and recognition with receptors on 
the surface of the phagocyte. Functional plasma membrane receptors are found on 
macrophages and other phagocytes and determine many activities of the cell, including 
growth, differentiation, activation and recognition of foreign particles to name a few. 
Peritoneal macrophages were labelled with a specific primary antibody for the desired 
membrane antigen prior to the addition of a FITC secondary antibody, and quantified by 
flow cytometry. These analyses revealed specific alterations in the annexin Al null 
compared with WT macrophages. While no significant differences were found with 
respect to dectin I (the ß glucan receptor) expression (Figure 3.22B), a modest yet 
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significant reduction in the differentiation marker F4/80 was measured on macrophages 
lacking annexin Al (Figure 3.22A). 
Next, opsonic membrane markers (CD 11 b and FcyRII/III) were quantified by flow 
cytometry. No significant differences were found with respect to FcyRII/III levels 
between genotypes (Figure 3.23B). All this data is in line with the absence of a 
difference in phagocytosis of IgG complexes (see Figure 3.19A). The most evident 
difference was observed for CD11b expression, with approximately a 40% reduction in 
plasma membrane expression in the annexin Al null compared to WT macrophages 
(719 t 65 compared with 1254 ± 67 respectively, Figure 3.23A). This was reflected in 
a reduction in total CDI lb levels in annexin Al null cells, as assessed following cell 
permeabilisation with saponin (Figure 3.23A). This was further tackled by fluorescent 
imaging, showing the marked reduction in CDllb expression compared to WT cells 
(Figure 3.23). 
126 
Chanter 3 
I 
A 
c 
0 
1500-1 
1000- 
(D L. - 
0. ýCL 
(D v 
Co 500 
ý 
LL 
0- 
B 
c 0 
100- 
N 75- 
L 
Q^ 
X LL 
4) 2 50-ý 
ý 
C 
ý 
V 
d 
ý 
%.. 01 
25- 
OJ 
Results 
* 
Figure 3.22 Variations in annexin Al null peritoneal macrophage cell surface 
molecules. Peritoneal macrophages labelled with either anti F4/80 (clone CI: A31) and 
anti Dectin 1 (clone 2A11) prior to the addition of a FITC secondary antibody. Cell 
surface markers were measured by flow cytometry. (A) The monocytic cell surface 
marker F4/80 was down regulated in the annexin Al null. (B) Dectin I expression cell 
surface expression is unaltered in the annexin Al null compared with WT. All data are 
mean ± SEM of n=4-5 experiments performed with n=4-5 mice each. *P<0.05 
compared with WT cells. 
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Figure 3.23 Variations in annexin Al null peritoneal macrophage cell surface 
molecules. Peritoneal macrophages labelled with either anti CD Ilb (clone 5C6) and 
FcRyII/I11 (clone: 24G2) prior to the addition of a FITC secondary antibody. Cell 
surface markers were measured by flow cytometry. (A) CDI lb expression on the cell 
surface of annexin Al null peritoneal macrophages is reduced compared with WT, 
furthermore, this is true for whole cell CDI lb expression (saponin data). Confocal 
images (above), confirmation by cellular staining. (B) FcRyII/III expression cell surface 
expression was unaltered in the annexin Al null compared with WT. All data are mean 
± SEM of n=4-5 experiments performed with n=4-5 mice each. *11<0.05 compared with 
WT cells. 
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3.4.5 Markers of peritoneal macropha e activation 2 
During inflammation macrophages exerts pro-inflammatiory activities that involve 
phagocytosis of pathogens, release of mediators to promote vasodilatation and vascular 
permeability (e. g. PGE2), mitochondrial and cytotoxic actions (e. g. ROS and NO) and 
endothelial activation to facilitate leukocyte immigration (e. g. TNFa). 
3.4.5.1 PGE2 production in activated peritoneal macrophages 
Peritoneal WT and annexin Al null macrophages incubated with 200 µg/ml of zymosan 
were assessed for several parameters of macrophage activation, to clarify the down- 
stream events that follow zymosan phagocytosis. Initially, the eicosanoid PGE2 was 
measured over a 24 h time course. A marked accumulation of PGE2 was measured in 
the supernatant of both WT and annexin Al null macrophages during phagocytosis of 
non-opsonised zymosan, although the response was attenuated in the latter cell type 
(Figure 3.24), presumably in view of the lower extent of particle uptake. This reduction 
in eicosanoid production was evident at all time points investigated, though significance 
was reached only at 2 and 6h post-zymosan (Figure 3.24). A modest release of PGE2 
was detected in the absence of cell stimulation, with no difference apparent between the 
genotypes (Figure 3.24). To investigate if these zymosan abnormalities were specific to 
particle phagocytosis, soluble mediator activation was also investigated. WT peritoneal 
macrophages were incubated with IgG aggregates or LPS and PGE2 concentrations 
were again measured throughout a 24 h time course shown on Table 3.1. A noticeable 
increase of PGE2 was observed in the supernatant of WT macrophages, in response to 
these stimuli this response was augmented in the annexin Al null macrophage. This 
differential response to soluble mediators was apparent throughout the assay and 
reached significance at 6h with IgG aggregates and 20 h with LPS (Table 3.1). 
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Figure 3.24 PGE2 production in WT and annexin Al null macrophages following 
zymosan incubation. Peritoneal macrophages from WT and annexin Al null mice (1 x 
106 per sample) were seeded in a 24-well plate and activated with zymosan (200 µg/ml) 
and the time-course of PGE2 release in response to zymosan was assayed. Data are 
mean ± SEM of n= 3 experiments performed in triplicate with cells pooled from 7-10 
mice *P<0.05 compared with WT. 
No stimulus Heat Aggregated LPS 
Time IgG 
(h) Wild Annexin Wild Annexin Wild Annexin 
Type Al Type Al Type Al 
null null null 
2 33ý2 57ý 17 132f34 217± 53 255± 66 324t50 
6 40 ý 13 32 ý 10 114 ý6 320 ± 36 * 776+51 895 ý 110 
20 53 f 13 75 ý 17* 147 f 27 259 f 52 11 1± 19 1800 ý 175* 
Table 3.1 PGE2 release from peritoneal macrophage in response to different 
stimuli. Adherent macrophages (1 x 106) prepared from WT or annexin Al null mice 
were incubated for the reported times either alone (no stimulus), with heat aggregated 
IgG complexes (200 µg/ml) or LPS (10 ng/ml). At the end of the incubation period, 
PGE2 was assayed in the cell media. Data reported are PGE2 concentrations in pg/ml, 
and are expressed as mean ± SEM of n=3 experiments performed in duplicate. 
P<0.05 compared with respective WT values. 
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3.4.5.2 Inflammatory enzymes induction 
The inducible inflammatory enzymes iNOS and COX-2 were also measured. A modest 
COX-2 protein expression was detected in both WT and annexin Al null macrophage 
after adhesion to plastic, however this was markedly increased following cell activation 
with zymosan: annexin Al null cells exhibited a greater expression of the enzyme 
(Figure 3.25). Cell activation with heat aggregated IgG also led to pronounced COX-2 
induction, but with little difference between the genotypes. Incubation with LPS 
produced a substantial COX-2 induction and, alone amongst the stimuli investigated, 
also an induction of iNOS. Table 3.1 reports the PGE2 values from this set of 
experiments. In contrast to zymosan, soluble stimulants such as IgG complexes and 
LPS produced a greater release of PGE2 in annexin A] null macrophages that was 
particularly evident after longer incubation times (Table 3.1). 
WT KO WT KO WT KO WT KO 
iNOS (130 kDa) 
COX 2 (72 kDa) 
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Figure 3.25 WT and annexin Al null macrophage activation as measured COX- 
2 or iNOS expression. Peritoneal macrophages from WT and annexin Al null mice (1 
x106 per sample) seeded in 24-well plate and activated with zymosan (200 µg/ml), heat 
aggregated IgG (HA IgG; 200 pg/ml) or LPS (10 ng/ml) for a 20 h period. COX-2 and 
iNOS immuno-reactivity in cell extracts as measured following 20 h cell incubation. 
Gel representative of 2 distinct experiments. 
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3.5 The annexin Al null bone marrow derived macrophage 
Initial experiments were conducted to confirm the phagocytic ability of these cells 
compared to the resident macrophage. Subsequently the bone marrow derived 
macrophage was used due to its highly phagocytic nature and straightforward culture in 
the laboratory. 
3.5.1 Analysis of macrophage plasma membrane markers BMDMo 
Phagocytosis commences with the interaction and recognition of receptors on the 
surface of the phagocyte with the particle. Functional plasma membrane receptors are 
found on macrophages, determining many activities of the cell, including recognition of 
foreign particles. BMDMo were stained with a specific primary antibody to a given 
antigen prior to the addition of a FITC secondary antibody and cell surface markers 
were quantified by flow cytometry. Flow cytometry revealed specific alterations in the 
annexin Al null cell compared to WT cells. While no significant differences were 
noticed with respect to F4/80 expression (Table 3.2), there was a modest yet significant 
reduction in the opsonic membrane markers (FcyRII/III and CD 11 b) levels in 
macrophages lacking annexin Al (Table 3.2). 
3.5.2 BMDMo particle uptake both in vitro and in vivo 
A time course of fluorescent zymosan particle uptake was quantified, by measuring 
cellular fluorescence. BMDMo were incubated with either (FITC)-zymosan (MOI of 
1: 5), opsonised (FITC)-sheep red blood cells or (FITC)-Neisseria meningitides. Uptake 
was calculated at various times, by fixing cells prior to analysis by flow cytometry. 
Interestingly, in contrast to peritoneal macrophages; annexin Al null cells exhibited a 
reduced uptake of opsonised particles (sheep red blood cells) that was already 
significant by 15 min (WT 116 ±7 compared to 76 ±5 in annexin Al null cells) and 
marked at 30 and 45 min post-particle incubation. This impairment in the annexin Al 
null cells uptake of sheep red blood cells was mirrored during phagocytosis of (FITC)- 
Neisseria meningitides, where there was a noticeable difference by 5 min (Figure 
3.26B). Consistent with previous data produced with primary macrophages, uptake of 
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(FITC)-zymosan was significantly attenuated in the annexin Al null macrophages, for 
instance at 15 min the MFI values were 806 ± 16 compared with 371 ± 21 for WT and 
annexin Al null cells respectively (Figure 3.27A). As mentioned previously this assay 
does not differentiate between cell attachment and actual ingestion of zymosan particles 
per se. This point was addressed further by real time confocal studies. (FITC)- 
zymosan particles were incubated with BMDMo (MOI 1: 5) and cultured on glass 
coverslips and incubated at 37 T. Zymosan uptake was monitored via time-lapse 
microscopy over a1h period (a total of 239 images were captured; one every 15 
seconds). These results, shown in Figure 3.27B confirmed that the annexin Al null 
macrophage possess grossly impaired particle cell interaction compared to WT cells, 
resulting in a decreased phagocytosis observed in cells lacking annexin Al (see 
supplementary compact disc with video footage). 
Strain FcRyII/III CD11 b F4/80 
WT 170±6 215±8 128± 16 
Annexin 156 f7 160 f5* 111 ± 17 
Al null 
Table 3.2 Annexin Al null BMDMo expression of cell surface molecules. 
Macrophages labelled with either anti FCRyII/III (clone: 24G. 2), anti F4/80 (clone 
CI: A31) or anti CDI lb (clone: 5C6) prior to the addition of a FITC secondary antibody. 
Cell surface markers were measured by flow cytometry. All Data are mean ± SEM of 
n=4-5 experiments performed with n=4-5 mice each. *P<0.05 compared with WT cells. 
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Figure 3.26 Annexin Al null macrophages exhibit a defect in particle uptake. 
BMDMe from either WT or annexin Al null mice, were tested for their ability to 
phagocytose specific particles. (A) Cells (5 x105 per sample) incubated with (FITC) 
labelled opsonised sheep red blood cells (MOI of 1: 15) (B) Analysis of non-opsonised 
(FITC)-Neisseria association (MOI 1: 15). Samples were then fixed at particular time 
points and analysed by flow cytometry. The phagocytic ability of the annexin Al null 
BMDMe is significantly attenuated in contrast to WT cells. All data are mean ± SEM 
of n=3-4 experiments in duplicate, performed with n=2 mice each. *11<0.05 compared 
with respective WT value. 
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Figure 3.27 Annexin Al null bone marrow derived macrophages display a defect 
in (FITC)-zymosan uptake. (A) BMDMe (5 x105 per sample) incubated with non- 
opsonised (FITC)-zymosan (MOI 1: 5). Cytochalasin D was used as a control due to its 
ability to inhibit actin reorganisation. Samples were then fixed at particular time points 
and analysed by flow cytometry. Cytochalasin D control for WT and annexin Al null 
shown by   and Q (occluded by the black box), respectively. Data are mean ± SEM of 
n=4 experiments performed with n=2 mice each. *P<0.05 compared with the respective 
WT value. (B) Real time microscopy analysis of zymosan phagocytosis. (FITC)- 
zymosan particles administered to BMDMe (MOI 1: 5) cultured on glass coverslips, 
were mounted on a 37 °C preheated microscope chamber. Uptake of zymosan particles 
was monitored by time-lapse microscopy over aIh period (239 images were captured, 
one every 15 seconds). See additional CD for movie image files. This data exemplifies 
that phagocytosis is grossly impaired in the annexin Al compared to WT cells. 
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Figure 3.28 In vivo uptake of unopsonised (FITC)-zymosan by resident 
macrophages in WT and annexin Al null mice. Animals were injected with 6.25 
x107 particles of zymosan (in 0.5 ml of saline) locally into the peritoneal cavity. 
Animals were killed at particular time points and peritoneal lavage fluids were fixed 
and analysed by flow cytometry. Zymosan uptake in annexin Al null cells in markedly 
reduced at all times analysed compared with WT cells. All data are mean ± SEM n=3 
mice per group. *P<0.05 compared to respective WT value. 
Finally, to investigate if this phenomenon was solely isolated to in vitro assays, animals 
were injected with (FITC)-zymosan (6.25 x107 particles/mouse) locally into the 
peritoneal cavity, animals were killed at particular time points allowing resident 
macrophages to interact with the fluorescent particles for various periods of time and 
peritoneal lavage fluids collected fixed and cellular fluorescence analysed by flow 
cytometry. Zymosan uptake by annexin Al null cells was markedly attenuated at all 
times analysed compared to WT cells, even as early as 2 min post injection (WT 684 f 
103 compared to 346 ± 45 in the annexin Al null mouse, Figure 3.28). 
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3.5.3 BMDMo Cytokine production 
Inflammatory cytokines are commonly produced by macrophages during cellular 
activation. These proinflammatory mediators are powerful inducers of the 
inflammatory response and a central regulator of innate immunity. Initially, the 6h 
time point was investigated, allowing sufficient time to allow de novo synthesis and 
release of cytokines. WT BMDMo cells incubated with zymosan particles (MOI 1: 50) 
produced a typical time dependent increase of the inflammatory cytokines TNFcc and 
IL-6 (Figures 3.29,3.30 and Tables 3.3,3.4). 
Following a6h incubation with zymosan or LPS 10 ng/ml TNFa production was 
significantly exacerbated in cells lacking the annexin Al protein (Figure 3.29). A more 
detailed tissue culture was performed. This trend was observed at earlier time points as 
well (Table 3.3). IL-6 synthesis was also investigated, in cellular exudates. Incubation 
with zymosan, Neisseria (MOI 1: 50) or LPS 10 ng/ml for 6h provoked a substantial 
increase in IL-6 production in all cases (Figure 3.30). Annexin Al null cells generated 
elevated levels of IL-6 compared to WT cells. Excessive IL-6 production was most 
apparent in annexin Al null cells incubated with neisseria or LPS (Figure 3.30), this 
phenomenon persisted throughout the time course (Table 3.4). 
3.5.4 Annexin Al localisation during phagoc osis 
Only once these defects in phagocytosis had been confirmed in the annexin Al null 
BMDMe's, the cells were utilised for image analysis. Confocal imaging was employed 
to visualise and detect specific cellular protein distribution. (FITC)-zymosan particles 
were incubated with WT BMDMr cells adhered to glass cover slips (MOI 1: 5). Cells 
were incubated at 37 °C for either 5 min to monitor phagocytic cup formation or 1h to 
observe engulfment over a prolonged period of time. Subsequently, cells were fixed 
permeablised and stained for annexin Al and actin prior to being analysed by confocal 
microscopy. No morphological differences were observed between WT and annexin 
Al null cells, although cellular shape was modified due to adhesion to glass. 
The initial stages of phagocytosis are characterised by the formation of the phagocytic 
cup, this occurs as actin polymerises forming microfilaments around the engulfed 
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particle or phagosome. This is illustrated in Figures 3.31A, 3.32 and 3.33. Cytoskeletal 
structural arrangements appeared to be analogous in both genotypes, with an intense 
concentration of cytoplasmic actin formation surrounding the zymosan particle during 
the initial stages of phagocytosis. This focus of actin around the particle dissipated at 
later time points (Figure 3.31B, 3.34,3.35) in both genotypes. Next, annexin Al 
cellular distribution was observed during this process (obviously annexin Al null cells 
did not stain for the protein). Interestingly, during the initial stages of phagocytosis 
annexin Al's location in WT BMDMo mirrors that of actin with an elevated intensity of 
annexin Al surrounding the early phagosome (Figure 3.32). Nevertheless, through the 
later stages of phagocytosis annexin Al dissipates from the phagosome, spreading 
throughout the cytoplasm evenly (Figure 3.34). This set of data implicates a role for 
annexin Al during the initial stages of phagocytosis. 
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Figure 3.29 TNFa release from BMDMO in response to different stimuli. 
Adherent BMDMo (5x105) prepared from WT or annexin Al null mice were incubated 
for 6h with either (A) zymosan (MOI 1: 50), (B) Neisseria (MOI 1: 50) or (C) LPS (10 
ng/ml). At the end of the incubation period, cell free medium was collected and 
assayed for TNFa levels. Annexin Al null generation of TNFa was significantly 
amplified during activation by every stimuli, compared to WT cells. Data reported are 
TNFa concentrations in pg/ml, and are expressed as mean ± SEM from n= 3 
experiments performed in duplicate. * P<0.05 compared with respective WT values. 
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No stimulus Zymosan Neisseria LPS 
Time Wild nnncxin Wild Annexin WiI(I nnncxin Wild Anncxin 
(h) 
Type AI Type Al Type AI Type AI 
null null null null 
2 9+1 8.3±0.3 24t0.9 33±1.7' 47+11 57+3 291{). 3 42ý3 - 
4 8.3±1 9 48±1 103±2* 33±1 36±2 16±4 26±3 
24 8.3±0.3 8.3-1=0.3 8.3±2 8.3+0.3 8.3±0.3 8.310.3 8.3±0.3 8.310.3 
Table 3.3 TNFa release from BMDMO in response to different stimuli. 
Adherent macrophages (0.5x106) prepared from WT or annexin Al null mice incubated 
for the reported times either alone (no stimulus), with zymosan (MOI 1: 50), Neisseria 
(MOI 1: 50) or LPS (10 ng/ml). At the end of the incubation period, cells free medium 
was collected and assayed for TNFa levels. (Detection limit 8.3) Data reported are 
TNF concentrations in pg/ml, and are expressed as mean ± SEM from n=3 experiments 
performed in duplicate. * P<0.05 compared with respective WT values. 
No stimulus Zymosan Neisseria LPS 
Time Wild Annexin Wild Annexin Wild Annexin Al Wild Annexin 
(h) 
Type Al Type Al Type null Type Al 
null null null 
2 213±6 222±6 230±12 230±8 243±3 270117 250±5 306±14 
4 220±3 216±8 236±3 246±3 1250±51 3270±303 1350±145 2867±142* 
24 226±3 226±3 252±10 396±28 38620±2895 43427±3317 33620±3017 32383±1158 
Table 3.4 IL-6 release from BMDMO in response to different stimuli. 
Adherent macrophages (0.5x106) prepared from WT or annexin I null mice incubated 
for the reported times either alone (no stimulus), with zymosan (MOI 1: 50), Neisseria 
(MOI 1: 50) or LPS (10 ng/ml). At the end of the incubation period, cell free medium 
was collected and assayed for IL-6 levels. Data reported are IL-6 concentrations in 
pg/ml, and are expressed as mean ± SEM from n=3 experiments performed in duplicate. 
* P<0.05 compared with respective WT values. 
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Figure 3.30 IL-6 release from activated BMDMO in response to different 
stimuli. Adherent macrophages (5x105) prepared from WT or annexin Al null mice 
incubated for 6h with either (A) zymosan (MOI 1: 50), (B) Neisseria (MOI 1: 50) or (C) 
LPS (10 ng/ml). At the end of the incubation period, cell free medium was collected 
and assayed for IL-6 levels. Data reported are IL-6 concentrations in pg/ml, and are 
expressed as mean ± SEM from n=3 experiments performed in duplicate. * P<0.05 
compared with respective WT values. 
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Figure 3.31 Confocal microscopy illustrating actin localisation during the initial 
and late stages of zymosan phagocytosis. WT and annexin Al null BMDMc 
incubated with (FITC)-zymosan (green) particles for various times prior to cells being 
permeablised and stained with phalloidin (red). The left two columns demonstrate 
zymosan or actin alone, respectively with the right hand column illustrating the overlay 
of the two. (A) Following a 5-minute incubation with FITC-zymosan, actin cup 
formation was observed around the particles in both genotypes. (B) Ih post zymosan 
incubation zymosan uptake was reduced in the annexin Al null cells compared to WT 
cells. 
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Figure 3.32 Annexin Al and Actin localisation during the initial events of 
phagocytosis in WT BMDMe. WT BMDMe incubated with (FITC)-zymosan (green) 
particles for 5 min prior to cells being fixed and permeablised. Cells were subsequently 
stained for annexin Al (blue) and actin (red). The image is annotated accordingly, the 
top row accounts for the annexin Al antibody control and colours were labelled 
according to individual flurochrome. Demonstrating, after a5 min incubation with 
(FITC)-zymosan, actin cup formation occurs around the particle seen with the high 
concentration of actin, this response was coupled with a elevated density of annexin Al 
around the cup too, images representative of 10 images. 
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Figure 3.33 Actin localisation during the initial events of phagocytosis in annexin 
Al null BMDMe. Annexin Al null BMDMr incubated with (FITC)-zymosan (green) 
particles for 5 min prior to cells being fixed and permeablised. Cells were subsequently 
stained for annexin Al (blue) and actin (red). The plate is annotated accordingly, the 
top row accounts for the annexin Al antibody control and colours were labelled 
according to individual flurochrome. Demonstrated after a5 min incubation with 
(FITC)-zymosan, actin cup formation takes place around the particles with a high 
concentration of actin, this response was annexin Al staining and was lost in the null 
cells as expected. Images representative of 10 images. 
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Figure 3.34 Annexin Al and Actin localisation during the late events of 
phagocytosis in BMDMo. WT BMDMo incubated with (FITC)-zymosan (green) 
particles for 1h prior to the cells being fixed and permeablised. Cells were 
subsequently stained for annexin Al (blue) and actin (red). The plate is annotated 
accordingly, the top row accounts for the annexin AI antibody control and colours are 
labelled according to individual flurochrome. Following the Ih incubation with FITC- 
zymosan, actin cup formation observed at the earlier Figure 3.32 at 5 min post zymosan 
has diminished and actin is now dispersed throughout the cells this is analogous to 
annexin Al. Images representative of 10 images. 
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Figure 3.35 Actin localisation during the late events of phagocytosis in BM DMe. 
Annexin Al null BMDMo incubated with FITC-zymosan (green) particles for Ih prior 
to cells being fixed and permeablised. Cells were subsequently stained for annexin Al 
(blue) and actin (red). The plate is annotated accordingly, the top row accounts for the 
annexin Al antibody control and colours are labelled according to individual 
flurochrome. Following the 1h incubation with FITC-zymosan, actin cup formation 
observed at the earlier Figure 3.33 at 5 min post zymosan has disappeared and actin is 
now dispersed throughout the cells. Images representative of 10 images. 
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3.6 Are annexin Al macrophages still sensitive to glucocorticoids? 
Since its discovery in 1980, annexin Al has been shown to mediate many of the anti- 
inflammatory effects attributed to glucocorticoids in rodents and other species. With 
regards to macrophages, glucocorticoids suppress phagocytosis by inducing the 
secretion of a phagocytosis inhibitory protein (PIP) most likely to be annexin Al. Thus, 
in the last set of experiments the anti-phagocytic activity of hydrocortisone was tested. 
The reason for choosing this glucocorticoid is due to it being an endogenous active 
glucocorticoid thus giving physiological relevance to this set of results. 
Phagocytosis of FcOxyburst'' antigen-antibody complexes was monitored by real time 
flow cytometry over 204 seconds. Preliminary data illustrates that no differences were 
observed between peritoneal macrophages from WT and annexin Al null mice, with 
respect to phagocytosis and ROS production induced by immune complexes (Figure 
3.19A) and opsonised zymosan (Figure 3.18B). This is in line with data shown in 
Figure 3.36. However, when resident peritoneal macrophages were incubated with 10 
µM hydrocortisone for 60 min prior to the addition of FcOxyburstTM immune 
complexes, a reduction in both rate and maximum phagocytic profile in WT 
macrophages was observed with a degree of inhibition around 30% (Figure 3.36). In 
contrast, hydrocortisone's potent inhibitory effects disappeared in annexin Al null cells. 
Unfortunately so did the FcOxyburst" and locating additional supplies to continue these 
experiments proved problematic. 
Therefore, to pursue this line of investigation, the probe DHR 123 was used, which also 
conveys ROS production. Initially, experiments were re-confirmed (Figure 3.38). 
Peritoneal macrophages incubated with opsonised zymosan (200 mg/ml) produced a 
respiratory burst that was selectively inhibited by hydrocortisone in WT, C57BL/6 and 
FPR KO macrophages to -30% (Figures 3.38 and 3.39). However, hydrocortisone's 
inhibitory actions were yet again abrogated in the annexin Al null macrophage (Figure 
3.38). When the peptide Ac2-26 was incubated with either WT, C57BL/6, FPR KO or 
annexin Al null macrophages, the peptide inhibited ROS generation in all genotypes 
(Figures 3.38 and 3.39). Thus indicating that lack of annexin Al itself does not 
interfere with downstream signalling, which appears to be present and functional. 
147 
Chapter 3 Results 
A 
F 
NN 
750-1 
500H 
=C 
. 92 Z K 
LL 00 3 250- 
LL 
B 
0-J 
750 
9 
` 0500 
2 
0ý 250 
U- 
0 
CWT 
WT & 10 pM hydrocortisone 
0 50 100 150 200 250 
Time (seconds) 
-o- Annexin Al null 
Annexin Al null & 10 pM hydrocortisone 
0 50 100 150 200 250 
Time (seconds) 
Figure 3.36 FcOxyburstTM typical traces, during WT and annexin Al null 
macrophages IgG phagocytosis under the influence of hydrocortisone. Peritoneal 
macrophages incubated with hydrocortisone (10 µM) for 45 min prior to the addition of 
10 ml of RedOxyburstTM immune complexes. Uptake was monitored in real time using 
FACS analysis. (A) WT and (B) annexin Al null cells. Each point on the kinetic 
reaction plot above is the mean ± SEM of three readings. 
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Figure 3.37 Hydrocortisone does not influence IgG phagocytosis in annexin Al 
null macrophages. Peritoneal macrophages incubated with hydrocortisone (10 
mM ) for 45 min prior to the addition of 1Qnl of Red FcOxyburstTM immune 
complexes. Uptake was monitored in real time using FACS analysis. Inhibition by 10 
pM hydrocortisone of IgG phagocytosis from different genotypes. Hydrocortisone's 
inhibitory actions appear to be abrogated in the annexin Al null macrophage. 
Heterozygote data shows a partial inhibition. All data are mean ± SEM of n=4 
experiments performed with n=4-6 mice each. *P<0.05 compared with WT. 
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Figure 3.38 Hydrocortisone impedes phagocytic behavior of peritoneal 
macrophages in WT but not in annexin Al null macrophages. Peritoneal 
macrophages were incubated with 10 pM hydrocortisone for 1h or 30 min with 200 
pg/ml Ac2-26 preceding being loaded with di-hydrorodhamine 123. Subsequently, 
cells were incubated with opsonised zymosan. FACS analysis measured ROS 
generation at particular time points. Hydrocortisone inhibited ROS production during 
phagocytosis in WT macrophages yet the annexin Al null macrophages appear to be 
insensitive. The peptide Ac2-26 inhibits both WT and annexin Al null ROS production 
to a similar degree. All data are mean ± SEM of n=4 experiments performed with n=4- 
6 mice each. % Difference AUC basal compared with WT. 
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Figure 3.39 Hydrocortisone impedes phagocytic behaviour of peritoneal 
macrophages in both C57BL/6 and FPR KO. Peritoneal macrophages incubated 
with 10 pM hydrocortisone for Ih or 30 min with 200 µg/ml Ac2-26 proceeding being 
loaded with di-hydrorodhamine 123. Subsequently, cells were incubated with 
opsonised zymosan. FACS analysis measured ROS generation at particular time points. 
Hydrocortisone and Ac2-26 inhibited ROS production produced in C57BL/6 and FPR 
KO macrophages during phagocytosis of opsionised zymosan to an analogous degree. 
All Data are mean ± SEM of n=4 experiments performed with n=4-6 mice each. % 
Difference AUC. 
151 
CHAPTER 4 
DISCUSSION 
Chaoter 4 Discussion 
4.1 Annexin Al null neutrophils are more susceptible to inflammatory 
stimuli 
The recent generation of the annexin Al null mouse, with the initial characterisation of 
their inflammatory phenotype (Hannon et al., 2003; Roviezzo et al., 2002; Yang et al., 
2004), presented an ideal opportunity to test and characterise the potential role of 
endogenous annexin Al in the circulating neutrophil. 
In several animal models of inflammation glucocorticoid drugs are potent suppressors 
of neutrophil accumulation, and are effective in virtually all-inflammatory conditions. 
Dexamethasone and hydrocortisone reduce both neutrophil rolling and migration in the 
inflamed vascular bed, observed following post-operative surgery (human) and 
experimental inflammation (rat), as determined by intravital microscopy (Kirveskari et 
al, 2002; Tailor et at, 1997). In this context, it is critical to remember that systemic 
administration of dexamethasone augments annexin Al levels in human, hamster and 
mouse circulating leukocytes by a factor of 2-3 fold (Goulding et al., 1990; Mancuso et 
al., 1995; Perretti & Flower, 1996). This elevated expression of annexin Al is 
associated with a delayed leukocyte migration, in the inflamed mouse peritoneal cavity, 
the rat arthritic joint and hamster cheek pouch models of inflammation (Mancuso et at, 
1995; Oliani et al., 2001; Perretti & Flower, 1996; Yang et al., 1997). The inhibitory 
glucocorticoid effects on leukocyte adhesion and emigration on the inflamed 
microvascular bed of the hamster cheek pouch and arthritic rat joint are abrogated by 
passive immunisation with the annexin Al neutralising antibody (Mancuso et al, 1995; 
Yang et at, 1997). Hence, the documented literature indicates annexin Al to be 
responsible, at least in part, for dexamethasone's anti-migratory properties. 
Exogenous annexin Al and its peptido mimetics have been shown to be potent 
inhibitors of neutrophil activation and recruitment in several models of inflammation 
(Euzger et at, 1999; Harris et at, 1995; Perretti & Flower, 1993; Perretti et at, 1995). 
The annexin Al mimetic Ac2-26 generates a potent dose-dependent inhibition of 
neutrophil migration in the inflamed murine air pouch and peritoneal cavity. Yet, the 
efficacy of Ac2-26 is two orders of magnitude less than recombinant annexin Al itself 
(Perretti & Flower, 1993). More recently, exogenous annexin Al and Ac2-26 have 
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been shown to inhibit leukocyte attachment to endothelial cells on the zymosan- 
inflamed murine mesenteric bed (Lim et al., 1998) and significantly abrogate PAF and 
MLP induced neutropenia (Harris et al., 1995; Perretti & Flower, 1993). 
Neutrophil migration is dependent upon strictly dictated sequential interactions between 
leukocytes and the endothelial cells (Panes et al., 1999), see section 1.2.3). Canonical 
inflammatory mediators are released in the inflammatory milieu to recruit circulating 
leukocytes. The ß2 integrins play a critical role in the complex process of leukocyte 
migration from the peripheral blood to the inflammatory site. The strength of the ß2 
integrins adhesiveness or avidity is determined by the intrinsic affinity of individual 
bonds, and the number of these bonds or valency. Leukocytes mobilise intracellular 
stores of ß2 integrins to the extracellular membrane in response to inflammatory 
mediators such as PAF or cytokines such as TNFa resulting in a 10-30-fold increase of 
expression, hence, increasing their valency and adhesiveness. This process permits firm 
adhesion of leukocytes to the endothelium (Ding et al., 1999). Earlier work has 
revealed dexamethasone reduces CD 11 b membrane expression on activated mouse 
eosinophils, in a concentration dependent fashion (Lim et al., 2000) and human 
neutrophils (Filep et al., 1997), as assayed by flow cytometry. At the outset of this 
thesis leukocyte CAM expression and neutrophil activation analysis was conducted on 
whole blood, evaluating a role for endogenous annexin Al and examining if this protein 
could modulate basic facets of neutrophil biology. 
To assess the role of endogenous annexin Al in the context of neutrophil activation the 
preliminary construction of concentration-response curves to various chemotatic 
inflammatory mediators measuring CD 1lb up-regulation was necessary. From these 
results it can be assumed that cells lacking the annexin Al protein are super sensitive to 
pro-inflammatory mediator activation, as CD 11 b up-regulation was significantly 
augmented in annexin Al null neutrophils and monocytes compared to their littermate 
(WT) controls at all concentrations of fMLP, PAF and PMA tested. Previously, 
dexamethasone has been shown to attenuate PAF induced CD 18 up-regulation and L- 
selectin shedding in human neutrophils (Filep et al., 1997). More recently Strausbaugh 
& Rosen (2001), have demonstrated that exogenous annexin Al induces a non- 
phlogistic L-selectin shedding on circulating neutrophils. Interestingly, L-selectin and 
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annexin Al are now known to co-localise, once annexin Al has externalised to the cell 
membrane (de Coupade et al., 2003; Strausbaugh & Rosen, 2001). Furthermore, AF-2 
(residues 246-254 of annexin Al) pre-incubated with PAF activated leukocytes 
attenuates L-selectin shedding and CD1 lb up-regulation (Zouki et al., 2000). 
Consequently, the lower basal CD 11 b expression observed in annexin Al null cells 
appeared to be redundant during neutrophil and monocyte stimulation. Thus, an over 
compensation mechanism may have evolved in these mice, regarding chemoattractant 
pro-inflammatory mediator activation. The present results demonstrate annexin Al 
null leukocytes augmented fMLP, PAF or PMA-induced CD 11 b expression in a 
concentration depended manner with a maximum increase of 3-fold from littermate 
(WT) controls. 
The construction of a concentration-response curve to PAF induced CD 11 b up- 
regulation proved problematic with neutrophils over expressing annexin Al, as these 
cells have a reduced efficacy with regard to mediator activation. Neutrophil CD 11 b up- 
regulation in these mice was considerably attenuated at all concentrations examined 
compared to littermate (WT) controls. The clear contrast in data between the annexin 
Al null mice compared with mice over expressing this protein, re-established annexin 
Al to be directly involved during neutrophil activation, and that the initial results were 
not due to a form of genetic plasticity. In conclusion, these data suggest endogenous 
annexin Al induces membrane molecule modification and tonic inhibition of CD1 lb 
amplification. This augmented expression accounts in part for the amplified neutrophil 
migration observed during zymosan peritonitis, with CD I1 b being the major leukocyte 
CAM involved in slow rolling induced by TNFa (Dunne et at, 2003). 
This increased CDI lb expression observed has no physiological relevance in isolation, 
other than that these cells are more prone to cellular CDllb up-regulation. Next, 
locomotor activity of these cells was tested, offering a more functional approach to the 
assessment of increased integrin expression. To address this question, locomotor 
activity was analysed with the aid of a chemotaxis assay. Murine annexin Al null 
isolated neutrophils placed on chemotactic chambers displayed significantly enhanced 
locomotor activity compared to littermate (WT) control neutrophils. Therefore, this 
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super sensitivity observed previously with CD1lb expression in response to 
inflammatory mediators was echoed during cell chemotaxis. Chemotaxis of annexin Al 
null neutrophils in response to fMLP and PAF produced an increase in migration index 
by -40% compared to littermate (WT) control. Upon neutrophil adhesion to the vessel 
wall, specific signalling mobilises and externalises annexin Al through a unknown 
mechanism resulting in down regulation of neutrophil migration (Perretti et al., 1996). 
The mechanism of annexin Al externalisation is central to the understanding of annexin 
Al biology. Two previous studies have illustrated annexin Al secretory pathways one 
in human semen (Christmas et al., 1991), the other, more recently, involving the ABC 
transporter of the folliculo-stellate cells in the pituitary (Chapman et al., 2003). In 
human neutrophils annexin Al is mainly found in the gelatinase granules, demonstrated 
by the co-localisation of gelatinase and annexin Al by confocal microscopy studies 
(Perretti et al., 2000). It is evident that annexin Al expression is increased once it has 
been externalised on migrated neutrophils associated with inflammatory conditions 
(Oliani et al., 2001). 
This data provides evidence that a lack of annexin Al augments neutrophil migratory 
behaviour, consistent with the documented literature over the past decade demonstrating 
annexin AI's potent inhibitory actions on neutrophil activation (in vitro) and migration 
(in vivo) (for review see (Perretti & Flower, 2004). Thus, this thesis demonstrates that 
mice deficient in annexin Al migrate to a greater degree towards chemoattractant 
gradients resulting in the accumulation and activation of leukocytes into the inflamed 
tissue. 
Furthermore, it has been described that the peptide Ac2-26 can act as chemoattractant 
for human neutrophils (Walther et al., 2000). A question addressed during the thesis 
was, whether Ac2-26 was chemokinetic or chemoattractant? The preliminary data 
produced here suggest that the peptide is chemoattractant and not chemokinetic. This 
is evident from checkerboard chemotactic analysis; neutrophils only travelled towards 
the peptide in a concentration dependent manner and locomotion was absent when the 
peptide was incubated together with the cells. Annexin Al null and littermate (WT) 
control neutrophils appear to be equally sensitive to Ac2-26 induced chemotaxis. Thus, 
the absence of the annexin Al protein does not affect cell responsiveness; hence, the 
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putative annexin Al receptor appears present and functional in cells taken from these 
mice. 
The transient polymerisation of monomer/globular actin subunits to filamentous/F-actin 
is among the initial intracellular events to occur following chemoattractant application 
(Norgauer et al., 1994), and is a prerequisite for neutrophil migration. The first step of 
neutrophil locomotion is the protrusion of a leading edge; this process relies primarily 
upon forces generated by actin polymerisation pushing the membrane outward (Alberts 
et al., 1995). Various inflammatory mediators induce this polymerisation of F-actin 
(Norgauer et al., 1994). More recently, peptide Ac2-26 has also been shown to induce 
actin rearrangement in the neutrophil and macrophage (Ernst et al., 2004). 
Physiologically, actin assembly and depolymerisation in the neutrophil allows for shape 
change and neutrophil spreading during migration (Pettit & Hallett, 1997). In this study 
PAF caused a transient polymerisation of actin in both annexin Al null and littermate 
(WT) controls with no apparent differences between genotypes. A recent paper has 
indicated Annexin A2 is an essential protein for actin filament bundling in a calcium 
dependent manner, in particular annexin A2 is critical for the assembly of actin 
structures at the cell membrane (Merrifield et al., 2001). It is of interest that in a 
number of cells and tissues examined from the annexin Al null mice an increased 
concentration of annexin A2 was found (Croxtall et al., 2003; Hannon et al., 2003). 
However, this was not true for all tissues examined, moreover, leukocytes obtained 
from the annexin Al over expressing mice exhibited a reduced concentration of annexin 
A2 (data unpublished), interestingly, blocking annexin A2 synthesis with RNAi 
generates a rise in annexin Al levels (Hayes M. by communication). These facts 
indicate annexin Al and A2 may have a symbiotic relationship, as one decreases the 
other increases. Augmented annexin A2 expression in annexin Al null cells may 
account for the delayed formation of F-actin observed following fMLP incubation. 
Furthermore, following neutrophil activation by proinflammatory mediators, a plethora 
of biochemical events occur. Previously Ac2-26 has been shown to be a potent 
inhibitor of elastase, ROS and free arachidonic acid release in the activated neutrophil 
(Euzger et al., 1999; Perretti et al., 1995). Congruent with earlier data, littermate (WT) 
control neutrophils incubated with PMA produced a concentration dependent increase 
in ROS production; neutrophils lacking annexin Al produced a significantly augmented 
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production of ROS compared to littermate (WT) controls. This data indicates annexin 
Al's anti-inflammatory effects are not restricted to the initial steps of leukocyte 
migration, but rather that it affects several activation steps down-stream of chemotaxis. 
In line with the documented literature a recurring theme arises regarding annexin Al 
and neutrophil activation; the addition of exogenous annexin Al or its mimetic 
decreases neutrophil susceptibility to proinflammatory mediators. Conversely, here it 
has been revealed that the removal of endogenous annexin Al with the creation of the 
null mouse significantly increases the leukocyte susceptibility to inflammatory agents, 
from neutrophil rolling on the endothelium to the production of ROS at the site of 
inflammation. 
Murine neutrophils lacking this vital anti-inflammatory protein possess an intensified 
pro-inflammatory response upon activation. Initial studies carried out by Hannon et al., 
illustrated that the annexin Al null mouse possesses an exaggerated inflammatory 
response. Several changes observed in these animals are congruent with the result from 
this thesis. In the carrageenin-induced paw oedema model, annexin Al null mice 
exhibited an escalated inflammatory response. The annexin Al null mice displayed an 
enhanced sensitivity to the inflammatory stimulus, with greater swelling observed at 
most time points especially 6,24 and 96 h (Hannon et al., 2003). Neutrophils in these 
mice have an enhanced tendency to adhere and migrate from post capillary venules 
(Hannon et al., 2003), perhaps due to the up-regulated CD62L expression and super 
sensitivity of the cells towards inflammatory mediators that up-regulates CDIlb 
expression, increasing chemotaxis and ROS production. In contrast, the annexin Al 
over expressing mouse displays a reduced neutrophil migration during zymosan 
peritonitis (Chatterjee et al., unpublished), conceivably due to a lower increase in 
CD 11 b expression. This functional CD 11 b up-regulation or inside out signalling 
induced by inflammatory mediators is critical during neutrophil firm adhesion (Stewart 
& Hogg, 1996), as neutrophils circulate in a non-adhesive manner prior to targeting and 
arrest at specific sites. Once CD 11 b engages with its ligand (ICAM-1) on endothelial 
cells, outside in signals trigger intracellular transduction events, in addition to mediating 
adhesion (Hogg et al., 2003). Consequently, the interactions annexin Al is having on 
these neutrophils may mediate more than cell adhesion alone. 
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Moreover, during chronic joint inflammation annexin Al null mice have demonstrated 
an exacerbated response, with an increase in cytokine production and joint swelling 
(Yang et al., 2004), possibly due to the super sensitivity of these neutrophils. This 
enhanced inflammatory response was echoed during zymosan-induced peritonitis, with 
a significantly augmented response in the annexin Al null mouse, with an increase in 
cytokine concentrations and neutrophil numbers in the cavity. The administration of 
dexamethasone during chronic (joint) and acute (paw) models of inflammation were 
only partially functional in these mice (Hannon et al., 2003; Yang et al., 2004). 
Therefore, the putative anti-migratory role of dexamethasone is lost in the absence of 
annexin Al. Yet, when Ac2-26 was administered to the null mouse, neutrophil influx 
into the cavity was significantly attenuated in both genotypes. These data illustrate 
annexin Al to be the primary mediator for dexamethasone's anti-migratory effects and 
the annexin Al receptor still to be present in these mice. 
ý 
T 
Figure 4.1 Annexin Al and the neutrophil. Neutrophils lacking the anti- 
inflammatory protein annexin Al are "super sensitive" to pro-inflammatory mediators, 
producing an exacerbated response. 
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4.2 Macrophages lacking annexin Al, possess an impaired phagocytic 
keno e 
Annexin Al has had a long and colourful association with the monocyte/macrophage 
lineage. Initial studies carried out in the 1980's on macrophages, illustrated annexin Al 
mediates the inhibition of prostaglandin and PAF-acether release from these cells, that 
was instigated by glucocorticoid's (Blackwell et al., 1980; Carnuccio et al., 1981; 
Parente et al., 1985). The efficacy of hydrocortisone and the cellular content of annexin 
Al has been shown to be intimately linked, illustrated by a simple yet ingenious 
experiment conducted in 1981. Following the depletion of annexin Al stores in 
peritoneal macrophages by prolonged incubation with steroids, hydrocortisone's 
inhibitory effects on PGE2 production vanished (Carnuccio et al., 1981). Only once 
annexin Al levels had been restored did the anti-PGE2 effects of hydrocortisone 
reappear. 
The recent generation of the annexin Al null mouse offered the prospect to investigate 
the potential role of endogenous annexin Al biology in resident and bone marrow 
derived macrophage. Earlier studies have demonstrated glucocorticoids augment 
annexin Al protein expression in human alveolar macrophages as well as in human 
monocytes and rodent peritoneal macrophages (Ambrose et al., 1992; Comera & Russo- 
Marie, 1995; Peers et al., 1993). During the acute inflammatory response the synthesis 
and release of pro-inflammatory mediators such as cytokines, prostaglandins and 
superoxide from activated resident macrophages is essential in the development of the 
inflammatory response. Previous data has illustrated dexamethasone inhibition of 
proinflammatory cytokine synthesis and superoxide release from activated macrophages 
(Maridonneau-Parini et al., 1989; Sudlow et al., 1996). These inhibitory actions of 
dexamethasone on monocyte cytokine release were abrogated by passive immunisation 
with the annexin Al neutralising antibody (Sudlow et al., 1996). Alveolar macrophages 
from patients with bronchial asthma treated with glucocorticoids displayed a significant 
inhibition of basal and stimulated PGE2 and LTB4 synthesis. Interestingly, this 
treatment caused enhanced levels of annexin Al, suggesting annexin Al to be 
responsible for these anti-inflammatory effects (De Caterina et al., 1993). Furthermore, 
the addition of exogenous annexin Al to activated monocytes and macrophages, mimics 
dexamethasone as assessed by superoxide generation, prostanoid release and enzyme or 
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cytokine expression (Comera & Russo-Marie, 1995; Maridonneau-Parini et al., 1989; 
Wu et al., 1995). More recently, the annexin Al mimetic peptide Ac2-26 (Perretti, 
1998) has been shown to inhibit IgG immuno-complex phagocytosis by mouse 
peritoneal macrophages, as determined by flow cytometry (Getting et al., 1997). 
Therefore, this thesis began by comparing macrophage phagocytosis and cell activation 
using a panel of soluble and insoluble stimuli. When zymosan particles were used, a 
striking difference in the rate of phagocytosis was observed between wild type and 
annexin Al null peritoneal macrophages. However, when zymosan was opsonised this 
difference disappeared. This is congruent with the absence of any detectable kinetic 
difference when IgG immuno-complexes were used as phagocytosing stimulus, since 
opsonisation leads to the formation of IgG around the foreign particle. 
Flow cytometry analysis of annexin Al null BMDMo confirmed this defect in zymosan 
uptake; in addition, these cells also possessed a significant impairment during the 
phagocytosis of Neisseria particles and opsonised sheep red blood cells. Furthermore, 
when zymosan particles were injected in vivo i. p. a decreased uptake was observed in 
peritoneal leukocytes from annexin Al null mice. The defect in zymosan phagocytosis 
was confirmed by electron microscopy (peritoneal macrophages) and real time 
microscopy (BMDM0). Electron microscopy analysis demonstrated that zymosan 
particles were only loosely attached to the external surface of the plasma membrane in 
the annexin Al null macrophages, rather than being actually ingested. Real time 
confocal studies illustrated that zymosan phagocytosis occurs at a considerably 
diminished rate in macrophages lacking annexin Al. 
The macrophage expresses several surface molecules involved in the recognition and 
adhesion of microorganisms and other foreign particles. These fall into two main 
categories: the receptors for immunoglobulin (FcR) and complement (CR3 or 
CD 11 b/CD 18) utilise opsonins for ingestion (Aderem & Underhill, 1999), whilst the 
dectin 1 receptor (Brown & Gordon, 2001) recognises conserved motifs on the ß glucan 
particle in conjunction with TLR-2, as well as lactosylceramide (Zimmerman et al., 
1998) and the TLR-2 (Underhill et al., 1999). Flow cytometry analysis demonstrated 
that there were no differences in dectin 1 levels on wild type and annexin Al null cells. 
This is an important finding since dectin 1 is the major receptor for both soluble and 
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particulate ß glucans on macrophages (Brown et al., 2002), able to regulate ß glucan 
cellular responses including cytokine production (Brown et al., 2003). In contrast, 
membrane levels of heterodimeric integrin CD 11 b were reduced in annexin Al null 
peritoneal and BMDMe cells. CD 11 b is the alpha subunit of a myeloid member of the 
ß2-integrin family, well known to be involved in the recognition of particles and other 
phagocytotic stimuli (Brown, 1991; Le Cabec et al., 2000). For instance, the 
macrophage uses CD1 lb to ingest iC3b opsonised particles (Ezekowitz et al., 1984). In 
addition CD1 lb also possesses a lectin-binding domain that recognises a variety of ß 
glucans, including zymosan (Ross et al., 1999). In addition, CD1 lb is also a ligand for 
a number of other soluble factors and compounds known to be internalized by 
macrophages, ranging from galectin-3 to antisense probes (Avni et al., 1998). 
The lack of this lectin-binding domain may account for several of the effects observed. 
The CD I1 b/CD 18 complex plays a crucial role during phagocytosis by maintaining the 
integrity of membrane protrusions around the loosely attached particles to facilitate 
their ingestion into the phagosome (Dewitt & Hallett, 2002). Both membrane and total 
(membrane + cytosolic) CD11b levels were markedly reduced (-30%) in annexin Al 
null cells. Thus, this annexin Al deficiency was not related to an altered process of 
exportation of this integrin. It is not known how intracellular annexin Al regulates 
CD1 lb gene expression, or whether this is a direct effect or through post-transcriptional 
events. Interestingly, glucocorticoids are known to reduce CD 11 b expression on 
circulating and resident granulocytes and monocytes (Burton et al., 1995; Das et al., 
1997; Lim et al., 2000) and this effect is cycloheximide sensitive (Filep et al., 1997). 
Flow cytometry membrane analysis yielded two further results. Firstly, wild type and 
annexin Al null macrophages displayed similar levels of membrane FcRy type II/III and 
this is in agreement with the lack of differences observed during phagocytosis of IgG 
complexes or opsonised zymosan. Secondly, a slight reduction in the F4/80 sensitive 
antigen was measured in annexin Al null peritoneal macrophages but not BMDMe. 
The significance of these findings is as yet unclear, as is the precise function of the 
ligand recognised by the F4/80 mAb. Nonetheless, it is certainly a marker of 
macrophage differentiation, with a significantly lower degree of expression in 
monocytes and higher levels in differentiated tissue macrophages (Hirsch & Gordon, 
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1983). Thus, it is possible that the absence of annexin Al might retard the process of 
macrophage maturation, a fact that recalls the differential expression of the endogenous 
protein in monocyte/macrophages demonstrated more than a decade ago (Ambrose et 
al., 1992). 
Particular changes were observed in the cellular inflammatory responses that follow 
phagocytosis of non-opsonised zymosan ingestion by annexin Al null cells. This 
functional data was only in part corroborated by COX-2 protein expression at 20 h post- 
zymosan, since a smaller increase was observed in extracts taken from annexin Al null 
cells. Studies in fibroblasts have shown a similar dissociation between PGE2 release 
and COX-2 expression in the absence of annexin Al, and these cells also displayed 
changes in cPLA2 activity (Croxtall et al., 2003). The stimulus-specificity of the 
responses that were altered in the absence of macrophage annexin Al was confirmed by 
testing the effect of soluble stimuli. Whereas heat aggregated IgG-mediated responses 
were unmodified in the absence of annexin Al, LPS activation led to a marked up 
regulation of COX-2 and iNOS protein expression, and this was associated with a 
prolonged and more pronounced release of PGE2 that may be due to over activity at the 
NFi B promoter that regulates COX-2 expression (Yamamoto et al., 1995). Again, 
these findings are congruent with studies performed with annexin Al-derived peptides 
or with the anti-annexin Al neutralizing antibody (often tested in conjunction with a 
glucocorticoid), in which iNOS and COX-2 expression, as well as soluble mediator 
release, was monitored (Ferreira et al., 1997; Minghetti et al., 1999; Wu et al., 1995). 
Following phagocytosis, macrophages produce a plethora of proinflammatory cytokines 
that orchestrate the inflammatory response observed during chronic inflammation, e. g. 
in the synovial fluid of rheumatoid arthritis patients (Feldmann et al., 1996). Mouse 
macrophages rapidly produced proinflammatory cytokines; TNFa, IL-6 and IL- 
1 ß, following the incubation with zymosan, Neisseria or LPS. Cells lacking annexin 
Al had a significantly augmented synthesis of these cytokines. Congruent with this 
data, several studies have illustrated during the acute inflammatory response 
recombinant annexin Al or its mimetic are potent inhibitors of cytokine synthesis 
(Sudlow et al., 1996). These data are further substantiated during zymosan peritonitis 
in the annexin Al null mouse, with a significantly amplified synthesis of these 
proinflammatory cytokines resulting in an amplified influx of neutrophils. This 
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suggests that although phagocytic dynamics are grossly impaired in these cells, down 
stream signalling is if anything considerably augmented. 
Other members of the annexin superfamily are known to be involved in membrane 
dynamics including endocytosis and lipid raft stabilisation (Gerke & Moss, 2002). In 
this context, it is worth remembering that annexin Al, as well as other members of the 
annexin super-family, has been found associated with the early endosomes and 
phagosomes of the J774 macrophage cell line during latex bead phagocytosis 
(Diakonova et at, 1997). In these cells, the protein co-localised with F-actin on the cell 
protrusions and microvilli tips. Punctuate membrane immuno-gold localization for 
annexin Al has also been reported in human adherent neutrophils (Oliani et at, 2000) 
and rat pituitary folliculo-stellate cells that belong to the macrophage lineage (Traverso 
et al., 1999). Initial structural studies using mutated proteins suggest that 
phosphorylation of Ser27 in the N-terminal region of the protein is crucial for 
phagosome association (Kusumawati et at, 2001). However, Kusumawati et al also 
showed that deletion of half or all the N-terminal domain (1-33) did not alter annexin 
Al association with phagosomes, as seen in J-774A. 1 cells (Kusumawati et at, 2001). 
This is an important indication that the core domain, that contains the repeating 
canonical annexin motif and the phospholipid binding sites (Gerke & Moss, 2002), 
might govern annexin Al localization to the phagosome. During apoptosis cytosolic 
annexin Al translocates to the membrane in discrete patches where it can bind to 
phosphatidylserine or other receptors from engulfing cells (Arur et al., 2003) suggesting 
a role for annexin Al during phagocytic clearance. Future analysis of reconstitution 
experiments, with cells taken from the annexin 1 null mouse, will help clarifying this 
puzzle. 
Relatively more studied has been the intracellular fate of annexins during primary cell 
phagocytosis. Previous studies have illustrated that annexin Al and A3 translocate to 
the phagosome following the internalisation of yeast by neutrophils (Ernst, 1991), 
however when cells are invaded by Chlamydia only annexin A3 is detected in 
phagosomes. Annexin Al has been shown to be differentially distributed during the 
phagocytosis of heat killed Listeria compared to live Listeria (Collins et al., 1997). In a 
study performed with Brucella, prominent annexin Al staining was associated along the 
phagosome (Harricane et al., 1996). This phenomenon was stimulus specific, such that 
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annexin Al localisation around the phagosome was not observed following macrophage 
ingestion of Escherichia coli (Harricane et al., 1996). In addition, intracellular re- 
location of annexin Al in relation to the phenomena of phagocytosis or exocytosis has 
also been reported (Sjolin et al., 1994). 
Interestingly, in annexin Al null fibroblasts cortical actin appears to be absent resulting 
in an altered morphology (Croxtall et al., 2003), possibly suggesting annexin Al to be 
responsible in regulating cell shape and motility in fibroblasts (Futter et a!., 
unpublished); however, no differences were observed in BMDMe cell shape and actin 
distribution between WT and annexin Al null cells. Analyses of cellular annexin Al 
localisation in macrophages have helped clarify the distribution and function of annexin 
Al during zymosan phagocytosis. These results demonstrate annexin Al to be present 
in cytoplasm of adherent macrophages, and during the early stages of zymosan 
phagocytosis annexin Al translocates to surround the phagocytic cup, where F-actin 
forms tightly in both the WT and annexin Al null phagosome. To assess whether this 
was a transient process annexin Al localisation was observed at later periods. 
However, by later points annexin Al had dissipated and returned to the cytoplasm. 
This putative cycle implies this protein could be important during the early, but not 
later, stages of phagocytosis. 
Fig= 4.2 Annexin Al during zymosan phagocytosis. 
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Aberrant effects of hydrocortisone in annexin Al null mice 
In early experiments glucocorticoids were observed to act as potent inhibitors of 
prostaglandin release from macrophages (Bray & Gordon, 1978). Not many studies 
have addressed the effect of glucocorticoids on macrophage phagocytosis. 
Interestingly, Grasso et al., (1988) have demonstrated that glucocorticoids inhibit 
phagocytosis through the secretion of a phagocytosis inhibitory protein (PIP (Becker & 
Grasso, 1988), partially purified from the media of macrophages incubated with 
dexamethasone. The inhibitory actions of PIP on macrophage phagocytosis were 
abrogated by passive immunisation with an annexin Al neutralising antibody; thus, this 
was presumptive evidence that an annexin Al-like protein could mediate the anti- 
phagocytic effect of glucocorticoids. Following the characterisation of annexin Al it 
was observed that the treatment of monocytes or macrophages with exogenous annexin 
Al inhibits cellular activation (Getting et al., 1997; Goulding et al., 1998). This was 
further confirmed by the addition of exogenous annexin Al to activated monocytes and 
macrophages mimicking dexamethasones inhibitory properties upon prostaglandin, 
superoxide and cytokine production (Maridonneau-Parini et al., 1989; Sudlow et al., 
1996). 
The uptake of aggregated IgG particles beads was examined by monitoring rate and 
maximum reaction kinetics by flow cytometry. The phagocytic profile was not 
different between annexin Al null and WT peritoneal macrophage phagocytosis, but the 
glucocorticoid hydrocortisone produced its expected inhibitory effect (20-30%) on IgG 
phagocytosis in WT cells, similar the effects found by Grasso et al., with 
dexamethasone. Importantly, the glucocorticoid was inactive in cells lacking the 
annexin Al protein. This is consistent with absence of any detectable kinetic 
differences during opsonised zymosan phagocytosis, as opsonisation leads to the 
formation of IgG complexes around the foreign particle. Glucocorticoids were again 
active in this system, but only in WT cells. Glucocorticoids are thought to function 
during phagocytosis by promoting the synthesis/externalisation of annexin Al from the 
cytoplasm to the cell membrane (Peers et al., 1993). Unpublished data from the 
department of Biochemical Pharmacology, has shown that following annexin Al 
mobilisation to the cell membrane, the NH2 terminal of annexin Al is cleaved between 
Valine 36 and Serine 37, resulting in a 37/33 KDa protein following leukocyte 
166 
Chanter 4 Discussion 
activation (Perretti et al., 1996) or recruitment in vivo (Vergnolle et al., 1995). This 
cleaved fragment has the potential to potently inhibit macrophage activation and 
phagocytosis (Getting et al., 1997), and could also induce a signal on cell surface FPR 
(Gavins et al., 2003; Walther et al., 2000). For all these reasons the efficacy of Ac2-26 
in these mice was analysed next in this system. The peptide Ac2-26 produced 
inhibitory effects in cells from both genotypes: indicating that the failure in 
phagocytosis in these cells was caused by a defect in sensitivity to annexin Al. This is 
congruent with data collected during zymosan peritonitis, where dexamethasone was 
inactive in inhibiting neutrophil influx in the annexin Al null mice yet the peptide was 
still active. However, there was no difference in response to either glucocorticoids or to 
Ac2-26 in FPR KO mice suggesting that the receptor for annexin Al must be another 
member of the FPR family (discussed below). This is in line with the documented 
literature illustrating that the anti-inflammatory effects of glucocorticoids are aberrant in 
the absence of annexin Al during both acute (Hannon et al., 2003) and chronic (Yang et 
al., 2004) in vivo models of inflammation. This is congruent with data in section 3.3.1 
where dexamethasone treatment had no effect on annexin Al null mice during 
zymosan-induced peritonitis. 
Interestingly, glucocorticoids have been shown to enhance phagocytosis of apoptotic 
neutrophils (Liu et al., 1999), to speculate for a moment, this may be due to the 
induction of annexin Al on the surface of the apoptotic neutrophil that binds to the 
PSR on the macrophage bringing about the resolution of inflammation (Fan et al., 2004) 
(Arur et al., 2003). An experiment worth pursuing could test if this glucocorticoid 
enhancing phagocytosis of apoptotic neutrophils (Liu et al., 1999) is annexin Al driven, 
with the aid of annexin Al blocking antibodies or Boc derivatives. In conclusion, 
annexin Al functions during the initial and final stages of the inflammatory response, as 
a pro and anti phagocytic protein, yet always acting as an anti-inflammatory 
(homeostatic) agent in the fight against inflammation. 
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4.4 Characterisation of FPR KO neutrophils 
Immediately prior to the commencement of this thesis Walther et at, published the first 
evidence of a putative annexin Al receptor, illustrating the functional involvement of 
human FPR in a series of in vitro assays (Walther et at, 2000). This novel data was 
later substantiated, at least in part, through in vivo experiments using FPR KO mice 
(Perretti et at, 2001). Initial studies carried out on human neutrophils with the FPR 
antagonist Boc (and its derivatives; Dalpiaz et at, 1999) on calcium flux and L-selectin 
shedding, illustrated the in vitro anti-migratory effects of Ac2-26 were abrogated by 
these antagonists (Walther et at, 2000). Furthermore, relatively low peptide 
concentrations caused calcium transients without activating downstream signalling 
pathways, which were instead activated by PMA. Subsequently, these Boc derivatives 
were found to exert potent antagonism on the anti-migratory effects displayed by Ac2- 
26 during zymosan induced mouse peritonitis; Ac2-26 lost nearly all its anti- 
inflammatory effects in the presence of these antagonists (Perretti et al., 2001). 
However, full length annexin Al retained a good degree of efficacy in both Boc-treated 
and FPR KO mice. Consequently, annexin Al binding to circulating FPR KO 
leukocytes was observed to be only partially reduced, signifying the existence of an 
additional receptor(s) or mechanism of action for annexin Al (Perretti et at, 2001). 
This system may be operative in more complex situations, since the cardio-protective 
property of peptide Ac2-26 during myocardial ischaemia reperfusion in the rat heart 
(D'Amico et at, 2000) is also abrogated in the presence of these FPR antagonists (La et 
al., 2001). The same has recently been shown for the peptide's anti-nociceptive effects 
(Pieretti et at, 2004). 
The recent generation of the FPR KO mouse, with the initial characterisation of its 
impaired infection phenotype (Gao et al., 1999), presented an ideal opportunity to test 
and characterise the potential role of this receptor on annexin Al biology in the 
circulating neutrophil. In this context it is worth remembering that direct activation of 
the FPR causes calcium transients and chemotaxis (Gao et al., 1999). The initial 
construction of a concentration response curve to fMLP induced CDI lb up-regulation 
in C57BL/6 and FPR KO mouse neutrophils, demonstrated that fMLP activates the 
mouse FPR at 3 µM, a slightly higher concentration than that previously reported (Gao 
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et al., 1999). However, the whole blood assay has been used in this thesis to minimise 
cell activation during cell separation procedures, hence allowing the possibility of 
plasma proteins binding some of this small peptide. In addition, 30 µM fMLP produced 
clear effects independent of the FPR activation observed in mice lacking this receptor. 
Although the FPR is absent in these mice, other receptors of this family are nonetheless 
present. RT-PCR and Western blotting of FPR KO peritoneal cells has shown 
ALXR/FPRrs-1 mRNA and protein expression to be present (Gavins et al., 2003). The 
affinity of fMLP to murine ALXR/FPRrs-1 is considerably lower compared to that for 
the FPR (with a reduced EC5o by 100 fold), therefore a higher concentration is required 
to achieve any effects. Boc 2 completely abrogated the effects of fMLP in both 
C57BL/6 and FPR KO neutrophils. This indicates that the lack of specificity suggested 
in human neutrophils (Perretti et al., 2001) applies in the murine system too. Under 
these experimental conditions Boc 2 acts upon another fMLP sensitive receptor, most 
likely ALXR/FPRrs-1, to abrogate fMLP's effects. 
Importantly, the peptide Ac2-26 also abrogates fMLP induced CD 1I b up-regulation, 
equally on cells taken from C57BL/6 and FPR KO neutrophils. In addition, at variance 
from Walther et al., and their study on the human FPR, in this system the addition of 
Ac2-26 alone to mouse whole blood did not produce any detectible changes in 
membrane CD I1 b expression. This set of data is perfectly in line with previous data 
described for recombinant annexin Al and human neutrophils: (Strausbaugh & Rosen, 
2001). In contrast, PAF activated both C57BL/6 and FPR KO neutrophils to an 
analogous degree. However, cells pre-incubated with peptide Ac2-26, produced a 
modest but significant damped down effect on PAF induced CD 11 b up-regulation; this 
is partially supported by reports in which the peptide reversed PAF induced neutropenia 
in vivo (Harris et al., 1995). These initial data in conjunction with the published 
literature, suggest that the peptide interacts with an fMLP receptor, instigating a 
complete inhibition of neutrophil activation, and this is unlikely to be the FPR. To 
clarify that these inhibitory actions were not occurring down stream of this receptor 
another autonomous proinflammatory GPCR (the PAF receptor) also known to generate 
stimulatory signals was activated (Ali et al., 1999). The peptide generated a partial 
reduction in CD 11 b up-regulation that equated to a total abrogation as observed with 
fMLP. Interestingly, activation of the FPR causes desensitisation of the PAF receptor; 
in contrast, PAF receptor activation does not interfere in FPR function (Ali et al., 1999). 
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The FPR family of receptors possess the ability to recognise bacterial chemical 
peptides. Therefore, this family of receptors have been proposed to play an important 
role during the inflammatory response. Stimulation of neutrophils with fMLP induces a 
plethora of cellular events including shape change, induction of adhesion molecules, 
phagocytosis and chemotaxis (Le et al., 2001). The mobilisation of neutrophils during 
the inflammatory response is critical in orchestrating this response. Gao et al., have 
demonstrated that FPR KO mice exhibited a decreased resistance to Listeria and a 
reduced chemotaxis (Gao et al., 1999) like other bacteria Listeria generates these N- 
formylpeptides). To determine whether isolated FPR KO neutrophils possessed altered 
locomotor activity, cells were placed onto chemotatic chambers. Both FPR KO and 
C57BL/6 neutrophils migrated towards PAF to an analogous degree, PAF also induced 
CD1lb up-regulation, with similar effects in these mice. In contrast, chemotaxis 
towards the peptide Ac2-26 is significantly reduced in FPR KO cells compared with 
C57BL/6 neutrophils indicating that the annexin Al mimetic is interacting with the 
mouse FPR as well as with another Boc 2 sensitive receptor. These data support the 
concept that the FPR activation culminates in cellular chemotaxis whereas ALXR/FPR- 
rsl activation might be linked to an inhibition of specific cellular responses. 
The initial studies carried out by Walther et al., suggested the unilateral involvement of 
the human FPR as a target of annexin Al biology, supported by the efficacy of these 
Boc derivatives known to inhibit FPR functions (Walther et al., 2000). This has 
recently been further clarified as the peptide Ac2-26 in now known to bind all three 
human fMLP receptors causing desensitisation of these receptors, and rendering 
leukocytes unresponsive (Ernst et al., 2004). Unpublished data from our department 
has illustrated through ligand binding assays that the peptide Ac2-26 competes at both 
the human FPR and ALXR/FPRL1, with an EC50 of 1.4 and 1.8 pM with a Hill 
coefficient of less than 1. 
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Figure 4.3 The human annexin Al receptor. Annexin Al and its mimetics 
have been shown to interact with the FPR, FPRLI/ALXR and FPRL2 (Taken from 
Perretti 2003). 
The story follows a similar theme in the mouse. The peptide Ac2-26 has known 
inhibitory actions during ischaemia reperfusion in the C57BL/6 mouse, however, these 
effects were abrogated by Boc 2 equally active in FPR KO mice (Gavins et al., 2003). 
Calcium flux assays have also demonstrated that Boc 2 is able to interact with the FPR, 
FPRLI/ALXR and FPRL2 on human neutrophils, raising doubts against the specificity 
of these antagonists for a given receptor in the FPR(s) family (Perretti et al., 2002). 
Returning to the murine model, endogenous annexin Al and the murine ALXR/FPRrs-1 
co-immunopreciptate in neutrophils collected from the inflamed air pouch, the peptide 
also specifically interacts and binds with the ALXR on neutrophils with a ICs() of 0.3 
µM, implying ALXR to be the annexin Al receptor in both the human and murine 
system (Perretti et al., 2002). John et al., have illustrated in the mouse pituitary (where 
annexin Al acts as a local hormone) that mRNA for FPR is absent, yet FPRrs-1 and 
FPRrs-6 mRNA was abundant (John etal., 2004), suggesting FPRrsI and FPRrs-6 were 
the target for annexin Al. All together, these data produced here are congruent with the 
documented literature indicating that the peptide Ac2-26 interacts with the murine FPR 
and another Boc 2 sensitive receptor, most likely ALXR, to produce its anti-migratory 
effects in both the mouse and human system (Ernst et al., 2004, Gavins et al., 2003, 
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Perretti et al., 2002). The idea of annexin Al acting upon the ALXR is intriguing, as 
the ALXR plays a pivotal role in the anti-inflammatory effects of LXA4. LXA4 exerts 
potent anti-inflammatory effects in several models of inflammation, spanning from the 
acute air pouch (Serhan et al., 2000) to sensitised and challenged lung inflammation 
(Levy et al., 2001). Annexin Al and LXA4 share several similar actions, including 
attenuation of CD 11 b up-regulation, chemotaxis and the detachment of adherent 
leukocytes from inflamed vessels (for review see (Kieran et al., 2004), although LXA4 
produces some of these effects through the induction of nitric oxide (Paul-Clark et al., 
2004). 
Therefore, it appears that the murine FPRrs-1/ALXR endogenous ligands act in a non- 
phlogistic manner; these effects seem to be specific for this member of the FPR(s) 
family of receptors. The delineation of a specific receptor for annexin Al biology in an 
inflammatory setting will help in the development of novel anti-inflammatory therapies. 
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4.5 Conclusion 
Inflammation has been shown to be a beneficial response to a foreign challenge or 
tissue injury that ultimately leads to the restoration of tissue structure and function. 
John Hunter was the first to conduct a scientific study of inflammation in the 1790's, 
concluding that vasodilatation, leukocyte migration and hyperalgesia all contributed to 
the inflammatory response. Two hundred years later modem research is still devoted to 
the identification and management of the inflammatory response. This thesis 
supplements the development of the annexin Al field over the past 20 years, indicating 
that annexin Al is a critical protein during the inflammatory response. 
This is the first study to take advantage of the recently generated annexin Al null mice 
to clarify a biological role for this endogenous protein in the processes of neutrophil 
activation / migration and macrophage phagocytosis. 
Characterisation of the annexin Al null neutrophil with the aid of both in vitro and in 
vivo techniques, has led to a better understanding of its mechanisms of action. The fact 
that there was augmented changes in the expression of crucial adhesion molecules, this 
being either a direct or indirect affect, lead to a heightened level of neutrophil 
chemotaxis with a consequent increase in ROS production in these cells. Neutrophils 
from mice lacking the FPR nonetheless demonstrated sensitivity towards the annexin 
Al mimetic, advocating the involvement of at least another receptor of this family to 
bring about its anti-inflammatory effects. Thus, endogenous annexin Al functions as a 
modulator of neutrophil activation. 
Annexin Al deficiency on both peritoneal and BMDMo is associated with subtle 
changes in the expression of key membrane receptors and this leads to inadequate 
phagocytosis with consequent alterations of down-stream markers of cell activation. 
Nevertheless, during macrophage activation these cells produce an augmented amount 
of proinflammatory cytokines and appear to be resistant to glucocorticoid inhibitory 
effects. 
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The generation of the annexin Al null mouse has offered the opportunity for addressing 
the patho-physiological role of this protein in the context of inflammation. A major 
dilemma associated with genetically modified mice is the global lack of the target gene 
product, throughout the body as well as during development. Therefore, there is 
sufficient opportunity to alter the expression of other functionally related genes, as 
observed with the up regulation of annexin A2 and COX 2 expression (Croxtall et al., 
2003; Hannon et al., 2003). Thus, these studies can also inform us about molecular 
plasticity. However, the data collected throughout this thesis complement and support 
the findings in the documented literature, for a negative regulatory role of annexin Al. 
This was further confirmed, at least in part, by the experiments conducted with mice 
over expressing annexin Al. 
The development of drugs that target annexin Al biology will surely aid in the combat 
against certain diseases that occur when this otherwise normal physiological response 
goes astray and becomes self destructive for the host. Upon reflection, it is likely that 
the experiments illustrated here will prompt further investigations into the processes of 
annexin Al biology relating to neutrophil and macrophage function. If time knew no 
boundaries and money flowed from granting bodies, further questions arising from this 
thesis would have been answered: 
How do annexin Al null neutrophils respond to exogenous annexin Al? 
Do annexin Al macrophages differ in response to diverse range of micro- 
organisms? 
Is phagocytosis of apoptotic neutrophils altered in annexin Al macrophages? 
Are FPR KO macrophages sensitive to annexin Al? 
Is the neutrophil signalling altered in cells lacking annexin A I? 
To repeat all these experiments in annexin Al over expressing mice. 
This thesis with the support of the documented literature implicates annexin Al in 
playing a critical function during the inflammatory response. 
John Hunter appreciated that when inflammation cannot achieve a "salutary process" it 
does "mischief". The future of annexin Al therapy in the inflammatory field shall 
surely reduce this mischief and aid the salutary process! 
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6.1 Glucocorticoids an overview 
Appendix 
GCs are the most powerful anti-inflammatory group of drugs in use today, fifty years after 
they were initially developed (Hench, 1951). Clinically, GCs are synthetic analogues of 
cortisol an important endogenous glucocorticoid hormone firstly identified in the 1930's 
and isolated from the adrenal gland. 
Corticosteroids are synthesised and released on demand, by the adrenal gland since they are 
not stored as preformed molecules. The synthesis of corticosteroids is under the direct 
influence of the HPA axis (see Figure 6.1). The main physiological stimulus for the 
synthesis and release of corticosteroids is the release of ACTH by corticotrophes in the 
anterior pituitary gland, under the partial regulation by CRH released by neurons in the 
hypothalamus. The HPA axis regulates and maintains the appropriate plasma levels of 
cortisol determining a diurnal rhythm. Plasma cortisol exerts a negative feedback loop 
down regulating hypothalamus activation and ACTH release. On the other hand, stress 
stimuli activate HPA axis with augmentation of ACTH and cortisol levels, (for review see 
(Chrousos, 1995). The adrenal cortex synthesises two main families of steroid hormones 
from the precursor cholesterol: the corticosteroids (the glucocorticoids and 
mineralocorticoids) and the androgens. In humans the major GC is cortisol also known as 
hydrocortisone whereas aldosterone is the main mineralocorticoid. The combined actions 
of these two endogenous steroid hormones, can affect wide ranging of biological activities, 
in both a permissive and suppressive fashion, with involvement in virtually every aspect of 
physiology including carbohydrate, protein and lipid metabolism, electrolyte and water 
homeostasis in all major organs and tissues (Goulding & Flower, 2001; Schimmer, 1995). 
Endogenous corticosteroids are also important regulation of leukocyte function and 
therefore play an important anti-inflammatory and immunosuppressive role in the body 
(Chrousos, 1995; Pitzalis. et al., 2001). 
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6.1.2 Glucocorticoid-associated side effects 
Clinically, GCs are used widely to treat a variety of inflammatory disorders, including 
allergic diseases, rheumatoid arthritis, inflammatory bowel disease and autoimmune 
diseases (Barnes, 1998). In the United Kingdom alone, it is estimated that over 250,000 
patients receive continuous oral GC therapy (van Staa et al., 2000), with respiratory disease 
being the most frequently recorded indication of oral GC treatment (van Staa et a1., 2000). 
The long-term consequences of high dose exogenous GCs exert a negative feedback 
pressure on the HPA axis resulting in inhibition of cortisol synthesis by the adrenal cortex 
and subsequent adrenal atrophy. The pleiotrophic activities of GCs can lead to further 
unwanted side effects, including increased susceptibility to infection, growth retardation in 
children, osteoporosis, myopathy, hypertension, hyperglycaemia, behavioural changes and 
fluid and electrolyte abnormalities (Rang et al., 1999). The development of novel (('s 
with an improved therapeutic index, targeted drug delivery and deposition by the increased 
use of inhaled GCs for respiratory diseases such as asthma has aided in reducing the extent 
of these side effects, yet physiological and metabolic changes are still observed. The 
commonest adverse effects associated with inhaled GC's are dysphonia (Williamson el 41/- 
1995) and susceptibility to oropharngeal candidasis due to local immunosuppression 
(Selroos et cal., 1994). High dose inhaled G(' therapy is also associated with marked 
adrenal suppression and reduction in bone density. The effects on bone density and growth 
retardation has raised concerns about the use of inhaled GC's particularly in asthmatic 
children, recent evidence on long term use of inhaled GC therapy in paediatric asthma 
suggest that the risks are not as great as previously thought (Skoner, 2002). 
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6.1.3 The GR and its mechanisms of action 
The precise mechanism of GC action is still remains elusive. The general understanding of 
the anti-inflammatory actions of GCs is associated with a reduction in the expression of 
proinflammatory mediators as well as an increased expression of anti-inflammatory 
molecules. In many cases these effects are known to be glucocorticoid receptor (GR) 
dependent and this area has aroused interest although novel mechanisms of GC action, 
especially with respect to their rapid effects are now gradually being pieced together. 
GCs cross the plasma membrane with ease, due to their lipophillic nature and low 
molecular weight; the subsequent actions of GCs are time and concentration dependent, 
which determines the nature of their action being either direct genomic or non-genomic 
effects (Croxtall et al., 2002). At the molecular level, GCs exert their biological activity by 
binding to their intracellular cytoplasmic OR. The GR is a member of the nuclear receptor 
superfamily and the first member to be cloned (Hollenberg et al., 1985), these receptors 
include the receptors for sex hormones (e. g. androgens oestrogens and progestins), 
mineralocorticoids, thyroid hormones and vitamin D. Hormone binding activates many of 
these receptors, resulting in DNA binding via conserved zinc-finger structures and 
activation of target genes (Goulding, 2004). The majority of human tissues express the GR, 
typically in the range of 3,000 to 30,000 receptor per cell, this includes all inflammatory 
cell types such as granulocytes, monocytes, macrophages and lymphocytes (Barnes, 1998). 
Cloning of the GR gene revealed that alternative splicing of the receptor pre mRNA 
generates an additional highly homologous mRNA and subsequently a protein isoform 
termed GRß as opposed to the original form known as GRa (Barnes, 1998). The a form is 
composed of 777 amino acids, while the ß form contains a truncated C-terminus with 742 
amino acids. This difference between the two isoforms results in an inability of the GRß 
form to modulate transcription after binding to its ligand (Chrousos et al., 1993). 
Nevertheless, the ß isoform may compete with the a isoform for DNA binding sites, which 
has led to the proposal that the former form may act as an endogenous inhibitor of GC 
mediated effects (Bamberger et al., 1995). 
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Faure 6.2 The GRa, with its three major domains. The N-terminal transactivation 
domain, the central DNA binding domain containing two zinc finger regions and the C- 
tenninal hormone-binding domain serves as a binding site for heat shock proteins and co 
activators (Adapted from (Smoak & Cidlowski, 2004). 
The GRa, possess three distinct domains (see Figure 6.2). Starting at the C-terminal end of 
the protein is the GC binding domain, this domain also serves as the binding site for heat 
shock proteins (Coghlan et al., 2003). The DNA binding region and the nuclear receptors 
are found at the core of the receptor. The DNA binding domain consists of two zinc finger 
regions formed by a zinc ion bound to four cysteine residues, which are critical for receptor 
dimerisation and targeted binding. Finally, the N-terminal region ('tl) is involved in 
transactivation and transrepression of target genes; this domain can also bind to other 
transcription factors. The human GC receptor also contains a second transactivating 
domain; this domain is an important motif for nuclear translocation of the receptor (Kumar 
& Thompson, 2003). 
Once GCs diffuse through the plasma membrane by a passive process they can then bind to 
intracellular GRa, which is held in the cytoplasm in a inactive complex, together with 
HSP90, HSP70, HSP56, HSP40, P23 and several iminunophilins (Dittmar & Pratt, 1997). 
Upon binding to GCs. the GRa becomes an activated transcription factor that dissociates 
from the multimeric complex proteins, particularly HSP90, now exposing its nuclear 
localization signals, allowing rapid translocation to the nucleus. Here, the Ii-, and- -receptor 
complex modulates (stimulates or inhibits) transcriptional responses of 
intlammatory genes 
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either by binding directly to DNA or by protein-protein interactions with other transcription 
factors, known to regulate proinflanunatory genes (see Figure 6.3). 
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cytoplasm complexes with chaperones until it becomes an activated transcription factor 
upon binding to ligand. At this point, GRa dissociates from the multimeric protein complex 
and translocates to the nucleus. The ligand-- -receptor complex can stimulate or inhibit 
transcriptional responses by binding to glucocorticoid response elements ("Taken from 
(Smoak & Cidlowski, 2004) . 
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6.1.4 Effects of GCs 
Appendix 
The classically described genomic effects of GCs are generally slow, occurring over a 
period of hours as would be the case with physiological concentrations of GCs. The GR 
heterodimer binds to DNA at consensus sites termed glucocorticoid response elements 
(GREs), in the upstream promoter region of GC-responsive genes, resulting in either 
induction (positive GRE) or repression (negative GRE) of gene transcription (See Figure 
6.3). It is estimated that 10 to 100 genes can be regulated by GCs in any given cell type. 
The means the activated GR locates this small number of GREs amongst 100,000 genes, 
and this process is not fully understood, but evidence suggests that the GR dimer initially 
binds non-specifically to DNA, and sequentially binds and dissociates along the length of 
DNA until a high GRE is located (Lieberman & Nordeen, 1997). The consensus positive 
GRE sequence is a palindromic 15 base pair sequence motif; AGAACAnnnTGTTCT 
(where n is any nucleotide). The process of transactivation begins with the binding of the 
GRa to a GRE, resulting in a conformational change in GRa promoting the recruitment of 
plethora coactivators to the GR-DNA complex (Barnes, 1998). These coactivators induce 
chromatin structure remodelling allowing further promoter and full GC effects. GCs 
increase the synthesis of certain anti-inflammatory mediators including; the IL-1 
antagonist, annexin Al, IL-10 and the mitogen-activated protein kinase phosphatase 1 an 
endogenous negative regulator of mitogen-activated protein kinase (Barnes, 1998; Toh et 
al., 2004), this synthesis is presumably through positive GRE dependent gene activation. 
Nevertheless, GCs pleiotrophic actions illustrates that the activation of these genes only 
makes up a minor portion of the anti-inflammatory actions of GCs. GRa also down 
regulates the inflammatory response by repressing pro-inflammatory genes; this is achieved 
in part by binding directly to a negative GRE. 
Negative GRE sequences have been rarely identified due to there sequences being highly 
variable, resulting in several mechanisms of negative GRE-mediated repression. However, 
to date the most potent anti-inflammatory effects of GCs results not from GRE interplay 
but rather from the interactions between the GRa and other pro-inflammatory transcription 
factors, in particular NF-KB and AP- 1. This process leads to the transrepression production 
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of a plethora of pro-inflammatory mediators including TNFa, IL-1 ß, IL-2, IL-6, IL-8, 
COX-2 and ICAM-1 (Almawi & Melemedjian, 2002). 
GRa can also repress gene expression apart from DNA binding through protein-protein 
interactions with other transcription factors. The documented literature has illustrated the 
transcription factor NF-xB to be vitally important in regulating the expression of 
inflammatory genes, these effects can be reversed by the use of GCs by interacting directly 
with these genes in the nucleus (Adcock et al., 1994). NF-xB is held in the cytoplasm as an 
inactive complex, through its interaction with the inhibitor IKB. This association masks 
NF-KB's nuclear localisation signals, preventing its translocation and DNA binding 
activity, similar to the GR. The classical model of NF-KB antagonism by GCs occurs when 
the GR binds NF-KB forming a GR-NF-KcB complex, which does not bind DNA (Adcock et 
al., 1995). More recently other mechanisms have been postulated including, GC 
involvement in the synthesis of the NF-KBs endogenous inhibitor IKB, a protein-protein 
interaction model where the GR represses NF-KB function/activation by blocking access to 
its DNA site, or by forming a complex with NF-xB which losses DNA binding capacity 
(For review see (Almawi & Melemedjian, 2002). This is just one example how GCs 
antagonise proinflammatory transcription factors to repress the inflammatory response. 
The genomic effects of GC on the inflammatory response as discussed above, occur in a 
time frame of 45 min - 18h. These mechanisms cannot explain some of the rapid effects 
observed following GC administration. The classical theory of GCs rapid mechanism of 
action, suggests high concentrations of GC intercalate in membrane phospholipids 
influencing cellular structure remodelling. This in turn affects the structure and function of 
constituent proteins and receptors (Schmidt et al., 2000). Another, recent study has 
indicated GCs may act through a membrane GR by modulating intracellular signal 
transduction mechanisms within minutes. More recently, membrane GR has been reported 
to increase on monocytes in response to LPS treatment (Bartholome et at, 2004). Finally, 
these rapid non-genomic effects may be mediated through the cytoplasmic OR, without 
nuclear translocation or effects on transcription: an example reported in the literature is the 
rapid inhibitory effects of GCs upon PLA2 activation (Croxtall et at, 2002). 
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In conclusion, the majority of GC anti-inflammatory effects appear to be mediated through 
transrepression of transcription factors, whilst the metabolic effects are likely to be 
mediated by binding to positive GRE (transactivation). This theory has led to development 
of novel GCs that selectively transrepress inflammatory genes, thereby reducing the side 
effects associated with GC therapy; this subset of drugs have been termed `dissociated' 
GCs. One example of this group of GCs is RU24858 that has demonstrated anti- 
inflammatory activity (Vayssiere et al., 1997); yet, others have suggested that this 
separation of activity does not translate to an increased therapeutic ratio (Belvisi et al., 
2001). Following a different approach, a novel GC subset with a NO releasing linker has 
been developed, e. g. nitro-prednisolone or NCX-1015, and shown to be 20 times more 
potent than its parent steroid prednisolone lacking the NO linker in a number of 
inflammatory models (Fiorucci et al., 2002; Paul-Clark et al., 2000; Paul-Clark et al., 
2002). These findings suggest that the up-regulation of anti-inflammatory genes by GCs 
may be of equal importance to their anti-inflammatory activity and transrepression alone 
may be insufficient to achieve a complete anti-inflammatory effect. Annexin Al is one 
such anti-inflammatory protein regulated by GCs, section 1.3 discusses the biological anti- 
inflammatory activity of this important mediator. 
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